Split (1)

train · 100k rows

text stringlengths 2 190k	url stringlengths 22 593	crawl_date timestamp[us, tz=UTC]date 2022-04-01 00:00:56 2022-09-19 05:15:05	id stringlengths 22 593	label bool 2 classes	minhash_count stringclasses 349 values
Inflation has reached levels not seen since 1981. Could the Federal Reserve have acted sooner? One former Fed official points to some human errors he says led to the inflation mess we're in today. Copyright 2022 NPR Inflation has reached levels not seen since 1981. Could the Federal Reserve have acted sooner? One former Fed official points to some human errors he says led to the inflation mess we're in today. Copyright 2022 NPR	https://www.kvnf.org/2022-06-24/the-feds-mistakes-that-led-to-this-inflation-mess	2022-06-24T22:06:57Z	https://www.kvnf.org/2022-06-24/the-feds-mistakes-that-led-to-this-inflation-mess	false	null
MLB Expanded Pitching Comparison For Games of Saturday, June 25 NOTE: Only games with one or both pitchers designated are listed below INTERLEAGUE ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ AMERICAN LEAGUE ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ NATIONAL LEAGUE ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ KEY TEAM REC-Team's Record in games started by today's pitcher. CAR-Career record versus this opponent. VS OPP-Pitcher's record versus this opponent.	https://www.theridgefieldpress.com/sports/article/MLB-Expanded-Pitching-Comparison-17264366.php	2022-06-24T22:08:04Z	https://www.theridgefieldpress.com/sports/article/MLB-Expanded-Pitching-Comparison-17264366.php	true	null
VANCOUVER, British Columbia, June 24, 2022 (GLOBE NEWSWIRE) -- Affinor Growers Inc. (“Affinor” or the “Company”) (CSE: AFI) (OTCQB: RSSFF) is pleased to announce it is undertaking a private placement of up to 10,000,000 units (the “Units”) at a price of CDN$0.20 per Unit for gross proceeds of up to CDN$2,000,000 (the “Offering”). Each Unit will consist of one common share in the capital of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to acquire one additional Share (a “Warrant Share”) at a price of CDN$0.30 per Warrant Share, for a period of 24 months from the date of issuance. Proceeds from the Offering will be used to increase production capacity in the Company’s current greenhouse and build the new Atlantis building for more production and allow for selling turnkey facilities as well as for working capital. The Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the approvals of the Canadian Securities Exchange (the “CSE”). All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities laws. A finder's fee may be paid in connection with the Offering to eligible arm's length finders in accordance with CSE policies and applicable securities laws. The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold absent registration or compliance with an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. About Affinor Affinor is a publicly traded company listed on the CSE under the symbol "AFI" and on the OTCQB under the symbol “RSSFF”. Affinor is focused on developing vertical farming technologies and using those technologies to grow fruits and vegetables in a sustainable manner. To learn more about Affinor, visit: https://www.affinorgrowers.com On behalf of the Board of Directors, Affinor Growers Inc. Nick Brusatore Director /CEO nick@affinorgrowers.com Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTION REGARDING FORWARD-LOOKING INFORMATION This news release includes certain statements that may be deemed "forward-looking statements". All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.	https://www.globenewswire.com/news-release/2022/06/24/2469036/0/en/Affinor-Growers-Announces-0-20-Unit-Private-Placement.html	2022-06-24T22:13:29Z	https://www.globenewswire.com/news-release/2022/06/24/2469036/0/en/Affinor-Growers-Announces-0-20-Unit-Private-Placement.html	true	3
DUBLIN, June 24, 2022 /PRNewswire/ -- The "Global Opioids Market By Application, By Product Type, By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering. The Global Opioids Market size is expected to reach $5.4 billion by 2027, rising at a market growth of 3.5% CAGR during the forecast period. Opioids essentially serve as pain relievers since they are composed of substances that relax muscles and alleviate pain and stress. Prescription opioids are mostly used to treat moderate to severe pain, while some opioids can be used to treat cough and diarrhea. Hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other prescription opioids are among them. Opioids are the most commonly prescribed pain relievers for people suffering from moderate to severe chronic pain. Individuals diagnosed with terminal illnesses suffering from severe and chronic physical pain are the main recipient of these analgesics. Due to an increase in demand for optimal products for treating various ailments, the opioids market is predicted to grow significantly throughout the forecast period. Increased usage of these pharmaceuticals to battle pain, as well as an increase in the senior population, which is more prone to orthopedic pain, are two significant reasons driving the market's expansion. Furthermore, rising disposable income in developing economies like India, China, and others contributes to market expansion. Prescription opioids, which include oxycodone, hydrocodone, and morphine, among others, are powerful pain relievers with both positive and negative side effects. According to the National Institutes of Health, opioids are commonly used to treat adults suffering from moderate to severe pain, while some opioids can also be used to treat cough and diarrhea. Since a few years, there has been an increase in the demand for opioids, which are used to treat pain. Increasing demand for opioids has been seen across areas as a result of increased knowledge of palliative care and favorable reimbursement policies, as well as the implementation of Opioids Maintenance Treatment (OMT). Extended opioid options to users in terms of effectiveness and convenience, as well as regulatory support, will create opportunities. Additionally, corporations are raising awareness of palliative care options in addition to painkillers. For top opioid firms, developing commercial and prospective formulations with enhanced efficiency and potency versions is projected to give potential opportunities. Fujian Cancer Hospital, for example, continued its Phase III clinical trial research of the fentanyl patch in September 2020 to investigate its safety and efficacy in opioid-naive patients with moderate cancer pain. COVID-19 Impact Analysis The outbreak of the COVID-19 pandemic has impacted every domain of the business sector. The disease quickly spread across the globe after its discovery in Wuhan. Furthermore, this virus causes a variety of symptoms in individuals, ranging from minor to severe. Fever, dry cough, and exhaustion are some of the most prevalent symptoms. Some of the most severe and alarming symptoms observed in COVID-19 patients are shortness of breath, chest pain and a progressive decline in speech and movement. Additionally, the virus has a significant fatality potential in the elderly population. Also, only a few handpicked vaccines have gained approval for preventive purposes. Market driving Factors: High incidence of chronic pain in adults Globally, physical pain is a major issue. According to estimates by NCBI5, 20% of adults worldwide suffer from some kind of physical pain, with 10% of those get newly diagnosed with chronic pain each year. Nonetheless, the problem of pain has been predominantly viewed as a medical issue, with little attention paid to it by the field of public health. Pain's ubiquity, incidence, and wide-ranging social and health repercussions necessitate that the public health community pay close attention to it. As a result, health care practitioners and public health professionals will have a better understanding of pain, as well as the best public health and social policy approaches to the problem. Demand for Strong Agonists An agonist is a pharmacological molecule that activates specific brain receptors. When only a small number of receptors are engaged, this agonist elicits a strong physiological/pharmacological response, indicating that the medication has high intrinsic activity. Fentanyl, morphine, dihydromorphinone, meperidine, oxycodone, and oxymorphone are all strong agonist opioids. COVID-19 wreaked havoc on the global health system. During the COVID-19 pandemic, health organizations around the world were focused on preventing infection and treating COVID-19 patients, which resulted in the cancellation of elective procedures and consultations, which had an impact on pain services provided by hospitals and pain clinics. Marketing Restraining Factor: Increasing Cases of Opioid Addictions and Overdoses The CDC continues to track opioid overdose deaths because the prevalence of drug overdose deaths involving opioids remains high. In 2019, opioids were responsible for almost 50,000 deaths, more than six times the amount of opioid-related overdose deaths in 1999. It's critical to figure out and classify which drugs are involved in an overdose, how frequently they're involved, and how their involvement evolves over time. We can better identify effective preventative and response efforts by identifying drug involvement. Historically, the National Vital Statistics System mortality data (NVSS-M) was utilized to analyze overdose death data, with the combined categories of natural, semi-synthetic, and synthetic opioids (including methadone) being used to report on overdose deaths involving prescription opioids. Key Topics Covered: Chapter 1. Market Scope & Methodology Chapter 2. Market Overview 2.1 Introduction 2.1.1 Overview 2.1.1.1 Market Composition and Scenario 2.2 Key Factors Impacting the Market 2.2.1 Market Drivers 2.2.2 Market Restraints Chapter 3. Global Opioids Market by Application 3.1 Global Pain Management Market by Region 3.2 Global Cough Treatment Market by Region 3.3 Global Diarrhea Treatment Market by Region Chapter 4. Global Opioids Market by Product Type 4.1 Global Methadone Market by Region 4.2 Global Oxycodone Market by Region 4.3 Global Hydrocodone Market by Region 4.4 Global Fentanyl Market by Region 4.5 Global Codeine Market by Region 4.6 Global Morphine Market by Region 4.7 Global Other Product Type Market by Region Chapter 5. Global Opioids Market by Region Chapter 6. Company Profiles 6.1 Johnson and Johnson 6.1.1 Company Overview 6.1.2 Financial Analysis 6.1.3 Segmental &Regional Analysis 6.1.4 Research & Development Expenses 6.2 AstraZeneca PLC 6.2.1 Company Overview 6.2.2 Financial Analysis 6.2.3 Regional Analysis 6.2.4 Research & Development Expenses 6.3 Boehringer Ingelheim International Gmbh 6.3.1 Company Overview 6.3.2 Financial Analysis 6.3.3 Regional & Segmental Analysis 6.3.4 Research & Development Expenses 6.3.5 Recent strategies and developments: 6.3.5.1 Approvals and Trials: 6.4 Endo International PLC 6.4.1 Company Overview 6.4.2 Financial Analysis 6.4.3 Segmental Analysis 6.4.4 Research & Development Expenses 6.5 Mallinckrodt PLC 6.5.1 Company Overview 6.5.1 Financial Analysis 6.5.2 Segmental and Regional Analysis 6.5.3 Research & Development Expense 6.6 Sanofi S.A. 6.6.1 Company Overview 6.6.2 Financial Analysis 6.6.3 Segmental and Regional Analysis 6.6.4 Research & Development Expense 6.6.5 Recent strategies and developments: 6.6.5.1 Acquisition and Mergers: 6.7 Pfizer, Inc. 6.7.1 Company Overview 6.7.1 Financial Analysis 6.7.2 Regional Analysis 6.7.3 Research & Development Expense 6.7.4 Recent strategies and developments: 6.7.4.1 Approvals and Trials: 6.8 Teva Pharmaceutical Industries Ltd. 6.8.1 Company Overview 6.8.2 Financial Analysis 6.8.3 Regional Analysis 6.8.4 Research & Development Expenses 6.8.5 Recent strategies and developments: 6.8.5.1 Product Launches and Product Expansions: 6.8.5.2 Approvals and Trials: 6.9 Sun Pharmaceutical Industries Ltd. 6.9.1 Company Overview 6.9.2 Financial Analysis 6.9.3 Regional Analysis 6.9.4 Research & Development Expense 6.10. Purdue Pharma L.P. 6.10.1 Company Overview For more information about this report visit https://www.researchandmarkets.com/r/ylbqq7 Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets	https://www.prnewswire.com/news-releases/global-opioids-market-to-2027---size-share--industry-trends-analysis-report-301575007.html	2022-06-24T22:14:17Z	https://www.prnewswire.com/news-releases/global-opioids-market-to-2027---size-share--industry-trends-analysis-report-301575007.html	true	6
Incyte Corporation (NASDAQ:INCY) Q1 2020 Earnings Conference Call May 5, 2020 8:00 AM ET Company Participants Michael Booth - Divisional Vice President of Investor Relations and Corporate Social Responsibility Hervé Hoppenot - Chairman, President, and Chief Executive Officer Barry Flannelly - Executive Vice President, General Manager, US Steven Stein - Executive Vice President, Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Dashyant Dhanak - Chief Scientific Officer Conference Call Participants Marc Frahm - Cowen & Company Cory Kasimov - JPMorgan Salveen Richter - Goldman Sachs Brian Abrahams - RBC Tyler Van Buren - Piper Jaffray Vikram Purohit - Morgan Stanley Matt Phipps - William Blair Tazeen Ahmad - Bank of America Jay Olson - Oppenheimer Michael Schmidt - Guggenheim Mara Goldstein - Mizuho George Farmer - BMO Capital Markets Reni Benjamin - JMP Securities Christopher Marai - Nomura Operator Greetings, and welcome to the Incyte 2020 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded. I would now turn the conference over to your host, Mike Booth, Head of Investor Relations. You may begin. Michael Booth Thank you, Kevin. Good morning, and welcome to Incyte’s first 2020 earnings conference call and webcast. The slides used today are available for download on the Investors section of incyte.com. I am joined on the call today by Hervé, Barry, Steven and Christiana, who will deliver our prepared remarks, and by Dash, who will join us for the Q&A session. During the question-and-answer session, I ask that you limit yourself to one question, and if needed one follow-up, as this will enable as many of you to ask questions as time allows. Before we begin, I’d like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for 2020 guidance, the commercialization of our products, and our development plans and expectations for the compounds in our pipeline, as well as the development plans of our collaboration partners. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our 10-K for the year ended December 31, 2019 and from time to time in our other SEC documents. In addition, I would like to caution everyone that COVID-19 pandemic is an evolving situation, and as it's still relatively early to be able to assess the full impact of governmental, business and social actions and policies and overall economic conditions on our business. Accordingly, it is important to keep in mind that our statements on this webcast speak as of today. We'll now begin the call with Hervé. Hervé Hoppenot Thank you, Mike, and good morning, everyone. I hope that all of you and your families are safe and healthy. During this unprecedented and uncertain time, it's evident that the COVID-19 pandemic has had a profound impact on almost every aspect of people's lives and has affected businesses all around the world. Before we begin, I want to take a moment to thank the millions of people who are at the frontline, from doctors, nurses to all other essential workers who are continuing to provide their much needed services. With this pandemic at the forefront of everyone's mind, I want to start our earnings call by providing an update as it relates to the COVID-19 impact on four areas of our business, namely our commercial, supply, regulatory, and clinical operations. When we enacted our global business continuity plans over two months ago, our key priorities were to ensure that patients continue to receive their life-saving medicines that we continue to provide our customers a support they need and importantly to do this in a manner that minimizes the health risk to our employees and our customers. I'm proud of the team here at Incyte for continuing to deliver throughout this period, and I'm extremely grateful to those working on-site to maintain our critical operations. Today, there has been no impact on our commercial business, and we saw continued strong performance in the first quarter. We have ample drug supply and our manufacturing processes are proceeding without interruption. On the regulatory front, there has been no impact to-date on key timelines. We recently announced one of our three anticipated approvals in 2020, and we continue to expect FDA decision on both capmatinib and tafasitamab in the coming months. We do not expect disruption to other key regulatory timelines, including the NDA submission of ruxolitinib cream for atopic dermatitis at the end of the year. With regards to clinical development, as of today, while our late-stage programs remain broadly on track, we anticipate that short-term effects may continue to emerge across different aspects of our global clinical trial programs, including new patient recruitment. The degree of impact may vary by disease state and by severity of disease as well as by geography as some regions are more adversely impacted. In terms of our effort to help address this pandemic, we have recently initiated the global Phase III RUX-COVID trial in partnership with Novartis to assess ruxolitinib in patients with COVID-19 associated cytokine storm. In the U.S., we are also starting another trial, evaluating ruxolitinib as a potential treatment for COVID-19 patients who are on mechanical ventilation. We have also opened an emergency expanded access program, which will allow eligible patients with severe COVID-19 to receive ruxolitinib. Studies are also ongoing with baricitinib where Lilly has recently entered into an agreement with the National Institute of Allergy and Infectious Diseases, which is part of the NIH, to study baricitinib as an arm in its COVID-19 clinical trial. Multiple investigator-initiated trials for both ruxolitinib and baracitinib are ongoing and planned as part of the global evaluation of whether JAK-inhibition plays a role in improving outcomes in COVID-19. Turning to our first quarter performance. The results reflect the benefit of our long-term strategy and our execution on the plans we have previously laid out. In the first quarter of the year, we continued our strong commercial execution with Jakafi achieving 22% growth over the first quarter of last year to reach $459 million and total product and royalty revenues growing by 24% year-over-year to $569 million for the quarter. Our financial position is also strong with $1.3 billion in cash at the end of Q1 2020. In the recent months, we also made significant progress on the regulatory and clinical development fronts. We recently received FDA approval of Pemazyre, which brings another inside discover molecule to market, and provides further testament to the strong R&D capabilities we have here at Incyte. By the end of 2020, with our respective collaboration partners, Novartis and MorphoSys, we could see two additional new product approvals with capmatinib as a treatment for certain patients with metastatic non-small cell lung cancer and tafasitamab for relapsed refractory DLBCL, both of which are under priority review with the FDA. In addition, we presented positive data from our TRuE-AD Phase III program at the revolutionizing atopic dermatitis conference, and we remain on track to submit an NDA for ruxolitinib cream at the end of the year. Despite the uncertainties brought down by COVID-19, I remain confident about our future prospects as we continue to execute on our goals. Slide 6 shows our ongoing revenue momentum over the last several years with four sources of revenue driving topline growth. We will be adding a fifth revenue stream following the recent approval of Pemazyre. Looking to the remainder of 2020, our key priorities are to maintain our revenue momentum and to drive continued growth of Jakafi in the U.S. We are also focused on executing a successful launch of Pemazyre, which Barry will cover shortly and preparing for the potential FDA approval of tafasitamab. Our LIMBER development program remains a key priority, and we are working towards the planned initiation of our BET and ALK2 programs and the expected opening of the pivotal RUX plus parsaclisib trial. 2020 is shaping to be a transformational year for Incyte, and I look forward to updating you throughout the year. I'll now pass the call over to Barry who will provide more detail on both first quarter Jakafi performance as well as our commercial activities for Pemazyre. Barry Flannelly Thank you, Hervé, and good morning, everyone. Slide 8 shows strong growth of Jakafi quarter-over-quarter, mostly driven by increases in patient volume. As expected, gross to net was much higher in Q1 due to our portion of the donut hole we are responsible for under Medicare Part D and the increase in TRuE-AD out-of-pocket cost or Troop that began in 2020. The chart on the right shows the total number of patients on therapy across all three indications. The total number of patients and new patients treated with Jakafi for MF, PV, and GVHD continues to grow. In GVHD, Jakafi is rapidly becoming the standard of care in the steroid-refractory acute setting. We are very pleased to have REACH2 published in a New England Journal of Medicine, underscoring the importance of Jakafi as a treatment option for patients with steroid-refractory acute GVHD. In the 300-patient randomized REACH2 trial, ruxolitinib demonstrated a 62% overall response rate versus 39% seen with best available therapy. REACH2 was the first randomized trial to show a benefit in this hard-to-treat patient population and showed convincingly that ruxolitinib was more effective than investigators' choice of therapy from a list of nine commonly used options in patients in whom steroid therapy had bailed. We also applaud the FDA for granting full approval of ruxolitinib last year based on the single-arm REACH1 trial. Results from REACH3 are study evaluating ruxolitinib in the steroid-refractory chronic GVHD are expected in the second half of this year. Our long-term outlook for Jakafi remains positive. Patient demand remains strong, and as a result, we are reiterating our guidance for the full year. It is during this time, however, that we must stay focused and work even harder to engage our customers to provide them with continued support and to drive disease awareness. We have much success in implement - we've had much success in implementing our digital and virtual strategies, and our top priority is to ensure that patients are able to receive their medicine. Our commercial focus in the U.S. remains on the success of Jakafi, and we take these learning’s and apply similar methods to our launch of Pemazyre. Pemazyre is the first treatment innovation for patients with cholangiocarcinoma in 25 years, and represents an important addition to our portfolio of oral cancer medicines. We have launched Pemazyre and are focusing on a targeted group of approximately 1,000 physicians, two-thirds of which are already prescribing Jakafi. This allows our commercial team to leverage existing relationships, helping to facilitate part of the promotional effort behind Pemazyre. We will also drive health care professional interaction through our virtual programs and digital promotional assets, building on some of the existing strategies we are already successfully utilizing with Jakafi. Our sales, market access and medical affairs teams are actively scheduling virtual appointments with our customers and are using the technology in place to share resources and materials in virtual meetings. All of these efforts complement our ongoing unbranded, educational campaign focused on cholangiocarcinoma. And of course, as more patients are treated with targeted therapies like Pemazyre, it's increasingly important to continue to educate and promote appropriate FGFR testing in order to enable the proper identifications of those patients who stand to benefit most from Pemazyre. While we appreciate that the commercial potential for cholangiocarcinoma may be relatively modest, every patient we can help matters. So we are also developing pemigatinib in other tumor types that are driven by FGFR alterations. With that, I'll turn the call over to Steven. Steven Stein Thanks, Barry. And good morning, everyone. Starting with ruxolitinib cream, we were very pleased to share with you the positive results from our Phase 3 TRuE-AD program at the revolutionizing atopic dermatitis conference a few weeks ago. As you can see on the graphs on the left, ruxolitinib cream achieved clinical and statistical significance in the primary endpoint of investigator global assessment treatment success, or IGA-TS at week eight. Similarly, clinical and statistical significance was demonstrated in a 75% reduction in the eczema area and severity index score or EASI-75, and in the analysis of the four-point reduction in the itch numerical rating scale, or NRS4, which is what the FDA has defined to be a meaningful endpoint in terms of itch reduction. With the highest concentration of 1.5%, we see substantial and more importantly, a very rapid reduction of itch with RUX cream within 12 hours of initiation of therapy. The strength of these data show ruxolitinib cream has been able to demonstrated motive action anti-inflammator and antipyretic activities, which together could make for a very effective therapy. As it relates to safety, there were no notable safety findings, either locally or systemically that were associated with treatment. We are on track with the development timelines for ruxolitinib cream. The long-term safety data have been collected and we continue to expect to submit the NDA for ruxolitinib cream at the end of this calendar year. The vitiligo trials remain ongoing and we continue to expect data in 2021. Turning now to Pemazyre. Pemazyre was approved based on data from the FIGHT-202 study, where treatment with pemigatinib resulted in an objective response rate of 36%, and a median duration of response of over nine months in patients with FGFR2 fusions or rearrangements. The most common adverse event was hyperphosphatemia, most of which was low-grade and manageable. The full data set from FIGHT-202 was recently published in the set we are very proud to offer a therapy for patients living with cholangiocarcinoma, where prognosis is poor and where there's been limited treatment options to date. We continue to study pemigatinib in clinical trials for bladder cancer, an 8p11 myeloproliferative neoplasm as well as the tumor-agnostic indications. Now turning to efforts in COVID-19. Cytokine storm is a severe immune overreaction that can be triggered by a viral infection and leads to serious complications, including acute respiratory distress syndrome, which is a form of respiratory failure that is one of the leading causes of mortality in COVID-19 patients. Patients with severe COVID-19 experience massive immune in filtration with associated pro-inflammatory cytokines, ultimately leading to damage. Many of the elevated pro inflammatory cytokines that perpetuate the cytokine storm, exemplified by interferon gamma, IL-6, GM-CSF and G-CSF signal either through JAK1 or JAK2. We believe that treating cytokine storm with ruxolitinib as an inhibitor of both JAK1 and JAK2, may mitigate COVID-19 associated cytokine storm and thus reduce the overall disease burden. We recently initiated our RUX-COVID program to evaluate ruxolitinib as a potential therapy for patients with COVID-19 associated cytokine storm. Our team in collaboration with our partners at Novartis initiated a global Phase 3 program. We anticipate recruiting approximately 400 patients with COVID-19 associated cytokine storm in RUX-COVID. And we'll be evaluating ruxolitinib, 5 milligrams BID plus standard of care versus standard of care alone. The composite primary endpoint is the proportion of patients who die, develop respiratory failure, require mechanical ventilation or acquire ICU care by day 29. We are also opening a second Phase 3 trial in the United States, the 369 trial that will evaluate ruxolitinib in patients with acute respiratory distressed syndrome secondary to COVID-19. ARDS is a type of respiratory failure, characterized by rapid onset of widespread inflammation in the lungs. And this trial will this trial will evaluate two doses of ruxolitinib, 5 milligrams BID and 15 milligrams BID and is expected to recruit around 500 patients. The key difference between RUX-COVID and the 369 trial is that patients in the former are not on ventilation, whereas those in the 369 trial are on mechanical ventilation. My last slide is our news flow summary. As you can see, we have begun the year well and have already announced several important milestones, including positive Phase 3 data from ruxolitinib cream and the recent FDA approval of premise. With that, I would like to turn the call over to Christiana for the financial update. Christiana Stamoulis Thanks, Steven. And good morning, everyone. The financial update this morning will include GAAP and number. For a full reconciliation of GAAP to non GAAP, please refer to slide 25 and 26 in the backup section of the deck and to the press release we issued this morning. Before turning to our results for the quarter, I'd like to review the accounting treatment for collaboration with MorphoSys. As a reminder, our collaboration with MorphoSys has two components. The co-development and co-commercialization of tafacitamab by Incyte and MorphoSys in the U.S. and the exclusive development and commercialization of tafasitamab by inside – outside the U.S. In terms of how we will be accounting for the collaboration, if tafacitamab is approved, MorphoSys will record will record all sales in the U.S. and Incyte will record wholesales outside the U.S. Our COGS will include only COGS outside of the U. S. as well as royalties payable to MorphoSys on net sales outside the U.S. Our R&D expense will include a 55% share of global and U.S.-specific development costs as well as 100% of any development costs, specific to territories outside the U.S. In addition, it will include any upfront and milestones that are payable prior to approval. Our SG&A expense will include only our commercialization cost for tafacitamab outside the U.S. Finally, we will record our 50% of the U.S. net commercialization profit or loss as a single line item in our financial results, as a revenue item when it constitutes as net profit or an operating expenses items when it constitutes a net loss. COGS and all costs associated with the commercialization efforts related to tafasitamab in the U.S. will be included in this profit or loss sharing line, not in the COGS and SG&A expense line. Now moving to our results for the first quarter. Revenue growth continued to be strong across all products, with total product and royalty revenues of $569 million, representing an increase of 24% over the first quarter of 2019. This is comprised of $459 million in Jakafi and $27 million in exclusive net product revenues, $56 million in Jakafi royalties from Novartis and $25 million in Olumiant royalties from Lilly. Our total cost and expenses for the quarter on a non-GAAP basis of $1.2 billion include the $805 million related to the upfront consideration to MorphoSys, which consisted of a $750 million upfront payment and $55 million premium on our purchase of MorphoSys stock. Excluding our R&D upfront and milestone expenses, total COGS, ongoing R&D and SG&A expenses for the quarter was $371 million on a non-GAAP basis. Ongoing R&D expense for the quarter was $251 million on a non-GAAP basis, representing a 3% increase from the prior year quarter. SG&A expense for the quarter was $98 million on a non-GAAP basis, representing a representing a 12% decrease over the entire year quarter. This was primarily due to the timing of certain expenses. Collaboration loss for the quarter was $2.1 million, which represents a 50% share of the U.S. net commercialization loss for tafasitamab. Our financial position continues to be strong as we ended the quarter with $1.3 billion in cash and marketable securities. The decrease from $2.1 billion at 2019 year-end reflects the upfront payment and stock purchase related to the MorphoSys collaboration, partially offset by the cash flow generated during the quarter. Moving on to our guidance for 2020, we are reiterating our revenue, COGS, R&D and SG&A expense guidance for the year. While Jakafi had exclusive performance in the first quarter was strong, the COVID-19 situation presents uncertainty. Therefore, we believe it is prudent to retain the full range of the previously communicated revenue guidance of $1.88 billion to $1.95 billion for Jakafi and $100 million to $105 million for Iclusig. For R&D, we are reiterating our previous guidance of $1.21 billion to $1.28 billion. As a result of reallocation funds between programs in our portfolio, we now expect this to cover also our 55% share of tafasitamab co-development costs. For clarity, this guidance range excludes the $805 million upfront consideration recoded in Q1 related to our collaboration with MorphoSys. Finally, at this early stage, we will not be providing guidance of Pemazyre sale or on our collaboration, net profit or loss resulting from the commercialization activities for tafasitamab in the U.S. Operator, that concludes our prepared remarks. Please give your instructions and open the call for Q&A. Question-and-Answer Session Operator Certainly. We’ll now be conducting a question-and-answer session. [Operator Instructions] Our first question is coming from Marc Frahm from Cowen & Company. Your line is now live. Marc Frahm Yes. Thanks for taking my questions and congratulations on the quarter. Maybe a question for Steven. It seems like we're going to be getting a decent amount of data out of the LIMBER program over the next six, nine months. Maybe if you can set the stage there. When we see PI3-kinase data in the first half, should we think of that as setting kind of the bar for all other combos to warrant advancement or do you think the combinations are likely to be effective in kind of different patient populations, and therefore they kind of need to be evaluated all on their own? Steven Stein Hi, Marc, it's Steven. Thanks for the question. So, obviously, as Hervé alluded upfront, I mean, this remains of critical importance to us and of major focus to us. And thankfully, despite the pandemic remains on track as well. In terms of this year's execution, there are three aspects beyond everything else going on in LIMBER, one is to get the monotherapy safety components of ALK2 and the BET program done and moved to the combinations of RUX plus ALK2 and RUX plus BET. And then as you alluded to, is start the pivotal Phase 3 of RUX plus PI3-kinase delta. They are slightly different. We don’t have a biomarker selection per se, but they're different intents behind the program. So if you look at ALK2, the combination there, it's important to both focus on enhancing efficacy, which we expect. But also safety in terms of anemia there and hopefully ameliorate the anemia through the hepcidin inhibition , which then would translate to being able to maintain ruxolitinib dosing and hopefully also enhance efficacy. So it's a dual play in that aspect. In terms of BET BRD inhibition, obviously, we've watched the consolidation data evolve both in the first-line and later settings. And if some maturity of that data needed, and we have to make sure there are apple-apple comparisons as much as possible in terms of patients treated, but the idea is to do the same thing there in terms of enhance the efficacy of ruxolitinib in those settings, particularly in second line and potentially in first line as well. And obviously, we'll just see where the data leads us in terms of getting that combination done as efficiently as possible. For delta, we very carefully built that data set. We've done different experiments with scheduling and dosing, we've now come down to the constant dosing being the way to go in terms of delta. In terms of the magnitude of the dose, we think we've weaved the therapeutic ratio correctly in terms of getting the efficacy we need from delta inhibition, but not the enhanced toxicity from it, and that's why we're initiating the Phase 3 studies. The bars may well end up being somewhat different in first line versus later lines. I think as we speak today, the first-line bar in terms of spleen volume response, which we set with ruxolitinib years ago remains a 35% measured reduction plus associated symptom reduction. In later line settings, we'll see as we work with regulators, whether a lower bar may be acceptable, for example something like a 20% screen volume reduction with associated clinical benefit in other endpoints like symptoms, and that remains to be worked out with regulators. So the programs are full steam ahead as much as possible given COVID-19, and we're confident that they are in a good place and then have slightly different intents to all three programs. Marc Frahm Okay. And if I can do a follow-up based on that. You mentioned one of the big things is the BET inhibitor getting eventually into a combination. In the press release, it says you're preparing a Phase 2, does that mean you started combination dosing already or is that Phase 2 the beginning of combination dosing? Hervé Hoppenot So Marc, just to remind you, we had a numerous BET inhibitors in the clinic over the last few years. We put ourselves on a hold from on target thrombocytopenia a little over a year ago and then sort of resurrected that second BET inhibitors to go into the clinic now. So, what I'm saying is we know that compound pretty well. Obviously, now we're dosing at a much smaller absolute dose in terms of about a 20% to 30% dose range versus what we were in the clinic before and expected on target toxicity should obviously be much less. We just need to prove that to ourselves hopefully relatively efficiently with monotherapy and then start the combination as soon as possible, so that will be the Phase 2 component, if you will, will be when we move into the combination part. But I think the semantics aren’t that important, what you call it here because it's about just getting sufficient safety and then go into combination as efficiently as possible. Marc Frahm Okay. Thank you. Operator Thank you. Our next question is coming from Cory Kasimov from JPMorgan. Your line is now live. Cory Kasimov Hey. Good morning, guys. Thank you for taking my questions. I wanted to ask you about your work that you're doing in COVID-19. And I guess, first, do you have much insight into the time lines for RUX in the COVID-19 studies, especially CRS? And when you're thinking about standard-of-care, do you think you're going to have to build remdesivir into your protocols? And then secondly, I recognize this isn't the primary purpose of this work, but can you discuss any general thoughts you have about the potential market opportunity if RUX were to ultimately be approved here? Thanks. Steven Stein So Cory, it’s, Steven. I'll start off and then hand it over to Herve for your second question. So again, there are two studies. There's RUX-COVID, the global study with Novartis in patients who are sick in hospital with evidence of elevated cytokines, but not ventilated yet, [indiscernible] hopefully not. And then the second protocol, the 369 protocol is in ventilated patients, and we're testing two dose levels there. We knew that the standard-of-care would likely evolve and would evolve relatively rapidly, so we routed in allowing standard-of-care in combination with the treatment arm, in this case, ruxolitinib as well as the standard-of-care arm to be as dictated on the day. So it's open to whatever would have evolved and very much had prepared for remdesivir being the potential standard -of-care, which it looks like it is now. So there's no issue related to that. What we will have to watch from a statistical point of view, obviously, is that the arms full with appropriate numbers of both patients. But given where we're conducting the studies in Europe with Novartis and here in the United States with us and the sites that are involved, we expect that to be the case, and remdesivir would be rapidly adopted as a standard-of-care and wouldn't be a problem. There's no interaction to worry about in terms of drug-drug interaction with that particular antiviral and ruxolitinib. So we're ready to do that. And then for the market opportunity part, I'll hand it over to Hervé. Hervé Hoppenot Yeah. Thank you. So first, I mean, obviously, we hope that it would be a relatively short-lived phenomenon. So frankly, we don't see COVID-19 as a commercial opportunity of any magnitude for ruxolitinib. We moved very fast. I mean, there is a very strong preclinical rationale. There is a lot of work that was done already with JAK inhibition in CRS from CAR-T treatment. So there is a very good science. We had the certainties, both at Novartis and Incyte, work together to put the program in place. And frankly, it was very interesting to see the speed at which we were able to work on this with Novartis, where we made the decision to go into the protocol on the phone with Velcea [ph] in a few minutes. We had the team's work over the weekend to get the protocol be prepared so that it could be submitted. And the speed at which everything moved was really driven by the emergency of trying to find a solution for this pandemic on the COVID-19 situation around the world. We think over time -- and then we put in place an already access program in the US that will be ease up already and will be providing the opportunity for all patients to receive ruxolitinib as part of this protocol free of charge. So that's where we are. The Phase 3 studies are starting. We will have the results, I assume, in Q3 and then we will work with the FDA to see what we do from there. But from our side, we don't it as a meaningful market opportunity. Over time, I think it's really trying to deal with the situation that we are all facing. Cory Kasimov All right. Great. Thanks so much for taking the question. Operator Thank you. Next question is coming from Salveen Richter from Goldman Sachs. Your line is now live. Salveen Richter Good morning. Thanks for taking my question. The first one maybe for Hervé. How are you thinking about capital allocation and BD strategy in the context of your launch outlook? You've got three this year and potentially three to four next year. And then given the pipeline outlook as well? And then a second question here with Pemazyre. Can you discuss how the groundwork around the launch in cholangiocarcinomas that you up for bladder cancer? Thank you. Hervé Hoppenot Yeah. So I'll let Barry speak about Pemazyre. On the capital allocation and the BD strategy, I think we are very much in a mode that has been demonstrated by what we have done over the past few months. I mean, we are trying to continue to build a portfolio that will grow our revenue line, continue to grow the revenue line at a fast pace over the next five, six years, so that we have a diversified portfolio in 2025 -- in that window, 2025 to 2030. I think the agreement with MorphoSys is a good example of that. It's synergistic from the commercial standpoint. It's dealing with the customer base that we know very well in hematology. It's adding a new product to our hematology portfolio, and it has a large potential to contribute to our revenue growth. So we will continue to look for that type of opportunity. There is a dermatology field that is also now the second divisions that we have -- that we are building. So it could be another place where if there are good opportunities in that field where we could also invest. We have a strong cash position now. We also have a very strong cash flow. So that's really the drive for our capital allocation and strategy is to continue to grow the revenue and diversify the portfolio with a target in the years 2025 to 2030 as a sort of where we want to see the impact of these new products and these investments. Barry Flannelly So the second part of your question, Salveen. So Pemazyre launch is going very well. We are very proud of the company that we got approved on a Friday night by the FDA, and we had drug in our distribution center. By Sunday, and we shipped out drug on Monday. So descriptions are coming in for Pemazyre. And to-date, we have no indication that there's been any problem with market access or payers not paying for it. So in our sense, it's actually going very well despite the fact and we're doing a virtual launch, and we've learned lots of things. We've been doing virtual activities, digital activities, for Jakafi for a while now, and we're getting even better on it for Pemazyre. So that's going very well. For bladder cancer, the most important thing for cholangiocarcinoma and then for bladder cancer is that physicians are, in fact, testing for FGFR alterations. And we think that as we continue to work to educate health care professionals on making sure they're testing in cholangiocarcinoma situation for FGFR2 fusions or rearrangements, that, that will then have us set up very well from moving to bladder cancer because, again, the most important thing is to identify the most appropriate patients that could benefit from Pemazyre in bladder cancer, when we have the data available. Salveen Richter Thank you. Operator Thank you. Our next question is coming from Brian Abrahams from RBC. Your line is now live. Brian Abrahams Hi. Thanks very much for taking my question. I guess a question on the commercial side for Barry. Just wondering if you're seeing any changes in prescription patterns for Jakafi exiting first quarter and maybe early in second quarter as a result of COVID-19, things like accelerations of refills or fills, longer duration scripts, any impact on compliance in either direction? And I'm wondering also if you're starting to see any impact to GVHD as transplant practices evolve. Thanks. Barry Flannelly Sure, Brian. So for the first part of your question is have we seen any changes in the amount of drug that patients are getting, and the answer is no. Generally speaking, all of our patients on Jakafi get a 30-day supply, that's particularly for MF or PV and that's there was only about 3% of patients that actually might receive a prescription for more than 30 days supply, and that hasn't changed. At least in the first quarter, and now moving into second quarter, we haven't seen any changes for that. As opposed to new patients starts, again, first quarter we had a very good first quarter. New patient starts were very good. And in fact, that should be able to carry us through for the next couple of quarters until we get back to a more normal state. So we're very confident in that sense. You know, there might be some indications those high-impact areas, whether it's for GVHD, MF or PV. So places like New York City, for example, you might see a slowdown in new patients start. But in fact because we are on oral therapy that's well-known, has been on the market for GVHD and of course, for MF and PV for long period of time. Those refills and those patients are coming back and that’s why we are still confident in our guidance that we provided today. Brian Abrahams That’s really helpful. Thanks. Operator Thanks. Our next question is coming from Tyler Van Buren from Piper Jaffray. Your line is now live. Tyler Van Buren Hi. Thanks. Good morning. I had another question on rux for COVID-19. So, I guess, recently had a call with Palm Nages [ph], who is the Head of an ICU COVID-19 taskforce and she was discussing the history of immunomodulators and respiratory distress syndrome. And clearly, CRS here manifesting a respiratory distress is a little different than CRS that you see with cell therapy. And see mentioned that immunomodulators historically have every single therapy or every single trial has failed in respiratory distress syndrome. So I guess, I want to ask you guys why maybe that history is not relevant here and why COVID-19 is different? Steven Stein Yes, Tyler, it's Steven. Thanks for your question. And it's always good -- to have these learnings from prior studies invoked. You know, I think, the central difference here and I have to be careful of just catching semantic labels to things that then apply to other things. If you look biologically and pathophysiologically at what’s going on, on the information we have out of China and now other places, in these patients there is elevation, moderate elevations of cytokines that have been documented like IL-6. There is evidence of acute phase reactants going up like [indiscernible] C-reactive protein and ferritin as well. And then -- we have evidence that with drugs like ruxolitinib, you can use appropriately suppress dose. And then -- the question is, will they translate to a clinical improvement in that setting. So just to be clear, it's not across the board for every single patient with this entity. These RUXCOVID is for sick patients in hospital, who are pre-ventilation, but have biochemical evidence of cytokine storm or cytokine elevation and acute phase reactants been positive, and then are randomized to ask the question very clearly. And in this setting, induced by COVID-19 does [indiscernible] those cytokines result in the clinical improvement. And it's different from ARDS due to other entities that in the past may have caused it. And that's why I think it's a key question to ask. And then you've seen the IL-6 data evolve. I mean now the question is beyond -- direct IL-6 inhibition there's a more broad inhibitor like JAK inhibitor like ruxolitinib or in – or baricitinib, able to modulate this cytokine elevations and then have a clinical benefit beyond that will be answered in the these randomized studies. So I think your word of caution is good, but this is a different entity, and we have to be careful of some of the semantics. Tyler Van Buren That's helpful. And maybe just a brief follow-up. As we think about JAK’s inhibition in comparison to IL-6 is there any reason to believe that JAK inhibition will be better? Dashyant Dhanak Yes. This is Dash. I will take that question. So, yes, in principle, as Steven mentioned, with something like an IL-6 antibody, you're only really blocking the one cytokine that's led to be involved in the disease process with something like JAK inhibition -- excuse me, you're now targeting multiple cytokines, which you know all signal downstream through, the JAKAFI pathway. So in principle, we would argue. And I think there's data out there to support this, that by going further downstream of targeting multiple cytokines, you should have a big event effect than targeting a single, protein that we know involved in the process. Tyler Van Buren Great. Thanks for taking my question. Operator Thank you. Our next question is coming from Vikram Purohit from Morgan Stanley. Your line is now live. Vikram Purohit Hi. Good morning. Thanks for taking my question. So I had a couple on tafacitamab. And so first, I first, I wanted to see if the MAA submission is still on track for mid-2020, in the EU? And secondly, I wanted to see if COVID-19 related disruption is having any impact to your build-out of the team and infrastructure, you'll eventually need to be commercializing tafacitamab in Europe. And lastly, for the initial Phase-I data I believe we're expecting, in first-line DLBCL by the end of the year. What can we expect to see there? And how should we frame our expectations for what the benchmark, should be there? Steven Stein So Vikram, its Steven. I'll do your first and third question. And then the commercial question, someone else will take. So just to cut to the chase, in terms of the MAA filing, yeah, it's completely on track. And we have had no problems getting that together and getting ready to submit it appropriately. In terms of first-line diffuse large B-cell lymphoma, the Phase I looks at the regimen of tafasitamab the Care Standard, R-CHOP. And its safety profile there versus tafa plus R-CHOP alone without the LIM addition. That is ongoing and that we should have data by the end of the year to then enable a decision on which of those two regimens should potentially be used against R-CHOP, in a larger randomized Phase III first line study. So that remains on track to be done, the safety component. Hervé Hoppenot And maybe I can speak about Europe and maybe Barry can speak about the U.S., which is coming sooner. So in Europe, we are at the stage of the submission. So we are sort of targeting next year. And as you know, we have in place a team in haematology, today already. We will be expanding that team and we hope and we expect that the expansion will take place after the confinement has been lifted in that case. If it's not the case, obviously, it will lead us to a different direction. Regarding the U.S. and the prep for the U.S., maybe Barry can say a word more. Barry Flannelly Sure. So obviously, we're co promoting with Morphosys. So MorphoSys has their team fully in place already, sales, medical, market access and so forth. We actually have our medical affairs and market access team in place. And in fact, they're actively bringing on our salespeople. As far as COVID-19 goes, in our current situation, it's a very good time actually for them to train and become experts in diffuse large B-cell lymphoma and tafacitamab, if they're not already there. So training continues to go on in action with health care professionals goes on, as we continue to prepare for this launch. But -- and we don't think it will interfere with it and even if we have to a lot of our launch of tafacitamab virtually. We're fully prepared to do that as well. Vikram Purohit Okay. Thank you. Operator Our next question is coming from Matt Phipps from William Blair. Your line is now live. Matt Phipps Good morning. Thanks for taking my questions, two quick ones on the I-O programs. Just the decision to not start a stage three non-cell lung cancer trial, I think that's probably prudent. But how do you think you get a return on investment with your PD-1 antibody? And then as a follow-up for the oral compound, when you see data late this year, is there a potential to kind of quickly advance this to later stage trials, if you hit kind of a pharmacodynamic and safety profile? Are we going to just move to a kind of mid stage expansion indications going more? Hervé Hoppenot Yeah. Maybe I can take the first question on the antibody on the PD-1 antibody 012, and Steven can speak about the perspective on the project for and the rest of the portfolio of on the oral products. I think if you remember, I mean, the rationale at the beginning, that is still totally true is that it is very useful as a portfolio to have a PD-1 antibody that you can combine with other products that would be potentially used in the same patient population. The typical example would be FGFR in bladder cancer, but there are many other combination that are being done and I think that rationale is a absolutely true. On top of it, we have the so-called niche indication program that where we could have in the relatively short-term potential for an approval of the product. So this is ongoing and doing well. And then we had this program in lung cancer and where we have one of the two Phase 3 studies in lung cancer in first line non-small cell lung cancer is ongoing. And we decided not to do the other one, mainly because the design of the study was such that it would be problematic to gain FDA approval without doing a study that was extraordinarily large or very risky. So we are in a situation where we believe there is a clear rationale of having an antibody anti-PD-1 in our portfolio, where we have a short-term opportunity with some of the niche indication. And we have to take a little bit more time, the potential to have that product approved in the first-line treatment of non-small cell lung cancer, and that would give us overall an ROI that would be very satisfying on top of strategic opportunity also to have a springboard for our oral PD-1 program. So I will let Steven speak about the oral program. Steven Stein Thanks, Hervé. In terms of the oral PD-L1 inhibitor, the number we call 550 been in the clinic for a little over a year now, obviously, started off with the first-in-human dose escalation to get to a recommended Phase 2 dose. That we know is in the pharmacologically active range in terms of PD-L1 inhibition and what we want to see in the tumor microenvironment as well. And then move on to treating tumors, which, in broadly speaking, we call benchmarking. But looking at areas that are potentially I-O naive settings like lung, melanoma, where we can treat those patients in that part of the world, and that's going on now to get that data to see the efficacy bars, the efficacy signals that we get from the drug in those various entities. Once we're able to look at that this year, internally, we would then decide, do we have proof of concept, where it exists and where to go. And the way we then approach it, which is the meat of your question is what are the rapid registration approaches then once we have internal proof-of-concept and where we want to go and chase those various entities, and then look more broadly, given that it's an oral therapy, given that it lends itself to maintenance and adjuvant settings, again, if we've achieved proof of concept, have the efficacy we've seen, look at those bigger Phase 3s in those sort of settings and then include potentially large tumor types as well. But the program continues to progress well. And we're enrolling patients as we speak in the benchmarking setting to work as quickly as we can to proof-of-concept. And I think we've demonstrated once we hit that and once we're comfortable internally, we could move to later trials very quickly. Matt Phipps Thank you. Operator Our next question is coming from Tazeen Ahmad from Bank of America. Your line is now live. Tazeen Ahmad Good morning. A couple of questions. Going back to Jakafi estimates for the year. On reiterating your guidance, I just wanted to get a little bit of color on your thoughts maybe about mix, can you give us an idea of what percent of sales right now are coming from Medicaid? And what part of maintaining guidance assumes that, that proportion stays the same. And I'm asking this question. Because the unemployment rate that we temporarily has picked up higher, how does that come into your calculations about revenue streams from Jakafi for the rest of the year? And then a pipeline question, if I might also ask, what have you been able to learn from the launch of BALVERSA? And the reason for this question is more to get a sense of how you're thinking about hemi second indication in urothelial and if there's any learnings you've gotten from that? Thank you. Hervé Hoppenot Sure, Tazeen. So as far as our mix of patients, so I guess, in this situation, we're fortunate that most of our patients are in fact covered by other government programs, Medicare Part D, Va, DOD, Tricare and so forth. Our commercial patient population is about 30%, 35% that makes up. And yes, Medicaid is really only about 4% of our payer mix right now. Could it go up? Sure. But again, if it's like 30%, it's going to go up 10%, we really don't think it's a big factor at all. And as we go forward with our forecasting for the rest of the year and the guidance that we provided today, we'll have to see. Obviously, there's uncertainty there. But nevertheless, we think we're okay with reinforcing our current guidance. As what we learned from BALVERSA, I don't know what we've learned. We haven't heard a lot from Janssen or at least I haven't heard left from Janssen, they don't seem to be releasing their sales on BALVERSA themselves. And the most important thing perhaps is that they're continuing to educate on testing for FGFR alterations that could help us in the future. Operator Thank you. Our next question is coming from Jay Olson from Oppenheimer. Your line is now live. Jay Olson Hi. Thanks for taking the question. Curious about your work in dermatology. What are the gating factors to filing your topical RUX NDA for atopic dermatitis? And then what are your plans to build your dermatology commercial infrastructure? And for vitiligo, how is that study enrolling? And how has it been impacted by COVID-19? Thank you. Steven Stein Jay, Steven. Again I will do your first and third question and someone will take your middle one. So in terms remember, the atopic dermatitis studies have completed enrollment. Obviously, we've presented the data now, and we alluded to it in the prepared remarks. And we're moving full steam ahead to get that file in place. We were slightly worried about the impact of COVID-19 on the ability to go to sites, monitor and grab the data. But we haven’t had any problems to date and that’s why we said on the prepared remarks, we remain on track to do that submission by the end of this year. That remains the plan, and it's full steam ahead on that. It's why the end of the year, it's to wait for the safety follow-up. So we need that adequate range of safety follow-up from the last patient as to make the complete submission and get it in by the end of the year. In terms of the vitiligo studies, they were enrolled really well. There's a minor impact from COVID-19. But as Hervé said on his remarks, which I think are really important to remind you, different parts of the world have impacted at different times. And again, our studies remain on track there, and we remain on track to deliver those studies in 2021 as planned. Hervé Hoppenot On the commercial plan, so what we have said and it's still very true today is, in the US, we are in the process of building a team. So we have already an excellent clinical development team that is in place. We are looking at all the other components of what will be a commercial group that is of high-quality with a lot of experience in the field with market access, with medical affairs and with the commercial group. So all of that is that is ongoing. You heard the timeline. The submission is planned for the end of this year. So you can expect the end of next year as being the potential launch date, and so we are on track to doing that. Outside of the US, frankly, we are looking at many different optionalities, which could be going alone in Europe or having a partner and both options are still open, and we have discussions on going to identify what would be the best way to do it. I can tell you following the excellent data we had in atopic dermatitis. It certainly stimulated a lot of interest. And I would say for the rest of the world, we are more certain that we will need a partnership instead of building, and we are also looking at the right timing for putting these partnerships in place for Asia and some other regions of the year. So the plan is really being executed now, and it's in good shape. And for the US, as we said, I mean, the build-up of the commercial team is already starting with the first component with market access and some marketing people. Operator Thank. Our next question is coming from Michael Schmidt from Guggenheim. Your line is now live. Michael Schmidt Hey. Thanks for taking my questions. Maybe just going back to bladder cancer, could you just remind us of peers profile there and how you think it might compare not only to Balversa, but also to other recently launched drugs such as itacitinib [ph] genetic process. And then the second question was going back to tafacitamab and the US launch. We've obviously seen some early FDA action recently. And I was just wondering, more curious about potential overlap here in terms of marketing with your current Jakafi target market and the utilization of that sales force for launching itacitinib in the US? Steven Stein So Michael, it's Steven. I'll take your first question and thank you for it. So again, in terms of bladder cancer and FGFR3 being the driver there, obviously, we have the monotherapy data, both with intermittent dosing and continuous dosing coming in and looking at it. We already spoke on call a couple of weeks ago that there has been some COVID-19 impact and our ability to gather that data in house and present to it. So it's more likely in early 2021 that we'll have that monotherapy data for you. We have an ongoing first-line study in combination with a PD-1 inhibitor with pembro. And obviously, you alluded to how does it fit in, in terms of the Seattle drug. And we'll have to see. Again, this is a targeted agent for FGFR3 and there may be evolving cash standard, and we'll have to watch carefully, and we may have to change the first-line study as that market evolves and that profile of treating patients evolve. But we're on track in terms of getting that bladder data early next year. What's very important to us, though, is the tumor-agnostic program, given the potential ability to impact multiple different cancers with multiple different histology’s is enrolling incredibly well and there we’ve seen a little to no COVID-19 impact there. We're able to find those patients and get them into that study, and that's going to be important to our overall life cycle management of the drug. And then for your next question, I'll hand it over to Barry. Barry Flannelly Yes, Michael. So your comment about the FDA and approvals, we're prepared anytime between now and the PDUFA date to launch tafacitamab and yes, actually, the nice thing about tafacitamab and diffuse large B-cell lymphoma overlaps completely with our current target population for myelofibrosis, polycythemia, vera and GVHD. Michael Schmidt Great. Thank you and congrats on the progress. Operator Our next question is coming from Mara Goldstein from Mizuho. Your line is now live. Mara Goldstein Great. Thanks for taking the question. I appreciate it. Just on GVHD and Jakafi, do you have a sense of how the duration of treatment has evolved at this point? And then, I just had a question on the LIMBER program. And when you look at the totality of that program, do you see it enhancing the overall number of patients that can be brought into the MF population. Hervé Hoppenot So, I will take it for part and hand it over to Steven for the second part. So, duration of therapy, all we really have to go by it. It's a little bit harder to get the duration of therapy for GVHD than it is for MF and PV for example. But so, we just go by the clinical trials and approximately six months is what we believe for the duration of therapy for acute steroid-refractory GVHD Steven Stein And for your second question in terms of the LIMBER program and the potential ability to reach more patients with MF, I think the clean answer is yes. So, let me give you an example. So if you look at ALK2, one of the main reasons patients -- the small number of patients that discontinued therapy is due to the development of anemia that becomes unmanageable if the ALK2 effect on hepcidin inhibition works and manages that, then patients won't experience that. We'll be able to stay on drug and get extra benefit from it. In addition, it would open up potentially patients who can't go on drug, being able to be treated then with the combination. So that's one good example. If you look at our formulation work, the XR formulation, the once-daily formulation, I mean there's potentially convenience there in terms of once-daily being better for patients, although that hasn't been an issue to date, but that's a potential upside. In addition, if ultimately that drug has a -- because of its PK effect and having the less [indiscernible] that ends up having a flatter profile in terms of the induction of anemia, that's another issue where in MF patients there may be increased use there. And then lastly, I'll just add, beyond everything, whether it's with BET or with Delta, if you have the desired enhanced efficacy, then treating physicians will overall be more likely to use your product in that setting. So the clean answer on, yes, if we get everywhere we want to get, I think, is pretty clear. Mara Goldstein Thank you. I appreciate it. Operator Our next question is coming from George Farmer from BMO Capital Markets. Your line is now live. George Farmer Hi. Good morning. Thanks for taking my questions. Wondering, Hervé, if you can comment a bit more on the PD-1 strategy. What are your commercial expectations in front-line lung cancer and can you elaborate at all on any more -- on any of the niche indications that you had mentioned? Hervé Hoppenot So yes, as we said, the niche indications are relatively small in terms of the number of patients for each of them. They are potential way to have to product approved which could be very important for many other aspects of the program and the combination with some of our pipeline products, et cetera. In the first line non-small cell lung cancer, as you know the approach we have is a mid- to approach in the first-line treatment of patients receiving chemotherapy in non-small cell lung cancer. So it will be chemo plus 012 versus chemo and if this is successful and allows us to get FDA approval in that indication, it will give us a position where it will become an alternative to existing treatment in that setting. And frankly, it's such a large number of patients that we believe it can be productive from the revenue standpoint. It is also an opportunity to develop our oral PD-1 in the right setting, because as you can imagine, if you give chemotherapy to a patient, it's not the right place to use an oral PD-1 versus an IV PD-1, while after the chemotherapy is over, they are 18 months of treatment with single-agent injectable antibody that could be obviously better managed with an oral product. So there is a scenario where it will help us organize the treatment of patients with non-small cell lung cancer, where you receive chemo plus an injectable PD-1, and then you can have the consolidation of the next months of treatment being done with an oral product. So there is a number of ways where this can fit very well with our portfolio. And where by itself, it is not a small number of patients in first-line lung cancer. There are a number of ways where we could gain market share, just by having the approval in that indication. George Farmer Okay. Thanks very much. Operator Thanks. Our next question is coming from Reni Benjamin from JMP Securities. Your line is now live. Hello, Reni, perhaps your phone is not mute, please pickup your handset, if you can hear me, we cannot hear you. Reni Benjamin Hey, good morning. Thanks for taking the questions and congratulations on the quarter. Maybe for Steven, can you talk a little bit more about the data collection and validation disruptions on-site 201, is that something that's particular to that study and shouldn't impact other studies? Or if it could impact other studies like a true the -- what kind of measures you have in place to prevent that from happening? And then as a follow-up, maybe for Barry, I keep getting amazed like by the growth in MF. Every time I think we're hitting a plateau. You continue to find more patients. I see that it looks like about 8,000 patients for MF; 4,500 for PV; and 1,500 for GVHD roughly. Can you just talk a little bit more about how much growth you might potentially see in the MF and where these patients are coming from? Thanks. Steven Stein So Ren, it's Steven. I'll start. So across the board, there has obviously been a COVID impact on the program. In particularly, obviously, in places like New York City in terms of the ability to get studies done there and access sites to get data. And I think for fit 201, the particular issue was to try to get it ready to present it in a median in the second half of this year in time, just to meet those median time lines, and we realized from a site access point of view in terms of getting it in, we're just not going to be able to do that in a timely manner. So that's the issue peculiar to that related to the particular median and nothing more than that. Hervé Hoppenot Barry? Barry Flannelly So Ren – yes, so MF continues to be the backbone, even though PV continues to grow faster quarter-over-quarter in terms of new patients or total patients, but MF certainly hangs in there, 8,000 patients might be right. We think the prevalent population is 15,000. Obviously, we have about 3,500 to 4,500 new MF patients a year. But I think mostly it's because we're starting new patients earlier, physicians recognizing that when they start earlier, that's when their survival benefit really comes through. And obviously, the duration of therapy, we have many patients that have been on therapy for eight years or more, in fact, so it's really starting patients earlier, getting all the new patients that are newly diagnosed and the duration of therapy. Reni Benjamin Thanks for taking my questions. Operator Thanks. Our next question today is coming from Christopher Marai from Nomura. Your line is now live. Christopher Marai Yeah. Hey, good morning. Just a follow-up on some of your GVHD comment. For Jakafi, I was wondering if you could elaborate on the number of patients treated, whether that's just the acute setting or the acute and the chronic setting? And how do you look at growth going forward given the emerging competitive landscape there for Jakafi and GVHD? Hervé Hoppenot So the number of patients in GVHD, so if it is approximately 1,000 patients, maybe so far that are on it. Obviously, there is spontaneous use of Jakafi in chronic GVHD. So it's -- some of those patients included there. We think the chronic indication that's coming if we get data at the end of this year. Towards the end of this year for REACH 3, it's very important for the continued growth in that patient population. But Jakafi, as we said at the beginning in the prepared statements that it's fast becoming the standard-of-care in acute steroid-refractory GVHD. Some of the other studies, some of the other drugs that are being developed in acute GVHD or chronic GVHD so far that has been necessarily pivotal data, compelling data that would -- we would think – we would interfere with the current use of Jakafi in steroid-refractory or in chronic GVHD. Christopher Marai Okay. And then just thinking about your PD-1 antibody in some of those combination that you alluded to, when might we start to see some of the first combination data and perhaps what combination data would you be looking at as potentially most exciting relative to, I guess, combinations with your current internal pipeline? Thank you. Steven Stein Yeah. Thank you. Christ, its Stephen. Hi. So as Hervé said, the three niche tumours are on track, swelling cholangiocarcinoma, MSI-high endometrial and the Merkel. And then lung program, the -- what we call the sort of clone study is on track as well. But in addition, and thanks for bringing it up, there are multiple studies ongoing, looking at combinations preparing for the future here, if you will, on how to use the PD-1, so both with external compounds like JAK inhibitors. But internally as well, one that would be of particular importance to us is the FGFR combination. Those are enrolling now. And I expect we will present data in the next year. So it's more likely in 2021, you will be seen the data in medium. But we will getting enabling safety work with older than as we speak over this calendar year. Christopher Marai Okay. Thank you. Operator Thank you. We’ve reached the end of our question-and-answer session. I'd like to turn the floor back over to Mike for any further or closing remarks. Michael Booth So thank you all for your time today and for your questions. Of course the IR team will be available throughout the day for any follow-up questions you may have when we look forward to talking to you at our investor conferences in the coming weeks. But for now, we thank you again for your participation in the call today. And stay sage and have a good day. Operator Thank you. That does conclude today's teleconference. You may disconnect your line at this time. And have a wonderful day. We thank you for your participation today.	https://seekingalpha.com/article/4343257-incyte-corporation-incy-ceo-herve-hoppenot-on-q1-2020-results-earnings-call-transcript	2022-06-24T22:15:08Z	https://seekingalpha.com/article/4343257-incyte-corporation-incy-ceo-herve-hoppenot-on-q1-2020-results-earnings-call-transcript	true	1
Ukrainian troops say they destroyed Russian battalion tactical group. This item is part of our running news digest May 21, 2022 11:47 pm The group was liquidated while attempting to cross the Siversky Donets river near the village of Serebryanka in Donetsk Oblast, Ukraine's 30th Mechanized Brigade said. The Ukrainian soldiers said they had destroyed dozens of Russian troops and several units of equipment, as well as a pontoon bridge.	https://kyivindependent.com/news-feed/ukrainian-troops-say-they-destroyed-russian-battalion-tactical-group	2022-06-24T22:17:58Z	https://kyivindependent.com/news-feed/ukrainian-troops-say-they-destroyed-russian-battalion-tactical-group	false	null
The District 1 region of the American College of Obstetricians and Gynecologists, covering New England, called the Supreme Court decision to overturn Roe v. Wade, “a direct attack on the patient-physician relationship,” in a press release on Friday. On Friday, the Supreme court ruled to overturn Roe v. Wade, the landmark case that legalized abortion in its decision regarding Dobbs v. Jackson Women’s Health Organization. The organization claimed Dobbs v. Jackson will put physicians in fear of retribution for providing “lifesaving care.” “Physicians and practices in our country, depending on their location, will either be overwhelmed by an influx of patients forced to delay care to travel hundreds of miles away from their communities or will be forced to contradict their years of training and ethical obligations by withholding evidence-based care,” the group said the press release. Additionally, the organization states this “legislative decision” will not stop at abortion. The group fears that the “chilling effects” of Dobbs will impede miscarriage, ectopic pregnancy management and care for patients with pregnancy. Furthermore, this decision may lay the framework to target other essential care like contraception and gender-affirming care, according to the group. In a statement, conservative Supreme Court Justice Clarence Thomas stated the Supreme Court had a “duty” to review precedents including gay marriage and access to contraception. Marginalized communities will also be harmed the most by the Dobbs decision from the Supreme court, the organization stated. The American College of Obstetricians and Gynecologists states that it, “is committed to mitigating the fallout of this decision” by accommodating patients outside of its borders and advocating for patients and colleagues. Related Stories: - Roe v. Wade: US Supreme Court overturns abortion rights decision - Massachusetts abortion laws: If Roe v. Wade is overturned, how would state’s residents be affected? - Supreme Court set to strike down abortion rights: report	https://www.masslive.com/news/2022/06/roe-v-wade-overturned-new-england-region-of-american-college-of-obstetricians-and-gynecologists-condemns-ruling.html	2022-06-24T22:18:03Z	https://www.masslive.com/news/2022/06/roe-v-wade-overturned-new-england-region-of-american-college-of-obstetricians-and-gynecologists-condemns-ruling.html	true	1
Quick links: Image: BCCI/Twitter Dashing stroke-players Suryakumar Yadav and Sanju Samson will be returning to the India playing XI in place of Shreyas Iyer and Rishabh Pant in the two-match T20I series against Ireland starting Sunday. While chief coach Rahul Dravid is in Leicester with the Test squad, National Cricket Academy (NCA) head VVS Laxman, who is in charge of the T20I side for this particular series, is expected to follow the template set by 'The Wall'. With Iyer and Pant in the Test team, Surya, who is making a comeback from a wrist injury, and Samson, who is looking to make use of what could be his last chance to prove his worth, will be sure-shot starters. Surya has been a regular in the Indian T20I side for the past one year and will only get his place back. But as far as Samson is concerned, his alternative could be Deepak Hooda, who can also bowl a couple of overs of handy off-spin, besides possessing an ability to hit the ball hard. However, if one looks at coach Dravid's philosophy, he doesn't believe in casting his net too wide and exploring too many options. He also needs to close in on spots by the time India play the Asia Cup. While Ruturaj Gaikwad has not been very successful, the Chennai Super Kings opener might just get two more chances against a weak Ireland side, against whom he can score some runs and get his confidence back. Ishan Kishan, who has all but sealed the reserve opener's slot for the next few months, will continue in his role for the time being and will open with regular skipper Rohit Sharma in the England leg of the T20Is also. Stand-in captain Hardik Pandya, who batted at No. 5 in the last series, is expected to continue in that position with Dinesh Karthik coming a slot below him. However, with Karthik being assigned a specific role, he could also come ahead of Pandya, depending on the situation. But it is still not clear if Dravid or Laxman will try out 'Jammu Express' Umran Malik or blockhole specialist Arshdeep Singh in this series, or continue with Bhuvneshwar Kumar and Avesh Khan, with Axar Patel and Yuzvendra Chahal as the spinners. (Disclaimer: This story is auto-generated from a syndicated feed; only the image & headline may have been reworked by www.republicworld.com)	https://www.republicworld.com/sports-news/cricket-news/india-vs-ireland-will-sanju-samson-umran-malik-and-arshdeep-singh-get-a-chance-in-t20i-series-articleshow.html	2022-06-24T22:19:18Z	https://www.republicworld.com/sports-news/cricket-news/india-vs-ireland-will-sanju-samson-umran-malik-and-arshdeep-singh-get-a-chance-in-t20i-series-articleshow.html	true	5
NASA put an asteroid mission on hold Friday, blaming the late delivery of its own navigation software. The Psyche mission to a strange metal asteroid of the same name was supposed to launch this September or October. But the agency’s Jet Propulsion Lab was several months late delivering its software for navigation, guidance and control — a crucial part of any spacecraft. Engineers “just ran out of time” to test it, officials said Friday. Now the space agency is going to step back, and an independent review will look at what went wrong, when the spacecraft could launch again and even if it should go ahead, NASA planetary sciences chief Lori Glaze said. NASA has already spent $717 million on Psyche and its projected total cost, including the rocket to launch it, is $985 million. The small car-sized spacecraft was originally supposed to arrive at its asteroid in 2026 after a journey of more than 1 billion miles. Now that the software has been delivered, there’s no known problems with the spacecraft except “we just haven’t been able to test it,” said Lindy Elkins-Tanton, the Psyche mission lead scientist. “There is that one challenge we couldn’t overcome in time to launch in 2022 with confidence,” she said. There are still at least two launch opportunities next year and more in 2024 to get to the asteroid that sits in the belt between Mars and Jupiter, said JPL Director Laurie Leshin. That means Psyche wouldn’t arrive at its asteroid until 2029 or 2030. But calculating launch times is complicated because the mission needs the proper sunlight conditions and the asteroid “is spinning like a rotisserie chicken instead of like a top,” Elkins-Tanton said. Two other small missions were going to ride along on the SpaceX Falcon heavy rocket and NASA is looking at what will happen to those. Psyche is just the latest in NASA’s fleet of asteroid-exploring spacecrafts. Osiris-Rex is on the way back to Earth with rubble from the asteroid Bennu. Last year, NASA launched the ships Lucy and Dart to explore other space rocks and test if a rocket could knock off course an asteroid heading smack into Earth. ___ Follow Seth Borenstein on Twitter at @borenbears ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.	https://www.mytwintiers.com/hooked-on-science/ap-science/nasa-asteroid-mission-on-hold-due-to-late-software-delivery/	2022-06-24T22:19:29Z	https://www.mytwintiers.com/hooked-on-science/ap-science/nasa-asteroid-mission-on-hold-due-to-late-software-delivery/	true	27
Vincent Kompany accepts he has taken charge at Burnley at a “delicate and dangerous” time but is determined to turn the relegated Lancashire club around. The new Clarets manager has also confirmed he hopes to add Craig Bellamy, his former Manchester City team-mate who had a spell with rivals Blackburn, to his backroom staff at Turf Moor. Kompany was named as Sean Dyche’s permanent successor last week. The task ahead is daunting one with Burnley facing financial difficulties and having lost some key players since dropping out of the Premier League at the end of last season. Yet after guiding Anderlecht to successive third-placed finishes in what he feels were difficult circumstances, the 36-year-old is not fazed. “It’s really a very delicate and dangerous period of time when you’ve got these transitions,” said Kompany. “You can fall very far down or go very quickly back up. “The difference between (going) left and right is massive, (but it’s) just small details. “Obviously in my previous job I ended up the wrong side of it, we’d already gone too far down the wrong path and I can see it cripples the club. We are on the brink. That’s why I came here – to turn a corner.Vincent Kompany “There’s nothing you can do, you want to get players but you can’t and you have to sell players. That’s why I rated the job I did at Anderlecht as a fantastic job. “The advantage we have right now is we are on the brink. That’s why I came here – to turn a corner.” Kompany is keen to have former Liverpool, Newcastle and Wales striker Bellamy alongside him in the dugout. Bellamy played alongside Kompany at the Etihad Stadium from 2009-11 and also had a spell working alongside him in Belgium. “He’s one of the rumours that were actually correct, after the pics got out,” said Kompany at his first Burnley press conference on Friday. “He’s someone I have huge respect for. He’s incredibly gifted and he’s a typical misunderstood guy who gives so much. If I can have him with me, I will.” As a player Kompany won four Premier League titles with City, two of them coming under the guidance of the inspirational Pep Guardiola. Asked what he had learned from the Spaniard, Kompany said: “I met this fantastic coach, the best in the world and the simple thing I took from him was, not a style of football, but that he was the very best at telling his players why they were doing things on the pitch.” Kompany feels Burnley at least have better facilities than City had when he signed there prior to their takeover by Sheikh Mansour in 2008. He said: “This club is 10 times better. That’s a state-of-the-art facility (with) fantastic pitches, everything we need to be extremely demanding with the players. “It’s an incredible work environment but it’s a different era. Every club has invested since.” Kompany spent well over an hour speaking to media and did not shy away from one difficult subject. In 2020 a fan controversially organised a plane to fly over the pitch during a Clarets match towing a banner which read ‘white lives matter Burnley’. Kompany said: “If you start judging an entire organisation and the people and players because a couple of idiots are flying a banner… “You come in and you work hard together and build something. Sometimes you change mentalities in that way. “I’ve come in to coach a football club, to write a story. I always stay by my principles no matter what. There’s no way I would associate the football club with this.”	https://www.independent.ie/sport/soccer/i-am-here-to-turn-a-corner-vincent-kompany-says-burnley-are-at-dangerous-point-41788218.html	2022-06-24T22:21:18Z	https://www.independent.ie/sport/soccer/i-am-here-to-turn-a-corner-vincent-kompany-says-burnley-are-at-dangerous-point-41788218.html	true	12
The Denver Nuggets selected UCLA freshman Peyton Watson with the 30th selection in the 2022 NBA Draft. At 6’8” 200 lbs. with a 7’0” wing span Watson is a very athletic, bouncy wing with upside potential. In his only season with UCLA, the freshman logged 12.7 minutes, 3.3 points, and 2.9 rebounds per game. Watson did not earn as many minutes as he would have liked, but he was sitting behind the upperclassman of a UCLA team that made the elite eight for two straight seasons. In summary, Watson is a raw prospect at the young age of 19. With that being said, he does have the athletic tools to compete in the NBA. He does not profile to be a score-first player, instead, his current strengths lie on the defensive end. Although Denver desperately needs defensive help this upcoming season, it is expected that Watson refines his skills with Denver’s G-League affiliate Grand Rapids Gold until he is ready to grace the NBA hardwood. NBA Comparison: When I think of Peyton Watson, I see a Derrick Jones Jr./ Herb Jones type of player. His current skillsets relate more to Derrick Jones Jr with his supreme athleticism and unrefined offensive game. Herb Jones was a more NBA-ready prospect coming out last season, but Watson has all the tools to impact the game at the level Jones did for the Pelicans last season. Pros Although Watson might not be the most skilled wing in the draft, he is one of the most athletic. He has quick twitch, bouncy movements that are ideal for defending NBA wings and guards. His natural talent allows him to guard 1-4 with quick feet, and his lanky frame can provide tight contests of jump shooters. The most exciting part of his game to Nuggets fans should be his ability to block shots and create steals. Per 40 minutes, he averaged 1.9 blocks and steals per contest, so if he is given adequate playing time, his defensive prowess will be on display. Peyton Watson SWATTED that ❌ pic.twitter.com/CmhQWA8iFZ — ESPN (@espn) January 26, 2022 Many offensive actions are tailored around the screening game in the NBA and Watson has the ability to prevent such actions. He is slippery in these situations, so he can slip screens fairly smoothly, and his quick twitch ability will allow him to recover quickly. At the wing position, he is also a very strong rebounder, averaging 9.1 rebounds per 40 minutes. Take a look at Peyton Watson here. Active hands, skinny through screens. Absolute monster possession of on ball defense here. pic.twitter.com/TUJDRwV3N0 — Larry Golden (@_LarroHoops) July 5, 2021 Although Watson has struggled with his jump shot, he is still capable of being a force on the offensive end. Some scouts say he has underrated ball-handling ability which has created success in straight-line drives to the rim, and he has shown soft touch around the rim to finish over taller defenders. It is not great touch just yet, but it is there. Scouts also praise his feel in the passing game. He is an unselfish player who can be too unselfish at times, but in this Nuggets system, it is imperative to be able to analyze the entire floor. Cons His largest weakness to this point appears to be his scoring efficiency. He shot 32% from the field and 23% from three in his freshman season. Since he has the ability to create in ISO situations, he has been prone to hoisting questionable shots, but that notion can be understood when he was not entirely sure of his role with that UCLA team. Although some say he can provide strong basketball IQ, he does have the tendency to over-dribble resulting in turnovers. Scouts say this is a product of his inclination to rush shots, as he has not appeared to be a comfortable, smooth jump shooter just yet. Another weakness is his frame, but that is a con to the majority of draftees. He is lightweight for his size, and if he does not build more weight and strength, he will be taken advantage of when bigger players get their bodies into him. The NBA is moving towards positionless basketball and that is exactly what Watson is— a positionless prospect. With that ability of course comes the responsibility to guard all positions. He has the raw talent to do so at a college level, but at the NBA, he will need to fill out before he can handle stronger players at both ends of the court. Expectations The appears to be a pick for the future. Yes, I am like many of you Nugget fans who wanted an NBA-ready player or to trade those first-round picks into a proven veteran piece. Although that did not seem to happen with this pick, we should not turn our back on this prospect. Kevin Durant tweeted during the draft, “It’s a wings league.” Yes, Watson is a raw prospect, but his athleticism is rare, and if the Nuggets can develop him correctly for a couple of years, this could be a steal in the draft. With that being said, Denver’s championship window is closing as other Western Conference foes continue to enhance their chances at a ring. It is expected by many that Watson does not suit up for the Nuggets for a couple of years, so this pick does not help them win a championship this season. But I will end on this note. We have no idea the mentality that is in between the ears of Peyton Watson. He already has the raw talent to compete at a high level. He did not receive adequate playing time at UCLA, so he could be playing with a chip on his shoulder. We’ve seen players like Gary Payton II and Alex Caruso come out of the G-League and impact winning, championship basketball. Today’s society is so focused on immediate results, we often forget the process that forges champions. Since high school, Watson has added more than 20 lbs. to his frame, so he has shown the will to improve. If Peyton Watson is truly a hungry, gritty player we so often yearn for in Denver, he could be another fan favorite and possibly a piece that helps Denver compete for a championship.	https://www.denverstiffs.com/2022/6/24/23181850/denver-nuggets-nba-draft-2022-first-round-ucla-peyton-watson-champiosnhip-defense-block	2022-06-24T22:21:21Z	https://www.denverstiffs.com/2022/6/24/23181850/denver-nuggets-nba-draft-2022-first-round-ucla-peyton-watson-champiosnhip-defense-block	false	1
Español Italiano Français My Account My Account Notifications Log In QQQ – –% DIA – –% SPY – –% TLT – –% GLD – –% BTC/USD – –% Data & APIs Events Marketfy Premarket Contribute Español Italiano Français Sign in News Earnings Guidance Dividends M&A Buybacks Legal Interviews Management Retail Sales Offerings IPOs Insider Trades Biotech/FDA Freight Politics Government Healthcare Markets Pre-Market After Hours Movers ETFs Forex Cannabis Commodities Options Binary Options Bonds Futures CME Group Global Economics Previews Reviews Small-Cap Cryptocurrency Penny Stocks Digital Securities Ratings Analyst Color Downgrades Upgrades Initiations Price Target Ideas Trade Ideas Long Ideas Short Ideas Technicals From The Press Jim Cramer Rumors Best Stocks & ETFs Best Penny Stocks Best S&P 500 ETFs Best Swing Trade Stocks Best Blue Chip Stocks Best High-Volume Penny Stocks Best Small Cap ETFs Fintech News Podcast Events Newsletter Personal Finance Compare Online Brokers Stock Brokers Forex Brokers Futures Brokers Crypto Brokers Options Brokers ETF Brokers Mutual Fund Brokers Index Fund Brokers Bond Brokers Short Selling Brokers Stock Apps All Broker Reviews Insurance Auto Home Medicare Life Vision Dental Business Pet Health Motorcycle Renters Workers Comp Top Stocks Penny Stocks Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $50 Stocks Under $100 Alternative Investing Invest in Art Invest in Land Invest in Real Estate Invest in Wine Invest in Gold Mortgages Refinance Purchase Find a Mortgage Broker Alts Best Real Estate Crowdfunding Platforms REITs Versus Crowdfunding How to Invest in Artwork Best Alternative Investments Best Alternative Investment Platforms Crypto Get Started Is Bitcoin a Good Investment? Is Ethereum a Good Investment? What is Blockchain Best Altcoins How to Buy Cryptocurrency? DeFi Crypto and DeFi 101 What is DeFi? Decentralized Exchanges Best DeFi Yield Farms Digital Securities NFTs NFT Release Calendar What is a Non-Fungible Token (NFT)? How to Buy Non-Fungible Tokens (NFTs) CryptoPunks Watchlist Are NFTs a Scam or a Digital Bubble? Best In Crypto Best Crypto Apps Best Crypto Portfolio Trackers Best Crypto Day Trading Strategies Best Crypto IRA Best Cryptocurrency Scanners Best Business Crypto Accounts Best Crypto Screeners Cannabis News Earnings Interviews Deals Regulations Psychedelics TV YouTube Video Podcasts Trading School Personal Finance Compare Online Brokers Stock Brokers Forex Brokers Futures Brokers Crypto Brokers Options Brokers ETF Brokers Mutual Fund Brokers Index Fund Brokers Bond Brokers Short Selling Brokers Stock Apps All Broker Reviews Insurance Auto Home Medicare Life Vision Dental Business Pet Health Motorcycle Renters Workers Comp Top Stocks Penny Stocks Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $50 Stocks Under $100 Alternative Investing Invest in Art Invest in Land Invest in Real Estate Invest in Wine Invest in Gold Mortgages Refinance Purchase Find a Mortgage Broker Alts Best Real Estate Crowdfunding Platforms REITs Versus Crowdfunding How to Invest in Artwork Best Alternative Investments Best Alternative Investment Platforms Crypto Get Started Is Bitcoin a Good Investment? Is Ethereum a Good Investment? What is Blockchain Best Altcoins How to Buy Cryptocurrency? DeFi Crypto and DeFi 101 What is DeFi? Decentralized Exchanges Best DeFi Yield Farms Digital Securities NFTs NFT Release Calendar What is a Non-Fungible Token (NFT)? How to Buy Non-Fungible Tokens (NFTs) CryptoPunks Watchlist Are NFTs a Scam or a Digital Bubble? Best In Crypto Best Crypto Apps Best Crypto Portfolio Trackers Best Crypto Day Trading Strategies Best Crypto IRA Best Cryptocurrency Scanners Best Business Crypto Accounts Best Crypto Screeners Cannabis News Earnings Interviews Deals Regulations Psychedelics TV YouTube Video Podcasts Trading School My Stocks Tools Calendars Analyst Ratings Calendar Dividend Calendar Conference Call Calendar Earnings Calendar Economic Calendar FDA Calendar Guidance Calendar IPO Calendar M&A Calendar Retail Sales Calendar SPAC Calendar Stock Split Calendar Trade Ideas Insider Trades Trade Idea Feed Analyst Ratings Unusual Options Activity Heatmaps Short Interest Most Shorted Largest Increase Largest Decrease Calculators Margin Calculator 100x Options Profit Calculator Premium QQQ – –% DIA – –% SPY – –% TLT – –% GLD – –% BTC/USD – –% WILLIAMSBURG INVESTMENT TRUST (Form24F-2NT) Accepted: Form Type: 24F-2NT Accession Number: 0001580642-22-003196	https://www.benzinga.com/secfilings/22/06/27831259/williamsburg-investment-trust-form24f-2nt	2022-06-24T22:21:24Z	https://www.benzinga.com/secfilings/22/06/27831259/williamsburg-investment-trust-form24f-2nt	true	254241
NEW YORK (AP) — There is now a second COVID-19 option for kids ages 6 to 17 in the U.S. The Centers for Disease Control and Prevention on Friday announced it is recommending Moderna shots as an option for school-age kids and teens. This group has been able to get shots made by Pfizer since last year. CDC sets the federal government’s vaccine guidance for U.S. doctors and their patients. Last week, the Food and Drug Administration authorized the shots — full-strength doses for children ages 12 to 17 and half-strength for those 6 to 11. The doses are to be given about a month apart. An expert advisory panel this week voted unanimously to recommend that CDC endorse the Moderna shots, too. Moderna officials have said they expect to later offer a booster to all kids ages 6 to 17. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.	https://www.mytwintiers.com/news-cat/health-news/moderna-covid-19-shots-now-an-option-for-older-kids-in-us/	2022-06-24T22:21:35Z	https://www.mytwintiers.com/news-cat/health-news/moderna-covid-19-shots-now-an-option-for-older-kids-in-us/	true	31
Español Italiano Français My Account My Account Notifications Log In QQQ – –% DIA – –% SPY – –% TLT – –% GLD – –% BTC/USD – –% Data & APIs Events Marketfy Premarket Contribute Español Italiano Français Sign in News Earnings Guidance Dividends M&A Buybacks Legal Interviews Management Retail Sales Offerings IPOs Insider Trades Biotech/FDA Freight Politics Government Healthcare Markets Pre-Market After Hours Movers ETFs Forex Cannabis Commodities Options Binary Options Bonds Futures CME Group Global Economics Previews Reviews Small-Cap Cryptocurrency Penny Stocks Digital Securities Ratings Analyst Color Downgrades Upgrades Initiations Price Target Ideas Trade Ideas Long Ideas Short Ideas Technicals From The Press Jim Cramer Rumors Best Stocks & ETFs Best Penny Stocks Best S&P 500 ETFs Best Swing Trade Stocks Best Blue Chip Stocks Best High-Volume Penny Stocks Best Small Cap ETFs Fintech News Podcast Events Newsletter Personal Finance Compare Online Brokers Stock Brokers Forex Brokers Futures Brokers Crypto Brokers Options Brokers ETF Brokers Mutual Fund Brokers Index Fund Brokers Bond Brokers Short Selling Brokers Stock Apps All Broker Reviews Insurance Auto Home Medicare Life Vision Dental Business Pet Health Motorcycle Renters Workers Comp Top Stocks Penny Stocks Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $50 Stocks Under $100 Alternative Investing Invest in Art Invest in Land Invest in Real Estate Invest in Wine Invest in Gold Mortgages Refinance Purchase Find a Mortgage Broker Alts Best Real Estate Crowdfunding Platforms REITs Versus Crowdfunding How to Invest in Artwork Best Alternative Investments Best Alternative Investment Platforms Crypto Get Started Is Bitcoin a Good Investment? Is Ethereum a Good Investment? What is Blockchain Best Altcoins How to Buy Cryptocurrency? DeFi Crypto and DeFi 101 What is DeFi? Decentralized Exchanges Best DeFi Yield Farms Digital Securities NFTs NFT Release Calendar What is a Non-Fungible Token (NFT)? How to Buy Non-Fungible Tokens (NFTs) CryptoPunks Watchlist Are NFTs a Scam or a Digital Bubble? Best In Crypto Best Crypto Apps Best Crypto Portfolio Trackers Best Crypto Day Trading Strategies Best Crypto IRA Best Cryptocurrency Scanners Best Business Crypto Accounts Best Crypto Screeners Cannabis News Earnings Interviews Deals Regulations Psychedelics TV YouTube Video Podcasts Trading School Personal Finance Compare Online Brokers Stock Brokers Forex Brokers Futures Brokers Crypto Brokers Options Brokers ETF Brokers Mutual Fund Brokers Index Fund Brokers Bond Brokers Short Selling Brokers Stock Apps All Broker Reviews Insurance Auto Home Medicare Life Vision Dental Business Pet Health Motorcycle Renters Workers Comp Top Stocks Penny Stocks Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $50 Stocks Under $100 Alternative Investing Invest in Art Invest in Land Invest in Real Estate Invest in Wine Invest in Gold Mortgages Refinance Purchase Find a Mortgage Broker Alts Best Real Estate Crowdfunding Platforms REITs Versus Crowdfunding How to Invest in Artwork Best Alternative Investments Best Alternative Investment Platforms Crypto Get Started Is Bitcoin a Good Investment? Is Ethereum a Good Investment? What is Blockchain Best Altcoins How to Buy Cryptocurrency? DeFi Crypto and DeFi 101 What is DeFi? Decentralized Exchanges Best DeFi Yield Farms Digital Securities NFTs NFT Release Calendar What is a Non-Fungible Token (NFT)? How to Buy Non-Fungible Tokens (NFTs) CryptoPunks Watchlist Are NFTs a Scam or a Digital Bubble? Best In Crypto Best Crypto Apps Best Crypto Portfolio Trackers Best Crypto Day Trading Strategies Best Crypto IRA Best Cryptocurrency Scanners Best Business Crypto Accounts Best Crypto Screeners Cannabis News Earnings Interviews Deals Regulations Psychedelics TV YouTube Video Podcasts Trading School My Stocks Tools Calendars Analyst Ratings Calendar Dividend Calendar Conference Call Calendar Earnings Calendar Economic Calendar FDA Calendar Guidance Calendar IPO Calendar M&A Calendar Retail Sales Calendar SPAC Calendar Stock Split Calendar Trade Ideas Insider Trades Trade Idea Feed Analyst Ratings Unusual Options Activity Heatmaps Short Interest Most Shorted Largest Increase Largest Decrease Calculators Margin Calculator 100x Options Profit Calculator Premium QQQ – –% DIA – –% SPY – –% TLT – –% GLD – –% BTC/USD – –% PRUDENTIAL INVESTMENT PORTFOLIOS 2 (FormNPORT-P) Accepted: Form Type: NPORT-P Accession Number: 0001752724-22-143538	https://www.benzinga.com/secfilings/22/06/27831269/prudential-investment-portfolios-2-formnport-p	2022-06-24T22:22:12Z	https://www.benzinga.com/secfilings/22/06/27831269/prudential-investment-portfolios-2-formnport-p	false	254241
Everything Jessie James Decker & Estranged Brother John Have Said About Their Family Drama Jun. 24 2022, Published 4:27 p.m. ET From the outside looking in, country crooner Jessie James Decker seems to have it all: a handsome husband (35-year-old retired NFL star Eric Decker), three kids and a booming fashion business — but for years, she's been privately dealing with some heavy family drama, as her brother John James hadn't spoken to his loved ones in years. In a recent social media post, the star, 34, confessed she's been feeling down because of the situation. And though the brood just had a reunion, it seems like the "Wanted" crooner still has some things to work out with her sibling before she can move forward. "I had some family issues a couple years ago that I have struggled with tremendously and still to this day make me break down and cry," the mom-of-three began her post. "I wouldn't never chosen to deal with that publicly and open that door to such a personal family matter, but it happened, and it still hurts my heart. I don't handle social media or trolls like I used to." "During the private family matter a hate page on Reddit developed. I'm ripped apart constantly on a daily basis which kills me a little every day and makes me consider quitting everything sometimes and disappear," she continued, noting she's dealt with body image struggles for years. "With how progressive we are getting in this digital world of preventing bullying, I still don't know how a page like that is allowed and fear my sweet daughter seeing it someday." FIT & FABULOUS! SEE JESSIE JAMES DECKER'S HOTTEST BIKINI MOMENTS: PHOTOS In April, a few months before her candid social media upload, John revealed he and his wife, Ally, had zero communication with Jessie or Eric. Then, the following month, their mother, Karen Parker, held a family reunion, and the dad-of-two spilled some of the details on what went down when appearing on the podcast "The Spillover." "[My mom] wanted us to all be together for our birthday and I was really on the fence about going because I just didn’t want to go and then it be awkward," the fitness guru shared. "But we decided to do that for her. And it was honestly amazing. It was amazing, not only for us, but for the kids as well, like seeing all the kids play together was … it sounds silly to say, but it felt like a dream come true. [The kids are] so loving and so good with one another. So it was really amazing to see." John and Jessie also have sister Sydney, whom he reconnected with as well. "We were there a couple of days prior to me, like, actually seeing Jess and Eric. With Sydney, [we picked up] right where things left off. You know, we were having fun, joking, being stupid like we always have historically together," he said. "But it wasn’t until a couple of days after that we actually saw Jess. And it was just very cordial for the sake of my mother, I’d say. There was definitely no heart to hearts or anything." Though John and Sydney shared some photos from the gathering (seen below) Jessie didn't post any to her own account. None of the siblings have directly addressed what caused the rift, but according to Page Six, a Reddit user claimed that John accused Jessie of "forcing a conversation that wasn’t appropriate." Despite the tiff, John is hopeful for his family's future. "Not even just like for the sake of us, but for the sake of our kids because, you know, I don’t want our little girls missing out on some amazing aunts and uncles and cousins," he said when asked about a potential reconciliation. "So I definitely think it’s a start. A lot of wounds are still left to heal, but I definitely think it’s the start of something great.”	https://okmagazine.com/p/jessie-james-decker-estranged-brother-john-family-drama/	2022-06-24T22:25:51Z	https://okmagazine.com/p/jessie-james-decker-estranged-brother-john-family-drama/	true	1
President Biden will be in Europe for a G-7 meeting in Germany, before he heads to a NATO summit. Secretary of State Antony Blinken is in Berlin on Friday to join a UN conference on food security. Copyright 2022 NPR President Biden will be in Europe for a G-7 meeting in Germany, before he heads to a NATO summit. Secretary of State Antony Blinken is in Berlin on Friday to join a UN conference on food security. Copyright 2022 NPR	https://www.wkar.org/2022-06-24/biden-to-attend-germanys-g-7-meeting-this-weekend-blinken-talks-food-security-at-un	2022-06-24T22:27:38Z	https://www.wkar.org/2022-06-24/biden-to-attend-germanys-g-7-meeting-this-weekend-blinken-talks-food-security-at-un	false	null
Springer (elbow) remains on the bench Friday against the Brewers. Springer hasn't played since leaving Tuesday's game against the White Sox with left elbow discomfort. He underwent imaging Wednesday, the results of which are not yet public. Springer still isn't ready to start even after Thursday's off day, so Raimel Tapia will again start in center field. More News - Blue Jays' George Springer: Receives imaging for elbow • - Blue Jays' George Springer: Officially out Wednesday • - Blue Jays' George Springer: Likely out Wednesday • - Blue Jays' George Springer: Leaves with elbow discomfort • - Blue Jays' George Springer: Productive in Sunday's win • - Blue Jays' George Springer: Gets maintenance day •	https://www.cbssports.com/fantasy/baseball/news/blue-jays-george-springer-wont-start-friday-834292/	2022-06-24T22:30:29Z	https://www.cbssports.com/fantasy/baseball/news/blue-jays-george-springer-wont-start-friday-834292/	false	null
SACRAMENTO, Calif. (KTXL) — Senate President Pro Tem Toni Atkins and Assembly Leader Anthony Rendon introduced Senate Constitutional Amendment 10 earlier this month in response to the leaked Supreme Court ruling on Dobbs vs. Jackson Women’s Health Organization that signaled the highest court in the country was considering allowing states to restrict abortion access. With the Supreme Court’s official ruling being released this Friday that stated abortion access is not a constitutional right, California’s state leaders are certain to reaffirm their campaign to get the amendment on the state constitution. The amendment would prohibit the state government from denying or interfering with a person’s decision to have an abortion or use contraceptives. To get an amendment added to the state constitution is a two-step process that involves the legislature and the state’s voters. First, the Senate and Assembly would need to pass the amendment with a two-thirds vote, meaning 27 votes in the Senate and 53 in the Assembly. The amendment would then be included on the general election ballot in November, where it could pass with a simple majority vote, meaning that it would just need 50% plus one vote. Since SCA 10 was introduced in the Senate on June 6, the legislature has had the amendment on a fast track course. The bill passed through several Senate committees in a matter of days and then passed a Senate floor vote 29-8 on June 20. The amendment was then sent to the Assembly for consideration, where it has so far been approved by the Assembly Judiciary Committee. The amendment must pass the Assembly by June 30 to get onto the November ballot. The full text of the proposed amendment reads: The state shall not deny or interfere with an individual’s reproductive freedom in their most intimate decisions, which includes their fundamental right to choose to have an abortion and their fundamental right to choose or refuse contraceptives. This section is intended to further the constitutional right to privacy guaranteed by Section 1, and the constitutional right to not be denied equal protection guaranteed by Section 7. Nothing herein narrows or limits the right to privacy or equal protection. Sente Constitutional Amendment 10	https://fox5sandiego.com/news/politics/how-far-along-in-the-process-is-californias-constitutional-amendment-related-to-abortion-access/	2022-06-24T22:31:36Z	https://fox5sandiego.com/news/politics/how-far-along-in-the-process-is-californias-constitutional-amendment-related-to-abortion-access/	false	4
Severance star Adam Scott discusses Inni Mark’s reaction to a photo of his wife. The noteworthy Severance series on Apple TV+ has largely built its viral value on big secrets and big revelations. And no moment was more crushing than Inni Mark’s revelation of the truth about his wife in the final episode of “We Are.” Viewers, of course, knew the truth about Auty Mark’s supposedly dead wife Gemma—that she hadn’t actually died and was living on the severance pay floor as Miss Casey’s healthy lifestyle consultant—starting with episode 7. But Inni Mark didn’t find out about it. the full truth until the very tense final moments of episode 9, when he and his colleagues Helly and Irving experienced the outside world for the first time thanks to their covert capture of Lumon’s overtime. Unfortunately, this was the end of the revelations, as Milchik grabbed Dylan and canceled unforeseen circumstances, waking up Mark Auty just at the moment when his inni was telling Devon the truth about Gemma. Outie Mark will no doubt be shocked when, at some point in the second season of Severance, he finds out that his wife is alive and is actually being held captive by Lumon. For his part, Inni Mark was stunned to see the whole truth put together as he looked at his wedding photo and Gemma’s photo during the thrilling climax of the first season finale. In a conversation with Variety, Scott talked about Inni Mark’s feelings at that moment and how his discovery of Lumon’s terrifying deception pushed him even further to losing all faith in his own reality.: I think that for Inni Mark, despite the fact that his views and relationships with this company have changed over the first season, this is a step that he never imagined they would take. Everything is falling apart, and seeing this photo is more than he could have imagined. Of course, the first season of Severance is in many ways the path of Inni Mark, who turns from a naively loyal employee of the company into a skeptical doubter. But his discovery that Lumon apparently faked Gemma’s death, gave her an entirely new identity, and imprisoned her on severance pay certainly raises the stakes for the evil he believes the company is hiding. Scott himself has now confirmed that Inni Mark really completely destroyed his perception of Lumon the moment he discovered a photo of him and Gemma at their wedding and put it all together. Obviously, in the second season of Severance, we will have to delve into the consequences of the discovery of not only Inni Mark, but also the discovery of Helly, whose appearance turned out to be the daughter of Lumon CEO Jayme Egan. Of course, you can’t just go back to the state they were in for most of the first season, when Mark, Helly, Dylan and Irving were idling at their jobs in Lumona, from time to time venturing to make discoveries about goats. For their part, Lumon faced a very serious crisis situation after three of their cut-off workers went out into the outside world and began to learn more than they ever should have known about their real lives. But, of course, Lumon would never cancel the severance program, which means that they will undoubtedly do everything possible to return everything to what it was before Inni Mark made his devastating discovery in the finale of the first season of “The Gap.”	https://www.somagnews.com/severance-adam-scott-talks-about-inni-marks-reaction-to-his-wifes-photo/	2022-06-24T22:33:01Z	https://www.somagnews.com/severance-adam-scott-talks-about-inni-marks-reaction-to-his-wifes-photo/	true	1
The White House has reacted somberly to the Supreme Court ruling that has overturned Roe v. Wade. President Biden said there's little he can do on his own to change the situation. Copyright 2022 NPR The White House has reacted somberly to the Supreme Court ruling that has overturned Roe v. Wade. President Biden said there's little he can do on his own to change the situation. Copyright 2022 NPR	https://www.kdlg.org/2022-06-24/biden-says-it-is-up-to-voters-if-they-want-to-see-abortion-rights-restored	2022-06-24T22:33:55Z	https://www.kdlg.org/2022-06-24/biden-says-it-is-up-to-voters-if-they-want-to-see-abortion-rights-restored	true	null
DETROIT (AP) — Alexander Jefferson, a member of the celebrated Tuskegee Airmen during World War II, has died at age 100, officials said Friday. Jefferson was born in Detroit and remained a lifelong resident. The city announced last fall that it plans to honor him with the Lt. Col. Alexander Jefferson Plaza at Rouge Park where he flew model airplanes as a child. “Col. Jefferson not only represented the best of Detroit and our nation, he represented the very best of humanity,” Mayor Mike Duggan said. In recent years, the Tuskegee Airmen have been the subject of books, movies and documentaries highlighting their courage in the air and the doubts they faced on the ground because of their race. Jefferson, who was Black, flew 18 missions before he was shot down and held as a prisoner of war for eight months in 1944-45. He returned to Detroit and was a teacher and school principal for decades.	https://www.ncadvertiser.com/news/article/Detroit-man-who-was-Tuskegee-Airman-dies-at-100-17264484.php	2022-06-24T22:34:38Z	https://www.ncadvertiser.com/news/article/Detroit-man-who-was-Tuskegee-Airman-dies-at-100-17264484.php	false	13
Groundbreaking ceremony held for Waseca hospital expansion, renovation WASECA, Minn. (KEYC) - A special groundbreaking was held at Mayo Clinic Health System in Waseca Friday. A ceremony kicked off a $4.2 million expansion and renovation of the Emergency Department. Mayo says the finished product will include an improved floor plan and vehicle entry points to increase efficiency. It will also have a new wing of patient rooms and a multi-functional ambulance garage. “This is going to produce an environment for the next several generations of Wasecans to have state-of-the-art facilities in the Emergency Room and really enhance the care that we provide,” stated Waseca Medical Director Martin Herrmann. Mayo says construction will take about a year to complete, and the department will remain fully operational during construction. Copyright 2022 KEYC. All rights reserved.	https://www.keyc.com/2022/06/24/groundbreaking-ceremony-held-waseca-hospital-expansion-renovation/	2022-06-24T22:35:22Z	https://www.keyc.com/2022/06/24/groundbreaking-ceremony-held-waseca-hospital-expansion-renovation/	true	null
Today is the last day, well, at least of classes. The final pieces of culminating assignments and other term work will all wrap up today if they haven’t already done so for some courses. It is hard to believe that 10 months have already passed and it’s almost time for another summer break. Exams begin tomorrow, Thursday, June 23, at 9 am. The second and third period exams will occur on Friday, June 24 at 9 am and 12:30 pm, respectively. Fourth period exams will be held at 9 am on Monday, June 27. The full exam schedule that includes what classes have exams each day can be found on the Guidance 2021-2022 Google Classrooms or MSS’s Instagram or Facebook page. Good luck to all the students writing exams! You got this! An exam joke for you: Father: Why did you get such a low score in that exam? Son: Absence! Father: You were absent on the day of the exam? Son: No, but the boy who sits next to me was! Friday, June 17 was Grade 8 shadow day. Grade 8 students from the Island elementary schools came to MSS to see what the day of a high school student looks like. The day began with introductions to student leaders, Jocelyn Kuntsi, myself (Rachael Orford), Lane Phillips and Katie Chapman, followed by introductions and a few words from Mr. Wiwchar, Ms. McCann, Ms. Marshall and Mr. Theijsmeijer. Grade 8 students and Grade 9 and 10 volunteer mentors then played a huge game of “rock, paper, scissors, cheer” in the gym. After the game, the Grade 8s met up with the mentor they were paired with and headed off to a second period class. For lunch, Mr. Balfe prepared soup, so Grade 8s were welcome to go to the Foods room and see what a high school ‘soup day’ looks and tastes like. To wrap up the day, students were given tours by student leaders which was followed up by some school trivia and freezies for those who answered the questions correctly. We finally have a Spymaster winner! It was many long weeks of students being afraid to sit in the cafeteria and running through the halls trying not to get caught. One by one, participants slowly were eliminated from the game. Finally, as of last week, two people remained—two Grade 12 students as well. Then on Friday, a winner was declared. Congratulations to Zoe Redmond who was officially the last spy standing! Another award was given out to the person who caught the most targets throughout the span of the entire game. The winner of that award was Mr. Debassige. Congratulations! Great job to all the participants of Spymaster, and we hope that everyone had lots of fun! Graduation is in less than a week! Now that the graduation rehearsal has come and gone, it is time for the official ceremony. The ceremony will be held in the gymnasium beginning at 7 pm on Tuesday, June 28. Graduates are to be at the school by 6:15 pm. With all that being said, it is now my pleasure to announce the valedictorian for the MSS graduating Class of 2022. Congratulations to Eliza Ermilova! Joke of the week: An elderly person had serious hearing problems for a number of years. They went to the doctor, and the doctor was able to have them fitted for a set of hearing aids that allowed them to hear 100 percent. They went back in a month and the doctor said, “Your hearing is perfect. Your family must be really pleased that you can hear again.” The person replied, “Oh, I haven’t told my family yet. I just sit around and listen to the conversations. I’ve changed my will three times!” Upcoming events include exams and summer break! Until the next time, “Dream and Believe. Learn and Achieve!”	https://www.manitoulin.com/m-s-s-kids-in-the-halls-29/	2022-06-24T22:35:42Z	https://www.manitoulin.com/m-s-s-kids-in-the-halls-29/	false	1
DEAR NEIL: My red oak’s trunk has a large crack. What should I do to it? Dear Reader: First and foremost, have a certified arborist look at it closely. He or she needs to examine it for any signs of active decay. Many Texas live oaks and red oaks suffered serious damage from the cold of February 2021. Known as “radial shake,” the damage took the form of vertical cracks in the bark that subsequently popped open to expose internal wood of the trees’ trunks. That’s probably what has happened here. Hopefully it’s only in this one spot, although I see bark to the left that looks like it also might be impacted. Don’t pull on bark, however, to see if it’s still attached. It will let you know early enough. If the loose bark extends no more than halfway around the trunk then the tree will likely be able to recover and grow new bark across the wound. Hopefully that will begin soon. That’s one of the things for which the arborist will be looking. Beyond that, there isn’t anything you can do except wait. People are also reading… DEAR NEIL: We’ve been gardening for 60 years and this year, for the first time, no tomatoes. The plants are growing well, but no blooms and, therefore, no tomatoes. They are the variety Celebrity as we always grow. Do you have any idea what the problem might be? We did get them planted late. Dear Reader: The late planning did not help since we turned so hot so early. There is also a possibility that your garden may have more shade than it has had in the past, perhaps from trees that have grown larger. If you are growing tomatoes in the same soil year after year, problems like nematodes can build up in the soil. It’s a good idea to move your crops around. Farmers refer to it as “crop rotation.” I guess it’s also possible that your plants were mislabeled at the nursery, although you would expect any tomato variety, mislabeled or otherwise, at least to bloom. Beyond that, I really don’t have any other brainstorms. If it’s any consolation, a couple of my veteran gardening friends have reported similar experiences this spring. DEAR NEIL: Something is attacking and killing the potted plants on my porch. What is it and what is the treatment? Dear Reader: These are mealybugs. As insect pests go, they are among the most obnoxious. They are soft-bodied scale insects. They migrate in their younger stages and attach to the plants’ stems and leaves and then suck the sap out of the plants’ tissues. Some types of plants are extremely vulnerable, for example, coleus and plumerias and other succulents. They are generally a more serious problem on plants indoors or in greenhouses, but they will occasionally show up on plants in flowerbeds. If you have only a few mealybugs you can generally use a cotton swab dipped in rubbing alcohol to eradicate them. For larger populations, however, you will need to use a properly labeled insecticide. It almost always takes several applications on two- or three-week intervals to get rid of them. My best advice is don’t let them get started. DEAR NEIL: This tropical milkweed has popped up in my yard. Is it true that it’s bad for monarchs? Should I keep it or remove it? Dear Reader: Being a horticulturist and not an entomologist, I thought I’d do a bit of reading on the topic. I rarely post entire URL links in my answers, but this write-up is too good to pass up. It’s an excellent explanation of why we here in Texas should be careful in growing tropical milkweed. It doesn’t say that we shouldn’t grow it. It just says that we should prune it back severely a couple of times each year and it explains why. Note: It was written in 2016, but there is nothing in it that is dated. https://monarchbutterflygarden.net/is-tropical-milkweed-killing-monarch-butterflies/ DEAR NEIL: We built a rose garden last winter and planted seven roses. They bloomed beautifully this spring, but today the plants are spindly and now have yellowed, blotchy leaves. I don’t know what to do. Any advice? Dear Reader: A photo would have helped, but please Google “photo roses black spot.” I suspect that the fungal disease has knocked the leaves off your plants. It hits in the cool, moist days of spring. The leaves develop yellow blotches with dark brown or black spots. Infected leaves soon drop leaving the plants almost completely bare. If that’s the case your best bet is to trim them back by 30-35 percent and start a weekly spray program with any fungicide labeled for control of black spot. Next time, look into the Texas A&M EarthKind roses that have been shown to be almost bulletproof against the disease. DEAR NEIL: We have 1,000 square feet of St. Augustine in our backyard. We are going to be away for 16 days. If we water it really well before we leave will it survive? It’s been planted for 14 months. Do we need to have someone water it? Dear Reader: Have someone water it. That’s too long to be without. Be wary, too, of chinch bugs. This is prime time for their attacks and if the grass is in a sunny location you could come home to brown turf. Have a question you’d like Neil to consider? Email him at mailbag@sperrygardens.com. Neil regrets that he cannot reply to questions individually.	https://wacotrib.com/news/local/neil-sperry-crack-in-red-oak-needs-to-be-examined/article_d9ffd08a-f262-11ec-bdfe-57fe3c6d4463.html	2022-06-24T22:35:55Z	https://wacotrib.com/news/local/neil-sperry-crack-in-red-oak-needs-to-be-examined/article_d9ffd08a-f262-11ec-bdfe-57fe3c6d4463.html	false	6
After twiddling my thumbs on the apps and being set up by various friends to meet up with their friends whom I “would just love”, I have been on a fair few first dates. Going on a first date can be nerve-wracking as it is, and putting together an outfit for the date shouldn’t be left on your list of things to worry about at the last minute. It’s all about nailing down your personal first-date outfit formula that you can tweak and repeat. While the perfect first date outfit can vary from person to person, one thing that stands for sure is, the look should always be both polished and low-key— you wouldn’t want someone to notice your clothes before they notice you. Keeping things low-key doesn't have to be boring, styling a cute pair of kitten heels or an interesting bright bag can elevate a regular ‘jeans plus a nice top’ look. A no-frills sundress peppered with some layered necklaces is a no-brainer, and if you are more into tailored pieces, try a fun pair of sneakers to off-set your favourite blazer. Aside from keeping things low key, it is important that you are comfortable. You should be able to pay attention to the conversation instead of worrying about if your neckline is falling or if you can hop to the next bar in those high-heeled shoes. Especially now, as we re-emerge from a sweatpants-laden life, it’s time to update your wardrobe with pieces that you can wear to your IRL dates. (Goodbye Zoom dates with patchy internet!) Below is a Vogue edit of looks to ease your first date jitters. You’re welcome!	https://www.vogue.in/fashion/content/my-foolproof-first-date-outfit-and-where-you-can-buy-yours	2022-06-24T22:36:12Z	https://www.vogue.in/fashion/content/my-foolproof-first-date-outfit-and-where-you-can-buy-yours	false	1
‘Serial rapist’ who preyed on women from dating apps likely has victims nationwide, police say MOORESVILLE, N.C. (WBTV/Gray News) – A man who investigators say is a serial rapist who preyed on women from dating apps was arrested this week. While 29-year-old Michael Brandon Shinn was ultimately arrested for two sex crimes police say he committed in North Carolina, police warn that Shinn could have victims nationwide, as far away as California. Officers with the Mooresville Police Department arrested Shinn after receiving reports of two recent rapes in the area. The first alleged rape happened June 16. The victim reported the assault to police a few days later, telling them she met Shinn online and had agreed to meet him. After the two met, the victim said she got into Shinn’s car where he drove her to a remote parking lot and raped her. The victim told police Shinn then left her in the parking lot without a phone or a vehicle. Detectives said they identified Shinn using the information provided by the victim and warrants were obtained for his arrest. While investigating that alleged crime, the Huntersville Police Department advised Mooresville police that a second victim was hospitalized in Huntersville. This victim provided a similar description of the suspect and the circumstances of the alleged crime, according to police. The victim said she met Shinn in the same parking lot on June 21, just five days after the first reported rape. Following the report from the second victim, more warrants were obtained for Shinn’s arrest. Police did not elaborate on the second victim’s injuries or why she was hospitalized. During the investigation of both assaults, detectives said they discovered that Shinn was targeting women online and is likely involved in similar crimes in other areas nationwide. Detectives said they are working with multiple surrounding agencies who have similar cases involving the suspect, including agencies as far away as California. Shinn was arrested and charged with two counts of second-degree forcible rape and one count of second-degree forcible sex offense. He is being held at the Iredell County Detention Center under a $600,000 secured bond. Police are asking for more victims to come forward. If you or anyone you know may have been a victim of or had contact with Shinn, you are encouraged to contact Detective Saladino with the Mooresville Police Department at 704-664-3311. Copyright 2022 WBTV via Gray Media Group, Inc. All rights reserved.	https://www.kfvs12.com/2022/06/24/serial-rapist-who-preyed-women-dating-apps-likely-has-victims-nationwide-police-say/	2022-06-24T22:36:27Z	https://www.kfvs12.com/2022/06/24/serial-rapist-who-preyed-women-dating-apps-likely-has-victims-nationwide-police-say/	true	12
OKOTOKS, AB, June 24, 2022 /PRNewswire/ - (TSX: MTL) Mullen Group Ltd. ("Mullen Group", "We", "Our" and/or the "Corporation") reports that Stephen Clark, the Corporation's Senior Financial Officer, is on extended leave for health reasons. In his absence, Carson Urlacher, Senior Accounting Officer has assumed Mr. Clark's responsibilities. About Mullen Group Ltd. Mullen Group is one of North America's largest logistics providers. Our network of independently operated businesses provide a wide range of service offerings including less-than-truckload, truckload, warehousing, logistics, transload, oversized, third-party logistics and specialized hauling transportation. In addition, we provide a diverse set of specialized services related to the energy, mining, forestry and construction industries in western Canada, including water management, fluid hauling and environmental reclamation. The corporate office provides the capital and financial expertise, legal support, technology and systems support, shared services and strategic planning to its independent businesses. Mullen Group is a publicly traded corporation listed on the Toronto Stock Exchange under the symbol "MTL". Additional information is available on our website at www.mullen-group.com or on the Corporation's issuer profile on SEDAR at www.sedar.com. Contact Information Mr. Murray K. Mullen - Chair, Senior Executive Officer and President Mr. Richard J. Maloney - Senior Operating Officer Mr. Carson P. Urlacher - Senior Accounting Officer Ms. Joanna K. Scott – Senior Corporate Officer 121A - 31 Southridge Drive Okotoks, Alberta, Canada T1S 2N3 Telephone: 403-995-5200 Fax: 403-995-5296 View original content: SOURCE Mullen Group Ltd.	https://www.14news.com/prnewswire/2022/06/24/mullen-group-ltds-senior-financial-officer-taking-extended-leave-absence/	2022-06-24T22:39:31Z	https://www.14news.com/prnewswire/2022/06/24/mullen-group-ltds-senior-financial-officer-taking-extended-leave-absence/	false	46
(The Center Square) - The Utah Democratic Party is calling on lawmakers to hold a special legislative session to overturn a law that allows an abortion ban. The U.S. Supreme Court overturned the 49-year-old Roe v. Wade decision and said it is up to states to decide if abortion is legal. The Utah Legislature passed Senate Bill 174 in 2020. It prohibited elective abortions except in cases of rape, incest or medical emergencies. "The U.S. Supreme Court's official opinion will now be sent to the Legislature's general counsel to determine if Utah's statute may take effect," Aundrea Peterson, spokesperson for the Utah Senate, told The Center Square. "If the legislative general counsel determines that SB174 meets the requirements to take effect, the general counsel will certify to members of the Legislative Management Committee that the bill is in effect." The Utah Democratic Party called the decision "earth-shattering" to women across the country and called on state lawmakers to act. "Most Utahns do not want to see this restrictive ban go into effect in our state," the organization said in a statement. "We call on GOP leadership to convene a special session of the legislature to repeal their extremist ban and listen to the voices of a majority of Utahns who don't want to see the government take away freedom of choice from the women of our state." Utah Attorney General Sean D. Reyes said his office is ready to defend any challenges. "The Supreme Court pronouncement is clear. It has returned the question of abortion to the states," Reyes said in a statement." And the Utah legislature has answered that question." Gov. Spencer Cox and Lt. Gov. Deidre Henderson issued a joint statement backing the decision. "We wholeheartedly support this Supreme Court ruling and are encouraged to see abortion law will be left to elected state representatives," they said in a joint statement. "As pro-life advocates, this administration is equally committed to supporting women and families in Utah. We all need to do more to support mothers, pregnant women, and children facing poverty and trauma."	https://www.thecentersquare.com/utah/utah-democrats-want-special-session-to-overturn-state-abortion-law/article_92a1df56-f3e5-11ec-88c9-9f7bec1b739a.html	2022-06-24T22:40:57Z	https://www.thecentersquare.com/utah/utah-democrats-want-special-session-to-overturn-state-abortion-law/article_92a1df56-f3e5-11ec-88c9-9f7bec1b739a.html	false	1
JINJIANG, China, June 24, 2022 /PRNewswire/ -- Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) ("Antelope Enterprise" or the "Company"), a leading Chinese manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial buildings, and which also engages in business management, information system consulting, and online social commerce and live streaming, today announced its receipt of a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq"). The Company received the deficiency letter on June 23, 2022, which notified the Company that for the last 30 consecutive business days the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The deficiency letter does not result in the immediate delisting of the Company's common stock from the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the "Compliance Period Rule"), the Company has been provided an initial period of 180 calendar days, or until December 20, 2022 (the "Compliance Date"), to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the bid price for the Company's common stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company is not in compliance with the Bid Price Rule by December 20, 2022, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split. If the Company does not regain compliance with the Bid Price Rule by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock may be delisted. The Company would then be entitled to appeal the Staff's determination to a NASDAQ Listing Qualifications Panel and request a hearing. There can be no assurance that, if the Company does appeal the delisting determination by the Staff to the NASDAQ Listing Qualifications Panel, that such appeal would be successful. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which could include effecting a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule. About Antelope Enterprise Holdings Limited Antelope Enterprise Holdings Limited is a leading manufacturer of ceramic tiles in China. The Company's ceramic tiles are used for exterior siding, interior flooring, and design in residential and commercial buildings. Antelope Enterprise's products, sold under the "Hengda" or "HD", are available in over 2,000 style, color and size combinations and are distributed through a network of exclusive distributors as well as directly to large property developers. The Company also engages in business management, information system consulting, and online social commerce and live streaming in China. For more information, please visit http://www.aehltd.com. Safe Harbor Statement Certain of the statements made in this press release are "forward-looking statements" within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, the continued stable macroeconomic environment in the PRC, the PRC real estate, construction and technology sectors continuing to exhibit sound long-term fundamentals, our ability to bring additional ceramic tile production capacity online going forward as our business improves, our ceramic tile customers continuing to adjust to our product price increases, our ability to sustain our average selling price increases and to continue to build volume in the quarters ahead, and whether our enhanced marketing efforts will help to produce wider customer acceptance of the new price points; and our ability to continue to grow our business management, information system consulting, and online social commerce and live streaming business. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as "may," "will," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "estimate," "continue," "plan," "point to," "project," "could," "intend," "target" and other similar words and expressions of the future. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2021 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC's Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made. View original content: SOURCE Antelope Enterprise Holdings Limited	https://www.actionnews5.com/prnewswire/2022/06/24/antelope-enterprise-holdings-ltd-receives-deficiency-letter-nasdaq-under-nasdaqs-bid-price-rule/	2022-06-24T22:49:25Z	https://www.actionnews5.com/prnewswire/2022/06/24/antelope-enterprise-holdings-ltd-receives-deficiency-letter-nasdaq-under-nasdaqs-bid-price-rule/	false	14
The Houston Chronicle’s Jonathan Feigen and Danielle Lerner discuss a surprising draft night for the Rockets that saw them net Auburn’s Jabari Smith Jr., who had been projected to be the top pick by many, along with LSU’s Tari Eason and Kentucky’s TyTy Washington. They also discuss the newcomers’ fit in the frontcourt and whether the Rockets’ defense finally improves on this episode of the Texas Sports Nation podcast. Subscribe to the Texas Sports Nation podcast on Apple Podcasts, Google Play, Overcast, Spotify, Stitcher or your favorite podcast app.	https://www.houstonchronicle.com/texas-sports-nation/podcast/article/Rockets-draft-picks-fit-Jabari-Smith-Tari-Eason-17264383.php	2022-06-24T22:49:42Z	https://www.houstonchronicle.com/texas-sports-nation/podcast/article/Rockets-draft-picks-fit-Jabari-Smith-Tari-Eason-17264383.php	true	null
The City of Greenville has hired Christopher Smith, assistant chief deputy for Dallas County Sheriff’s Department as its new police chief, the city announced late Friday afternoon. Smith began his career in law enforcement in 1989 as a detention officer and he has worked for the Dallas County Sheriff’s Department for 33 years. During this time, Smith has served in various divisions within the department, including jailer, deputy sheriff, sergeant, lieutenant, and captain. He was recently promoted in 2020. Smith received his Bachelor of Science degree in criminal justice from Lamar University. He has attended the International Enforcement Administration School of Police Management and is an FBI National Academy graduate. Smith also holds a Master Peace Officer certification, Master Jailer certification, Basic TCOLE Instructor certification, and Firearms Instructor certification. Smith’s father made the U.S. Army his career and retired as a lieutenant colonel. Both Smith and his brother went on to become career law enforcement officers. He is proud to come from a family of service to the community. This year, Smith celebrates 33 years in law enforcement. “We are pleased to have Christopher join our leadership team. We are confident that he will continue to lead the department with encouragement, strength, compassion, and leadership,” the city said in a statement.	https://www.heraldbanner.com/community/city-names-smith-new-police-chief/article_70421cdc-f408-11ec-b7bb-738841c3724c.html	2022-06-24T22:52:53Z	https://www.heraldbanner.com/community/city-names-smith-new-police-chief/article_70421cdc-f408-11ec-b7bb-738841c3724c.html	false	2
Some fear rollback of LGBTQ and other rights following Roe v. Wade SCOTUS decision The U.S. Supreme Court's decision allowing states to ban abortion stirred alarm Friday among LGBTQ advocates, who feared that the ruling could someday allow a rollback of legal protections for gay relationships, including the right for same-sex couples to marry. In the court's majority opinion overturning the 1973 Roe v. Wade decision, Justice Samuel Alito said the decision applied only to abortion. But critics of the court's conservative majority gave the statement no credence. “I don’t buy that at all,” said Lawrence Gostin, a professor of medicine at Georgetown University and director of its Institute for National and Global Health Law. “It really is much more extreme than the justices are making it out to be.” He added: “It means that you can’t look to the Supreme Court as an impartial arbiter of constitutional rights because they’re acting more as culture warriors.” Gostin and others pointed to a separate concurring opinion in which Justice Clarence Thomas said the court should review other precedents, including its 2015 decision legalizing same-sex marriage, a 2003 decision striking down laws criminalizing gay sex and a 1965 decision declaring that married couples have a right to use contraception. “Let’s just be clear. Today is about this horrifying invasion of privacy that this court is now allowing, and when we lose one right that we have relied on and enjoyed, other rights are at risk,” said Jim Obergefell, the plaintiff in the landmark ruling legalizing same-sex marriage, who is now running as a Democrat for the Ohio House. Abortion opponents celebrated the potential for states to ban abortion after nearly 50 years of being prevented from doing so. Some argued that the case did not have implications beyond that, noting Alito's words. “And to ensure that our decision is not misunderstood or mischaracterized, we emphasize that our decision concerns the constitutional right to abortion and no other right,” Alito wrote. “Nothing in this opinion should be understood to cast doubt on precedents that do not concern abortion.” Kristen Waggoner, legal director for the Alliance Defending Freedom, which helped defend the Mississippi abortion law at issue in the ruling, said the high court's decision makes it clear that “the taking of human life is unlike any other issue.” She said raising other issues shows the weakness of critics' arguments about abortion. Still, said Paul Dupont, a spokesman for the conservative anti-abortion American Principles Project, conservatives are optimistic about the potential for future victories on cultural issues, though getting more states to ban abortion is “a huge enough battle.” “If there is a thought that this could apply elsewhere, you know, they're not going to say it here, and we're just going to have to see,” Dupont said. Other factors could protect those rulings on birth control and LGBTQ rights, too. The Obergefell decision that legalized same-sex marriage was based on equal protection, and hundreds of thousands of couples have relied on it to wed, a precedent that many courts would be loath to disturb. Still, a sharp increase in anti-LGBTQ rhetoric in the U.S. and opposition to specific kinds of birth control on the right have advocates concerned that those rights are vulnerable. Some abortion opponents treat some forms of contraception as forms of abortion, particularly IUDs and emergency birth control such as Plan B, also known as the “morning after” pill. Lawmakers in Idaho and Missouri last year discussed banning state funding for emergency contraception, and Idaho prevents public schools or universities from dispersing it. “It's all interconnected, because at its base, birth control and abortion are both types of health care that help people have bodily autonomy,” said Mara Gandal-Powers, director of birth control access for the National Women's Law Center, which supports abortion rights. “I'm very concerned about where this is going to go.” The Supreme Court's three most liberal members argued that the majority decision “breaches a core rule-of-law principle, designed to promote constancy in the law" and “places in jeopardy” other rights. At the White House, President Joe Biden pledged to do everything in his power to defend a woman’s right to have an abortion in states where it will be banned. He warned that the ruling could undermine rights to contraception and gay marriage: “This is an extreme and dangerous path.” Then there is Thomas' concurring opinion, which Sarah Warbelow, legal director for the pro-LGBTQ-rights Human Rights Campaign, called an invitation for “stirring up fringe organizations, fringe politicians who want to harm the LGBTQ community.” “There are clearly members of the court who have an outdated notion of what America looks like today and have a fantasy of returning to their painted idealism of a 1940s, 1950s America, certainly not what it really was in the 1940s and '50s,” she said. “And that is terrifying.” Jason Pierceson, a University of Illinois political scientist, said he doesn't see the conservative majority stopping with abortion. “They are sending signals to the conservative legal movement, which has a lot of momentum right now because of this victory, to keep going and to keep bringing cases to them over the next several years that will give them opportunities to go further,” Pierceson said. Connecticut Attorney General William Tong, a Democrat, called the decision “dangerous” and warned that it carves the nation into two parts. He predicted there will be “a tsunami of radical litigation and legislation aimed at further eroding rights we have taken for granted." “Make no mistake — this is just the beginning of a systematic right-wing effort to rewrite decades of bedrock legal precedent,” he said. ___ Associated Press writers Jessica Gresko in Washington, Susan Haigh in Hartford, Connecticut, Julie Carr Smyth in Columbus, Ohio, and Lindsay Whitehurst, in Salt Lake City, contributed to this report.	https://www.mynbc5.com/article/some-fear-rollback-lgbtq-other-rights-following/40412405	2022-06-24T22:54:09Z	https://www.mynbc5.com/article/some-fear-rollback-lgbtq-other-rights-following/40412405	false	22
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/toronto-blue-jays/articles/39891103	2022-06-24T22:57:07Z	https://sportspyder.com/mlb/toronto-blue-jays/articles/39891103	false	null
WASHINGTON (AP) — Back-to-back world leader summits in Europe opening this weekend will focus on uniting Western nations behind Ukraine in its fight against Russia’s invasion and overcoming Turkey’s opposition to NATO membership for Finland and Sweden. The Group of Seven leading economic powers — the United States, Britain, Canada, France, Germany, Italy and Japan — are set to hold their annual gathering Sunday through Tuesday in the Bavarian Alps in Germany, which holds the G-7’s rotating presidency this year. After the G-7 concludes, leaders of the 30 countries in the NATO alliance will then gather for their annual summit, which is being held Wednesday through Thursday in Madrid. A look at some of the key issues and themes on the table as President Joe Biden prepares to join both summits: UKRAINE UNITY Russia’s war in Ukraine will loom large over both summits as leaders seek to project a united front against Kremlin aggression that has devastated Ukraine and plunged Europe and much of the world into economic and other crises. Nations represented at the back-to-back gatherings have sent billions of dollars in aid and arms to Ukraine and closed ranks in their strident condemnation of Russian President Vladimir Putin’s invasion. Ukraine got another boost Thursday when European Union leaders swiftly and unanimously approved its application to become a candidate to join the 27-nation bloc, though the process of joining will likely take years. The United States and European Union have imposed damaging economic sanctions on Moscow and Putin’s oligarchs, but major markets including China and India continue to buy Russian oil, watering down the effects of Western sanctions. NATO FOR FINLAND AND SWEDEN A major unresolved issue for the NATO summit is membership for Finland and Sweden. Russia’s war in Ukraine spooked both Nordic countries enough that they abandoned long-held neutrality policies and applied to join the military alliance. All 30 member nations must sign off on the applications. NATO Secretary-General Jens Stoltenberg supports the bid, and Biden demonstrated his strong backing by hosting both countries’ leaders in the Oval Office. But Turkish President Recep Tayyip Erdogan so far has stalled their quick admission, objecting to membership and pressing both countries to alter their stance on Kurdish rebels that Turkey considers terrorists. All sides have been trying to find a way through the impasse, but whether Erdogan’s concerns can be addressed to his satisfaction in Madrid remained an open question. Sweden and Finland were invited and are expected to attend. COUNTERING CHINA Founded to contain the Soviet Union, NATO is set to declare for the first time that confronting China’s rise is also part of its mission. In Madrid, the alliance will unveil a new “Strategic Concept,” the first update to its guiding principles since 2010, that explicitly references addressing challenges from China. The alliance also has invited Pacific leaders from Japan, South Korea, New Zealand and Australia to the summit. The document marks a significant milestone in efforts by the U.S., under multiple presidents, to expand the alliance’s focus to China, even in the face an increasingly bellicose Russia. The Biden administration maintains that Russia’s invasion of Ukraine has “firmed up” democracies on the threats from autocracies in both Moscow and Beijing. Chinese foreign ministry spokesman Wang Wenbin accuses NATO of trying to “start a new Cold War” and warned against the alliance “drawing ideological lines which may induce confrontation.” CLIMATE Leaders of the G-7 economies will consider backing a package of new climate change measures that senior officials agreed to last month. These effectively require countries to quit burning coal for electricity by 2035, transparently report on their fossil fuel subsidies and ensure electric cars dominate new auto sales by the end of the decade. Senior G-7 officials also acknowledged for the first time the need to provide developing countries with additional financial aid to cope with the loss and damage already happening because of global warming. Wealthy nations have long resisted such a move, fearing they could be on the hook for costly compensation payments for decades of greenhouse gas emissions. Poor countries want the G-7 to commit actual money, having seen past pledges for $100 billion in climate aid by 2020 go unfulfilled. German Chancellor Olaf Scholz hopes they will also back his idea for an international “climate club” whose members would agree on minimum standards to avoid a patchwork of rules and emissions-related tariffs. Efforts to tackle climate change have been dealt a blow by the war in Ukraine and the resulting energy crisis, with countries scrambling to tap new sources of fossil fuel and make up shortfalls from Russia. Campaigners fear that G-7 leaders could water down some of the language they’ve previously agreed to, or even backtrack on existing commitments, so as to justify new oil and gas exploration projects. ENERGY Russia sees Europe’s need for natural gas as a wedge issue that could weaken the alliance backing Ukraine. That means Biden must bring as much liquefied natural gas from the U.S. to Europe as possible, which requires new terminals for shipping. Natural gas prices in the U.S. futures markets are up roughly 70% so far this year. Russia is also a major oil producer, and the war has sent global benchmark prices up about 40% so far this year, causing higher gasoline prices in the U.S. and around the world. Biden views near $5-a-gallon gas in the U.S. as a risk for fellow Democrats heading into the midterm elections, a preview of the risks European leaders could face this winter due to natural gas costs. Shortages of natural gas and higher prices are putting tremendous financial pressure on Germany, Italy, Austria, Netherlands, Poland, Bulgaria, Finland, the Czech Republic and Denmark, among others. Russia has cut exports of natural gas needed to generate electricity and provide heating, causing Germany, which has relied on Russia for 35% of its gas imports, to call on factories to cut power usage and shift toward coal as an energy source. FOOD SECURITY Summit participants will also discuss how Russia’s war is affecting global food security. Russia is blocking about 20 million tons of Ukrainian grain from being shipped to the Middle East, North Africa and parts of Asia, potentially worsening hunger and food security in those regions. A global fertilizer shortage is also of concern. In response, Western powers have pledged billions of dollars in assistance. The U.N. has been working on a deal that would enable Ukraine to export food, including via the Black Sea, and let Russia bring food and fertilizer to world markets without restrictions. To deliver Ukraine’s food supplies to the world, Europe is also looking to increase shipments by railroads and trucks, but their efforts have made up for only a fraction of the Black Sea ports capacity. Russia blames Western sanctions for the crisis, although the measures imposed by Europeans do not prohibit the import and transportation of Russian agricultural goods or payment for Russian imports. GLOBAL INFLATION AND THE ECONOMY The repercussions of higher food and energy costs appear likely to tip much of Europe into a recession, creating a troubling dynamic as Germany and other countries juggle both high inflation and the risks of a severe downturn. G-7 leaders likely will focus on how to simultaneously encourage growth while also reducing inflation, a unique challenge as central banks raise interest rates to slow economic activity. The value of the euro has tumbled over the past year relative to the U.S. dollar as multiple reports point to a slowdown taking hold. Biden, meanwhile, also is fending off predictions by top economists that a U.S. recession is likely. He told The Associated Press in an interview last week that a downturn is “not inevitable.” But avoiding a recession would require the Federal Reserve to raise its benchmark interest rates in order to pull inflation down from a 40-year high without causing a spike in unemployment. DOMESTIC SHADOWS Biden will arrive at both summits in a different place politically than he was last year. He is trailed to Europe by a U.S. public approval rating in the high 30s — the lowest of his presidency — and with consumers complaining about sticker shock at the grocery and gas pump. He also faces the prospect of his party losing control of Congress in November’s elections. Biden will face pressure from abortion rights advocates to act after the conservative-leaning U.S. Supreme Court on Friday overturned its landmark Roe v. Wade decision, ending constitutional protections for abortion that had been in place nearly 50 years. Some of Biden’s counterparts are in similar straits. British Prime Minister Boris Johnson is weakened after surviving a recent no-confidence vote. He suffered fresh blows this week when voters rejected his Conservative Party in two special elections and the party chairman quit after the results were announced. French President Emmanuel Macron overcame a strong challenge from a far-right rival to win reelection in April, but his centrist alliance later failed to win an absolute majority in parliamentary elections. ___ Associated Press writers Josh Boak and Zeke Miller in Washington, Frank Jordans in Berlin, Mike Corder and Samuel Petrequin in Brussels, and Joe McDonald in Beijing contributed to this report.	https://www.bigcountryhomepage.com/news/business/ap-business/solidarity-behind-ukraines-russia-fight-atop-summit-agendas/	2022-06-24T23:03:50Z	https://www.bigcountryhomepage.com/news/business/ap-business/solidarity-behind-ukraines-russia-fight-atop-summit-agendas/	false	38
JINJIANG, China, June 24, 2022 /PRNewswire/ -- Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) ("Antelope Enterprise" or the "Company"), a leading Chinese manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial buildings, and which also engages in business management, information system consulting, and online social commerce and live streaming, today announced its receipt of a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq"). The Company received the deficiency letter on June 23, 2022, which notified the Company that for the last 30 consecutive business days the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The deficiency letter does not result in the immediate delisting of the Company's common stock from the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the "Compliance Period Rule"), the Company has been provided an initial period of 180 calendar days, or until December 20, 2022 (the "Compliance Date"), to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the bid price for the Company's common stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company is not in compliance with the Bid Price Rule by December 20, 2022, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split. If the Company does not regain compliance with the Bid Price Rule by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock may be delisted. The Company would then be entitled to appeal the Staff's determination to a NASDAQ Listing Qualifications Panel and request a hearing. There can be no assurance that, if the Company does appeal the delisting determination by the Staff to the NASDAQ Listing Qualifications Panel, that such appeal would be successful. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which could include effecting a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule. About Antelope Enterprise Holdings Limited Antelope Enterprise Holdings Limited is a leading manufacturer of ceramic tiles in China. The Company's ceramic tiles are used for exterior siding, interior flooring, and design in residential and commercial buildings. Antelope Enterprise's products, sold under the "Hengda" or "HD", are available in over 2,000 style, color and size combinations and are distributed through a network of exclusive distributors as well as directly to large property developers. The Company also engages in business management, information system consulting, and online social commerce and live streaming in China. For more information, please visit http://www.aehltd.com. Safe Harbor Statement Certain of the statements made in this press release are "forward-looking statements" within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, the continued stable macroeconomic environment in the PRC, the PRC real estate, construction and technology sectors continuing to exhibit sound long-term fundamentals, our ability to bring additional ceramic tile production capacity online going forward as our business improves, our ceramic tile customers continuing to adjust to our product price increases, our ability to sustain our average selling price increases and to continue to build volume in the quarters ahead, and whether our enhanced marketing efforts will help to produce wider customer acceptance of the new price points; and our ability to continue to grow our business management, information system consulting, and online social commerce and live streaming business. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as "may," "will," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "estimate," "continue," "plan," "point to," "project," "could," "intend," "target" and other similar words and expressions of the future. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2021 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC's Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made. View original content: SOURCE Antelope Enterprise Holdings Limited	https://www.wrdw.com/prnewswire/2022/06/24/antelope-enterprise-holdings-ltd-receives-deficiency-letter-nasdaq-under-nasdaqs-bid-price-rule/	2022-06-24T23:07:02Z	https://www.wrdw.com/prnewswire/2022/06/24/antelope-enterprise-holdings-ltd-receives-deficiency-letter-nasdaq-under-nasdaqs-bid-price-rule/	true	14
Russia strikes at bridge across Dniester Estuary in Odesa Oblast for fifth time. This item is part of our running news digest May 17, 2022 3:59 pm According to Ukraine’s Southern Operational Command, the bridge is badly damaged and will require costly and time-consuming repairs. It’s impossible to start reconstruction at the moment, the military said.	https://kyivindependent.com/uncategorized/russia-strikes-at-bridge-across-dniester-estuary-in-odesa-oblast-for-fifth-time	2022-06-24T23:09:10Z	https://kyivindependent.com/uncategorized/russia-strikes-at-bridge-across-dniester-estuary-in-odesa-oblast-for-fifth-time	false	null
SBS News - Google - ShortsOther ways to listen Anthony Albanese angers crossbench MPs by reducing their staffing levelsPlay00:49SBS News - Google - ShortsOther ways to listen Get the SBS Radio appOther ways to listenDownload (768.75 KB)Published 25 June 2022 at 8:00amSource: SBS News .Published 25 June 2022 at 8:00amSource: SBS NewsSHARELatest podcast episodesEight men charged over damage to Melbourne mosqueUkrainian troops ordered to withdraw from SievierodonetskUS Supreme Court ruling removes constitutional right to abortion First Nations students to create history in national sports competition	https://www.sbs.com.au/news/podcast-episode/anthony-albanese-angers-crossbench-mps-by-reducing-their-staffing-levels/akpj41mdr	2022-06-24T23:10:37Z	https://www.sbs.com.au/news/podcast-episode/anthony-albanese-angers-crossbench-mps-by-reducing-their-staffing-levels/akpj41mdr	false	null
The man accused of stabbing the mother of his unborn child to death, which also resulted in the death of the baby, has been apprehended and facing the rest of his life in prison. William Bunch, 43, was charged in Racine County Circuit Court Friday with one felony count each of first-degree intentional homicide and first-degree intentional homicide of an unborn child with use of a dangerous weapon. Each charge carries a minimum mandatory sentence of life in prison. Cause of death determined The Racine County Medical Examiner determined Anderson, 31, died of multiple blunt force trauma, and her baby died of suffocation after its oxygen supply was cut off when Anderson died. She was beaten with a broom handle and stabbed multiple times with a pair of scissors, and there were quantities of blood in various rooms in her apartment. She was nine months pregnant and scheduled for a C-section two weeks after her death. Bunch admitted he and Anderson had a sexual relationship but denied being the father of her child because his wife said she would leave him, the complaint continues. A post-mortem DNA test confirmed Bunch was the father of the child. A witness told officers Bunch left his phone at home so it wouldn’t ping a location near Anderson’s apartment and that a few days before Anderson’s death, Bunch asked them for a crowbar to break into Anderson’s home to “take care of the situation.” Bunch also apparently tried to clean up, and the witness’s statements to police confirmed what they found on the scene. Anderson was the mother of 12- and 13-year-old girls. A family member last fall told CBS 58 News they were devastated and “drowning in hurt,” over the violent death of their mother. “She was one of kind, she was her own individual, she was exactly the way she was suppose to be,” LaShunda Anderson, Vanessa’s sister, told the news station. Bunch was assigned a $1,000,000 cash bond. He will next be in court on June 29 for his preliminary hearing. Stay up to date with emergency, crime and police encounters. The Racine County Eye and Kenosha Lens is your source for local news that serves our diverse communities. Subscribe today and never miss a beat. Visit our Police & Fire section to read more. Follow us on Facebook: Racine County Eye or Kenosha Lens, and Twitter to make sure you get the latest news.	https://racinecountyeye.com/man-arrested-21-stabbing-death-pregnant-woman/	2022-06-24T23:11:03Z	https://racinecountyeye.com/man-arrested-21-stabbing-death-pregnant-woman/	false	1
Abortions now banned in Ohio after fetal heartbeat is detected COLUMBUS, Ohio (WTVG) - Abortion in Ohio is now illegal after a fetal heartbeat is detected. Ohio’s Heartbeat bill became law Friday just hours after the Supreme Court overturned Roe v. Wade, allowing states to ban abortions, and after Ohio Attorney General Dave Yost filed an emergency motion in federal court to dissolve the injunction blocking the bill. A judge made the ruling late Friday night, lifting the stay put on the 2019 law when Roe v. Wade was still precedent. Abortion providers could face felony charges and prison time for performing an abortion after a fetal heartbeat could be detected. There are no exceptions for rape or incest. A heartbeat can be detected as early as 6 weeks into a pregnancy, before many women know they are pregnant. You can read the full text of the law below. Related coverage: Local leaders, politicians react to SCOTUS abortion rights ruling Ohio Attorney General files motion to reinstate heartbeat law How overturning Roe v. Wade impacts Michigan Biden vows abortion fight, assails ‘extreme’ court ruling How US states have banned, limited or protected abortion Some US clinics stop doing abortions as ruling takes hold With Roe dead, some fear rollback of LGBTQ and other rights Ohio Heartbeat bill by Sarah McRitchie on Scribd See a spelling or grammar error in our story? Please include the title when you click here to report it. Copyright 2022 WTVG. All rights reserved.	https://www.13abc.com/2022/06/24/abortions-now-banned-ohio-after-heartbeat-is-detected/	2022-06-24T23:11:48Z	https://www.13abc.com/2022/06/24/abortions-now-banned-ohio-after-heartbeat-is-detected/	false	1
Jammu-Srinagar national highway reopened, stranded vehicles allowed towards Kashmir The 270-km highway was blocked since Tuesday due to landslides, mudslides and shooting stones at 33 places in Ramban and Udhampur districts. “The highway has been reopened for traffic. On June 20, highway was closed due to shooting stones at Panthiyal. So, traffic was stranded”, Senior Superintendent of Police (SSP) national highway, Shabir Ahmad Malik told reporters on Friday night. Malik said while all blockades were removed and traffic cleared, the major problem of washing away of the road patch at Dewal bridge near Samroli on June 21 took three-and-half-days to be cleared. “The base of road was washed away. A new road patch was created and traffic was restored tonight”, he said. Traffic was allowed towards Kashmir, and with this, over 1,500 vehicles that were stranded since almost four days, including the convoys carrying langars for the Amarnath Yatra, were let go, he said. On Saturday, traffic from Srinagar to Jammu will be allowed, he added. A 150-feet-long road stretch and an under-construction bridge on the highway were also washed away due to flash floods triggered by heavy rains. On Thursday evening, officials were upbeat about clearing the approximately 1,300 stranded vehicles on the highway by this evening, saying the road clearance work was being carried out on a war footing. However, it took a major hit this afternoon as a fresh landslide occurred on the hill top, bringing the restoration work at Dewal bridge near Samroli to a halt, officials said. Deputy Commissioner, Ramban, Mussarat Islam, who personally monitored the road clearance operation, said the district administration made arrangements for night stay, meals and other facilities for the stranded passengers. “The shuttering of under-construction Peerah bridge was washed away due to heavy rains (on highway)”, a police official said, adding that the one which is normally used for traffic is safe.In Udhampur district, a 150-foot stretch of the Jammu-Srinagar highway was washed away on Wednesday near Toldi Nallah, 16 kilometres away from the town, they said. - As part of our 'Walled City dictionary' series that explores the names of Old Delhi places. Despite being a mere courtesan, Anarkali dares Emperor Akbar with a spunky dance. Golcha cinema, in Daryaganj, is screening the digitally coloured version of the classic Mughal-e-Azam. The single-screen hall shut down six years ago (last movie screened was Kahani 2). Golcha came up in 1954. The theatre is now a ghost of its recent past. - Jammu and Kashmir to host G20 summit next year, 5-member panel formed The Jammu and Kashmir government has constituted a five-member high-powered panel for overall coordination of G20 meetings to be held in the union territory next year. Acting upon a communique from the Union ministry of external affairs dated June 4, the principal secretary to the J&K government, Manoj Kumar Dwivedi accorded sanction for the constitution of the five-member panel. - NIA conducts searches in Jalalabad bomb blast case The National Investigation Agency on Friday conducted searches at multiple locations in Punjab in the last year's Jalalabad bomb blast case. The NIA conducted searches at 6 locations in the districts of Ferozepur, Fazilka and Tarn Taran and digital devices (mobile phones, SIM cards, memory cards, DVRs) , ammunition and other incriminating documents/materials were seized. - ‘Last time this happened in 1992’: Omar on Jammu and Kashmir assembly missing Prez poll Former J&K chief minister Omar Abdullah said that after the Independence of the country, only for the second time assembly members from J&K can't take part in the presidential elections scheduled for next month. Earlier in 1992, when militancy was at its peak and J&K was under Governor's rule, the erstwhile state had no assembly then so legislators from J&K couldn't participate in the elections for the country's President. - Ahead of Amarnath Yatra, L-G Manoj Sinha reviews security scenario With barely six days to go for the annual Amarnath Yatra, lieutenant governor Manoj Sinha reviewed the security arrangements and preparations for the ensuing pilgrimage at a unified command meeting in Srinagar on Thursday, said officials here. The meeting was attended by the chief secretary and senior security officers from the home department, J&K Police, army, intelligence agencies, CRPF, and others. It will conclude on August 11 on the festival of Raksha Bandhan.	https://www.hindustantimes.com/cities/chandigarh-news/jammusrinagar-national-highway-reopened-stranded-vehicles-allowed-towards-kashmir-101656107785993.html	2022-06-24T23:14:02Z	https://www.hindustantimes.com/cities/chandigarh-news/jammusrinagar-national-highway-reopened-stranded-vehicles-allowed-towards-kashmir-101656107785993.html	false	1
The week started out with Meridian’s high of 100 being the only triple digit temperature reported in Mississippi. But in the last few days, other cities across the state have hit the century mark or higher. Tuesday, Meridian reached 100 again and Greenwood and Tupelo both had highs of 101. On Wednesday, Meridian had the hottest temperature so far this week– 103. Hattiesburg hit 102, Tupelo’s high was 101 and Pascagoula reached 100. Then, on Thursday, five cities had triple digit temperatures– Meridian, Hattiesburg and Pascagoula, all at 102, Gulfport at 101 and McComb at 100. The worst of the heat today should be in west-central and south Mississippi, where a heat advisory remains in effect. In this part of central Mississippi, Saturday could be the hottest day with expected highs near 100 in Kosciusko, Carthage and Philadelphia.	https://www.newsbreak.com/news/2644331795430/heat-advisory-until-8-p-m	2022-06-24T23:15:13Z	https://www.newsbreak.com/news/2644331795430/heat-advisory-until-8-p-m	false	null
Russians reportedly stealing metal from occupied Mariupol. This item is part of our running news digest May 29, 2022 3:34 pm For the second day in a row Russian ships are being loaded with metal in the port of Mariupol, allegedly to bring it to Rostov-on-Don, according to Petro Andriushchenko, an advisor to the Mariupol mayor. The port housed about 200,000 tons of metal and cast iron worth $170 million before the occupation, ombudsman Lyudmyla Denisova said on May 28.	https://kyivindependent.com/uncategorized/russians-reportedly-stealing-metal-from-occupied-mariupol	2022-06-24T23:18:26Z	https://kyivindependent.com/uncategorized/russians-reportedly-stealing-metal-from-occupied-mariupol	false	null
Juul can continue to sell its electronic cigarettes, at least for now, after a federal appeals court on Friday temporarily blocked a government ban. Juul filed an emergency motion earlier Friday, seeking the temporary hold while it appeals the sales ban. The e-cigarette maker had asked the court to pause what it called an “extraordinary and unlawful action” by the Food and Drug Administration that would have required it to immediately halt its business. The FDA said Thursday that Juul must stop selling its vaping device and its tobacco and menthol flavored cartridges. The action was part of a sweeping effort by the agency to bring scientific scrutiny to the multibillion-dollar vaping industry after years of regulatory delays. To stay on the market, companies must show that their e-cigarettes benefit public health. In practice, that means proving that adult smokers who use them are likely to quit or reduce their smoking, while teens are unlikely to get hooked on them. The FDA said Juul’s application left regulators with significant questions and didn’t include enough information to evaluate any potential health risks. Juul said it submitted enough information and data to address all issues raised. U.S. & World A three-judge panel of the U.S. Court of Appeals for the District of Columbia Circuit granted Juul's request for a hold while the court reviews the case. While Juul remains a top seller, its share of the U.S. e-cigarette market has dipped to about half. The company was widely blamed for a surge in underage vaping a few years ago, but a recent federal survey showed a drop in the teen vaping rate and a shift away from Juul's products. The devices heat a nicotine solution into a vapor that’s inhaled, bypassing many of the toxic chemicals produced by burning tobacco. The company said in its Friday court filing that it submitted a 125,000-page application to the FDA nearly two years ago. It said the application included several studies to evaluate the health risks among Juul users. Juul said that the FDA cannot argue that there was a “critical and urgent public interest” in immediately removing its products from the market when the agency allowed them to be sold during its review. The company noted that the FDA denied its application while authorizing those submitted by competitors with similar products. The FDA has OK'd e-cigarettes from R.J. Reynolds, Logic and other companies, while rejecting many others. In 2019, Juul was pressured into halting all advertising and eliminating its fruit and dessert flavors after they became popular among middle and high school students. The next year, the FDA limited flavors in small vaping devices to just tobacco and menthol. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.	https://www.nbcboston.com/news/national-international/federal-court-blocks-fda-ban-on-juul-e-cigarette-sales-in-us/2756456/	2022-06-24T23:27:57Z	https://www.nbcboston.com/news/national-international/federal-court-blocks-fda-ban-on-juul-e-cigarette-sales-in-us/2756456/	true	73
Shares of BorgWarner Inc. BWA, +2.50% advanced 2.50% to $35.69 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +3.06% rising 3.06% to 3,911.74 and the Dow Jones Industrial Average DJIA, +2.68% rising 2.68% to 31,500.68. The stock's rise snapped a two-day losing streak. BorgWarner Inc. closed $14.40 below its 52-week high ($50.09), which the company reached on January 13th. The stock underperformed when compared to some of its competitors Friday, as Honeywell International Inc. HON, +3.12% rose 3.12% to $180.02, Cummins Inc. CMI, +4.91% rose 4.91% to $195.02, and Magna International Inc. MGA, +2.79% rose 2.79% to $57.87. Trading volume (2.1 M) eclipsed its 50-day average volume of 2.0 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.	https://www.marketwatch.com/story/borgwarner-inc-stock-rises-friday-still-underperforms-market-01656103274-e7bd1c428161	2022-06-24T23:30:03Z	https://www.marketwatch.com/story/borgwarner-inc-stock-rises-friday-still-underperforms-market-01656103274-e7bd1c428161	false	3658
According to reports, Ezra Miller has been accused of housing kids in an unsafe environment. Rolling Stone magazine revealed Miller has been housing a 25-year-old mother and her three children on a farm in Vermont that includes guns and marijuana. The father of the children among others has deemed this situation unsafe for the kids. More specifically, there were guns lying around the home. According to Rolling Stone, one incident involved the one-year-old picking up a bullet and putting it in its mouth. In a video sent to the outlet, Rolling Stone found an estimated eight assault weapons around the living room. This is while sources were concerned of proper ventilation due to marijuana smoking. Read more via The Guardian. READ MORE: - Verzuz’ battle (06/23/22): How to wach Omarion vs. Mario - ‘Jeopardy!’ fans call out a small mistake the show made - Elliot Page feels joy since coming out as transgender; praises the way ‘The Umbrella Academy’ added his personal journey in season 3	https://www.pennlive.com/life/2022/06/ezra-miller-accused-of-housing-children-on-unsafe-farm-with-guns-and-marijuana.html	2022-06-24T23:33:13Z	https://www.pennlive.com/life/2022/06/ezra-miller-accused-of-housing-children-on-unsafe-farm-with-guns-and-marijuana.html	true	1
Weak German Ifo reading reminds us that stagflation is the base case Short-lived optimism After two months of improving business sentiment, Germany’s most prominent leading indicator, the Ifo index, just delivered a reality check and dented any premature optimism. The Ifo index dropped to 92.3 in June, from 93.0 in May. In March, the Ifo stood at 90.8. Both the current assessment and the expectations component weakened in June, with expectations almost back down to the March levels. The reasons for dampened optimism are clear: the war in Ukraine, lockdowns in China and the consequent supply chain frictions, higher costs and prices, and weakening demand. It is actually not the first time German business sentiment seems to have had a delayed reaction to global events. Stagflation remains our base case scenario for the German economy Yesterday, the German PMI fell for the fourth consecutive month, to the lowest level since the fourth wave of the Covid-19 pandemic. The PMI details showed another sharp inventory build-up and a cooling in the services sector, a combination that definitely doesn’t bode well for future economic activity. In fact, supportive factors for the economy such as post-lockdown reopenings and filled order books have been losing momentum rapidly. Weaker global demand, supply chain frictions, and high inflation denting consumption are hitting the German economy. Supply chains continue to be disrupted due to the Shanghai lockdown and the war in Ukraine. Some might be disrupted for good. Elevated uncertainty and fear will weigh on both supply and demand in the coming months. Real disposable incomes of households will suffer, and companies will have increasing difficulties dealing with the costs of higher energy and commodity prices, putting corporate profit margins under pressure. Not a happy-go-lucky story. The German economy will definitely not plunge as it did during the 2020 lockdowns. However, consumer confidence is already in clear recession territory and today’s Ifo reading, as well as yesterday’s PMI reading, both suggest that the manufacturing sector is quickly following suit. Stagflation for the rest of the year remains our base case scenario for the German economy, and an outright recession is our risk scenario. Source: ING	https://www.hellenicshippingnews.com/weak-german-ifo-reading-reminds-us-that-stagflation-is-the-base-case/	2022-06-24T23:33:38Z	https://www.hellenicshippingnews.com/weak-german-ifo-reading-reminds-us-that-stagflation-is-the-base-case/	true	1
Juul can continue to sell its electronic cigarettes, at least for now, after a federal appeals court on Friday temporarily blocked a government ban. Juul filed an emergency motion earlier Friday, seeking the temporary hold while it appeals the sales ban. The e-cigarette maker had asked the court to pause what it called an "extraordinary and unlawful action" by the Food and Drug Administration that would have required it to immediately halt its business. The FDA said Thursday that Juul must stop selling its vaping device and its tobacco and menthol flavored cartridges. The action was part of a sweeping effort by the agency to bring scientific scrutiny to the multibillion-dollar vaping industry after years of regulatory delays. To stay on the market, companies must show that their e-cigarettes benefit public health. In practice, that means proving that adult smokers who use them are likely to quit or reduce their smoking, while teens are unlikely to get hooked on them. The FDA said Juul's application left regulators with significant questions and didn't include enough information to evaluate any potential health risks. Juul said it submitted enough information and data to address all issues raised. A three-judge panel of the U.S. Court of Appeals for the District of Columbia Circuit granted Juul's request for a hold while the court reviews the case. While Juul remains a top seller, its share of the U.S. e-cigarette market has dipped to about half. The company was widely blamed for a surge in underage vaping a few years ago, but a recent federal survey showed a drop in the teen vaping rate and a shift away from Juul's products. The devices heat a nicotine solution into a vapor that's inhaled, bypassing many of the toxic chemicals produced by burning tobacco. The company said in its Friday court filing that it submitted a 125,000-page application to the FDA nearly two years ago. It said the application included several studies to evaluate the health risks among Juul users. Juul said that the FDA cannot argue that there was a "critical and urgent public interest" in immediately removing its products from the market when the agency allowed them to be sold during its review. The company noted that the FDA denied its application while authorizing those submitted by competitors with similar products. The FDA has OK'd e-cigarettes from R.J. Reynolds, Logic and other companies, while rejecting many others. In 2019, Juul was pressured into halting all advertising and eliminating its fruit and dessert flavors after they became popular among middle and high school students. The next year, the FDA limited flavors in small vaping devices to just tobacco and menthol. Juul can keep selling e-cigarettes as court blocks FDA ban By TOM MURPHY	https://abc7.com/juul-ban-fda-e-cigarette-court-ruling/11993685/	2022-06-24T23:37:53Z	https://abc7.com/juul-ban-fda-e-cigarette-court-ruling/11993685/	true	73
Schlumberger (SLB) Gains But Lags Market: What You Should Know Schlumberger (SLB) closed the most recent trading day at $35.06, moving +0.23% from the previous trading session. This move lagged the S&P 500's daily gain of 3.06%. At the same time, the Dow added 2.68%, and the tech-heavy Nasdaq lost 0.08%. Heading into today, shares of the world's largest oilfield services company had lost 25.08% over the past month, lagging the Oils-Energy sector's loss of 12.66% and the S&P 500's loss of 4.31% in that time. Schlumberger will be looking to display strength as it nears its next earnings release, which is expected to be July 22, 2022. On that day, Schlumberger is projected to report earnings of $0.39 per share, which would represent year-over-year growth of 30%. Our most recent consensus estimate is calling for quarterly revenue of $6.27 billion, up 11.23% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.85 per share and revenue of $26.07 billion. These totals would mark changes of +44.53% and +13.71%, respectively, from last year. Investors might also notice recent changes to analyst estimates for Schlumberger. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Schlumberger is currently sporting a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that Schlumberger has a Forward P/E ratio of 18.96 right now. This represents a discount compared to its industry's average Forward P/E of 19.3. Investors should also note that SLB has a PEG ratio of 0.41 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Oil and Gas - Field Services was holding an average PEG ratio of 0.41 at yesterday's closing price. The Oil and Gas - Field Services industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 84, which puts it in the top 34% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >>Click to get this free report Schlumberger Limited (SLB): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.	https://www.nasdaq.com/articles/schlumberger-slb-gains-but-lags-market%3A-what-you-should-know-2	2022-06-24T23:39:01Z	https://www.nasdaq.com/articles/schlumberger-slb-gains-but-lags-market%3A-what-you-should-know-2	false	38
Ever since Covid, the Neest has seen an eruption of pop-up, open-air cafes and beer gardens. Quite right, too. The only thing better than going to an eatooterie is going to an ootside eatooterie. My most precious memories of holidays doon the decades are of sipping heady cocktails in stunning locations and feeding my face with fine food. Maybe that’s because my very first meal like that had such a dramatic – in more ways than one – conclusion. Sweet 16 and barely kissed, adolescently ecstatic when the boatmen from Sorrento to Capri, Josef, asked me oot that Saturday night: a dead ringer for that hunky Italian Davide on Love Island. (Of course I watch it!) My pal’s mum, our chaperone, rightly forbade the date, but no one was keeping Mo from her Romeo. Moonlight-bathed table at the end of a pier. Juicy pizzas. Instantly in love, trying to look grown-up, in spite of a huge dod of cigarette ash dropping into my wine – yet, still going to drink it, until he wheeched it away. We’ll dra’ a veil ower the denouement, when he volunteered to tour me roon the famous beach caves – dirty sod. Cracking lobsters in Jamaica while a steel band played Island in the Sun. Jerk chicken and salt fish on a beach in Barbados where, sadly, native sand critters ca’ed jiggers became illegal immigrants, taking up residence and laying eggs between my taes. After weeks of useless dermatitis diagnoses, inspired doctor Derek Gray was the one who finally spotted ‘em and prescribed humongous horrors of beastie-buster tablets, the affa naisty side effects well worth the jigger-nuking. It’s obviously still a bit of a hit or miss if Aiberdeen cooncillors give permission for al fresco catering There were sizzling suppers by lapping waves in Cannes, where utterly charmant waiters expertly filleted oor sole meunière – until the bill revealed they’d filleted us even better. Happy days. Go al fresco (but bring a jacket) It’s obviously still a bit of a hit or miss if Aiberdeen cooncillors give permission for al fresco catering. This week, a new beer garden at the back of Golden Square’s Barbelow got the go-ahead. But, the marquee ootside Number 10 got the dunt because of complaints about litter and taking up a teenie bittie of a public park. Ken ‘is – I reckon there’s barely been two dozen locals occupying that exact space in a decade. Shame. Mind you, a bit of true grit doesn’t go amiss when you dine ootski ’n’ abootski in this neck of the woods. A pucklie weeks ago, slaverin’ ower the prospect of lamb hotpot in a beer garden up the coast, the patio heater beside us went kaput just as a North Sea haar seeped in, like Marley’s ghost. We ended up inside. Last week, soaking up the sunshine in a bonnie garden pub, chilli-topped burgers were not only a treat for us but for the dozens of ruddy wasps which materialised from a nearby bush. Guess far we ended up? Moreen Simpson is a former assistant editor of the Evening Express and The Press & Journal, and started her journalism career in 1970	https://www.pressandjournal.co.uk/fp/opinion/columnists/4450902/eat-out-aberdeen-restaurants-pubs-moreen-simpson-opinion/	2022-06-24T23:40:31Z	https://www.pressandjournal.co.uk/fp/opinion/columnists/4450902/eat-out-aberdeen-restaurants-pubs-moreen-simpson-opinion/	true	1
You need to enable JavaScript to run this app.	https://sportspyder.com/mcb/arizona-wildcats-basketball/articles/39892492	2022-06-24T23:42:24Z	https://sportspyder.com/mcb/arizona-wildcats-basketball/articles/39892492	true	null
Daily Crunch: Months after rejecting a $17B bid, Zendesk sells to private equity group for $10.2B To get a roundup of TechCrunch’s biggest and most important stories delivered to your inbox every day at 3 p.m. PDT, subscribe here. Hey, folks, and welcome to the Friday edition of Daily Crunch. As you might've seen, the Supreme Court issued a major decision on abortion today, effectively overturning Roe v. Wade in declaring that the Constitution doesn't guarantee the right to abortion. While the outcome was expected — a draft of the decision leaked months ago — the implications for the tech industry are only starting to become clearer. Stay tuned as my colleagues and I parse the developments. In other news, TechCrunch's Summer Party yesterday was a major success — thanks to all who turned up! Not to sound like a broken record, but on the events front, don't forget about the upcoming TC Sessions: Robotics in July. And on the distant horizon, TechCrunch Disrupt will return to San Francisco on October 18. I can't wait to see your smiling faces there. Need reading or listening material in the meantime? Consider giving TechCrunch's podcast and newsletter library a look. I'll bet there's a large enough backlog to keep you occupied — and, more importantly, informed! — Kyle The TechCrunch Top 3 Move over, there’s a new copilot in town: Proving that GitHub isn’t the only platform with the chops to launch an AI-powered pair programmer, Amazon this week debuted CodeWhisperer, a tool that can autocomplete entire functions based on only a comment or a few keystrokes of code. As Frederic writes, Amazon trained the system — which currently supports Java, JavaScript and Python — on billions of lines of publicly available open source code and its own codebase, as well as publicly available documentation and code on public forums. Please hold while your company is being acquired: Zendesk has had a rough go of it lately, what with activist investors hounding the customer service software vendor for changes and misguided attempts to boost its valuation. Still, the news of Zendesk's acquisition today came as something of a surprise, if only because of its suddenness. Ron notes that the $10.2 billion transaction — led by Permira and Hellman & Friedman — gave investors a way to get some return on their investment, albeit below the $17 billion offer they got in February. Who needs megapixels when you have Benjamins? Leica makes great digital cameras. But for the special edition, limited-run Leica M-A Titan, the German imaging firm decided to go the analog route. The Titanium-clad M-A Titan takes film, and — if that weren't unobtainable enough — costs an eye-watering $20,000. Haje reports on the thing, noting that Leica only sells about 100,000 cameras per year. Perhaps it can be forgiven for charging a premium. Startups and VC In drug-related news, a startup called Wondermed raised $4.6 million to offer at-home, ketamine-assisted treatments to patients. Now, you might ask, Is this safe? Wondermed claims that it is, as do rivals Mindbloom and Fieldtrip Health. But of course they would. Haje is little suspicious of how easy it is to get approved for ketamine treatment but points to clinical studies that prove the drug's efficacy as a therapeutic option for anxiety and depression. Elsewhere in tech: Delivering the goods — for a price: Offering evidence that the instant delivery market isn't toast just yet, Zomato this week acquired Blinkit, a struggling 10-minute grocery delivery startup, in a $568.1 million deal. Manish reports that investors have questioned Zomato's expansion into the space, given its punishingly high costs and low margins. Hold my battery: Package-transporting drones are cool. What's not cool is having to swap their batteries and payloads once they've landed. Fortunately, there's a startup for that. Airrow makes a device that operates similarly to a CNC machine or 3D printer, Brian reports, with a gantry that moves along X- and Y-axes to get the battery from the charger to the drone and back again. How nifty is that? The struggle is real: It's never a good look when, fresh from raising capital, a startup cuts a substantial portion of its staff. That's what happened this week with Ro, which laid off 18% of its full-time workforce to "manage expenses, increase the efficiency of [its] organization, and better map our resources to [its] current strategy." Natasha notes that former and current employees have previously spoken about the health tech company’s inability to gain meaningful revenue from newer products. Looking for a long-term partner: Communication is important in any relationship, but it doesn't always happen right off the bat. That's why Hinge this week introduced "Dating Intentions," a new profile feature that's designed to encourage users to be up front about their expectations. As per Aisha, the curated choices include "life partner," "long-term," "long-term, open to short-term," "short-term, open to long-term," "short-term'" and “figuring out my dating goals." When life gives you lemons, pivot to crypto: Solana, a startup founded by former engineers and designers from Essential, is shifting focus to embrace cryptocurrency. CEO Anatoly Yakovenko announced this week that its first product, the Osom OV1, will be an Android smartphone that supports decentralized apps reliant on the Solana blockchain. Reactions have been mixed, Jacquelyn reports. Don't eat the lentils: Daily Harvest is blaming the health problems a portion of its customers have been experiencing on lentils — specifically leeks and lentils. Following a Wall Street Journal article, the company recalled its French Lentil and Leek Crumbles product, which reportedly caused some people to have to undergo surgery to remove their gallbladders and might've contributed to liver damage and fevers. Daily Harvest is valued at over $1 billion and has been backed by a number of celebrities, Aisha notes, including Bobby Flay, Gwyneth Paltrow, and Serena Williams. Twitter Space: M13 managing partner Karl Alomar discusses fundraising during a downturn Image Credits: Getty Images/dblight On Monday, June 27 at 11:30 a.m. PT/2:30 p.m. ET, M13 managing partner Karl Alomar is joining senior editor Walter Thompson on a Twitter Space to share tactics and strategies for founders who plan to fundraise during this downturn. Alomar led startups through the dot-com bust of 2000 and the Great Recession of 2008 and will talk about whether investors are still prioritizing growth over profits and how to identify the proof points founding teams must define before their next raise. We’ll take questions, so please follow @techcrunch on Twitter and set a reminder for Monday’s chat. (TechCrunch+ is our membership program, which helps founders and startup teams get ahead. You can sign up here.) Big Tech Inc. The future has arrived. Sort of. San Francisco residents can now pay for a ride in an autonomous taxi, courtesy of Cruise's ride-hailing service. Darrell writes that Cruise’s offering will initially operate only between 10 p.m. and 6 a.m. and on designated city streets, but that in the future, those limits might change. It'll depend on how smoothly the service goes. Meanwhile, in India, the central bank is cracking down on fintech startups, reports Manish. The Reserve Bank of India (RBI) has informed dozens of vendors that it's barring the practice of loading "non-bank prepaid payment instruments" — prepaid cards, for instance — using credit lines. Some affected founders are pushing the narrative that incumbent banks lobbied the RBI to reach a decision favorable to them. In other news: Fresh coat of paint: As part of a broader update to Chrome, Google announced a handful of new features coming to the latest build of Chrome on iOS. Among the key additions, the Chrome app is gaining access to Google’s Enhanced Safe Browsing feature that proactively warns you about dangerous web pages, Lauren writes. Other updates include user interface changes and the ability to set Google’s password manager as the autofill provider. The slow pace of electric: What's not to like about EVs? The wait. As per Jaclyn, surging demand for this year’s most hotly anticipated EVs is smashing order books and lengthening waitlists. Rising supply chain costs mean that customers of the Lyriq and other EVs may pay hundreds or thousands of dollars more for a vehicle that arrives months later than expected. Bummer. Streaming still struggling: Ivan reports that Netflix this week laid off 300 people, the firm’s second layoff spree in 2 months. Among the headwinds the company is facing are the Russian invasion of Ukraine, the COVID pandemic and password sharing. Netflix lost more than 200,000 subscribers in the first quarter and expects to lose 2 million in Q2. Almost as good as the real thing: Frederic writes that at its re:MARS conference, Amazon announced synthetics in SageMaker Ground Truth, a new feature for creating a virtually unlimited number of images of a given object in different positions and under different lighting conditions. It's intended to help create synthetic data for training AI models in situations where real-world data isn't plentiful. Spyware reaches Android: Security researchers at Outlook recently tied a previously unattributed Android mobile spyware, dubbed Hermit, to Italian software house RCS Lab, Zack reports. Now Google threat researchers have confirmed much of Lookout’s findings and are notifying Android users whose devices were compromised by the spyware.	https://finance.yahoo.com/news/daily-crunch-months-rejecting-17b-220543204.html	2022-06-24T23:45:00Z	https://finance.yahoo.com/news/daily-crunch-months-rejecting-17b-220543204.html	true	3
Did you lose money on investments in Tupperware Brands? If so, please visit Tupperware Brands Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, June 24, 2022 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Tupperware Brands Corporation ("Tupperware" or the "Company") (NYSE: TUP) between November 3, 2021 and May 3, 2022, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934. Tupperware operates as a consumer products company worldwide. The Company manufactures, markets, and sells design-centric preparation, storage, and serving solutions for the kitchen and home, as well as a line of cookware, knives, microwave products, microfiber textiles, water-filtration related items, and an array of products for on-the-go consumers under the Tupperware brand name. Plaintiff alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants allegedly made false and/or misleading statements and/or failed to disclose that: (i) Tupperware was facing significant challenges in maintaining its earnings and sales performance; (ii) accordingly, Tupperware's full year 2022 guidance was unrealistic and/or unsustainable; and (iii) all the foregoing, once revealed, was likely to have a material negative impact on Tupperware's financial condition. On May 4, 2022, Tupperware announced its financial results for the first quarter of 2022. Among other items, Tupperware reported adjusted earnings per share from continuing operations and net sales that fell well short of consensus estimates, withdrew its full year 2022 guidance, and named a new Chief Financial Officer. The Company attributed the poor performance to the conflict in Russia and Ukraine. However, when pressed by analysts on a conference call, the Company acknowledged that Russia and Ukraine only accounted for 2% of its revenue. On this news, the Company's stock price fell $5.76 per share, or over 32%, to close at $12.15 per share on May 4, 2022. If you wish to serve as lead plaintiff, you must move the Court no later than August 15, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. If you purchased or acquired TUP securities, and/or would like to discuss your legal rights and options please visit Tupperware Brands Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years. ATTORNEY ADVERTISING. © 2022 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 pallocco@bernlieb.com View original content to download multimedia: SOURCE Bernstein Liebhard LLP	https://www.kplctv.com/prnewswire/2022/06/24/tupperware-brands-corporation-nyse-tup-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-deadline-file-lead-plaintiff-motion-securities-class-action-lawsuit-against-tupperware-brands-corporation-nyse-tup/	2022-06-24T23:46:56Z	https://www.kplctv.com/prnewswire/2022/06/24/tupperware-brands-corporation-nyse-tup-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-deadline-file-lead-plaintiff-motion-securities-class-action-lawsuit-against-tupperware-brands-corporation-nyse-tup/	true	58
Español Italiano Français My Account My Account Notifications Log In QQQ – –% DIA – –% SPY – –% TLT – –% GLD – –% BTC/USD – –% Data & APIs Events Marketfy Premarket Contribute Español Italiano Français Sign in News Earnings Guidance Dividends M&A Buybacks Legal Interviews Management Retail Sales Offerings IPOs Insider Trades Biotech/FDA Freight Politics Government Healthcare Markets Pre-Market After Hours Movers ETFs Forex Cannabis Commodities Options Binary Options Bonds Futures CME Group Global Economics Previews Reviews Small-Cap Cryptocurrency Penny Stocks Digital Securities Ratings Analyst Color Downgrades Upgrades Initiations Price Target Ideas Trade Ideas Long Ideas Short Ideas Technicals From The Press Jim Cramer Rumors Best Stocks & ETFs Best Penny Stocks Best S&P 500 ETFs Best Swing Trade Stocks Best Blue Chip Stocks Best High-Volume Penny Stocks Best Small Cap ETFs Fintech News Podcast Events Newsletter Personal Finance Compare Online Brokers Stock Brokers Forex Brokers Futures Brokers Crypto Brokers Options Brokers ETF Brokers Mutual Fund Brokers Index Fund Brokers Bond Brokers Short Selling Brokers Stock Apps All Broker Reviews Insurance Auto Home Medicare Life Vision Dental Business Pet Health Motorcycle Renters Workers Comp Top Stocks Penny Stocks Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $50 Stocks Under $100 Alternative Investing Invest in Art Invest in Land Invest in Real Estate Invest in Wine Invest in Gold Mortgages Refinance Purchase Find a Mortgage Broker Alts Best Real Estate Crowdfunding Platforms REITs Versus Crowdfunding How to Invest in Artwork Best Alternative Investments Best Alternative Investment Platforms Crypto Get Started Is Bitcoin a Good Investment? Is Ethereum a Good Investment? What is Blockchain Best Altcoins How to Buy Cryptocurrency? DeFi Crypto and DeFi 101 What is DeFi? Decentralized Exchanges Best DeFi Yield Farms Digital Securities NFTs NFT Release Calendar What is a Non-Fungible Token (NFT)? How to Buy Non-Fungible Tokens (NFTs) CryptoPunks Watchlist Are NFTs a Scam or a Digital Bubble? Best In Crypto Best Crypto Apps Best Crypto Portfolio Trackers Best Crypto Day Trading Strategies Best Crypto IRA Best Cryptocurrency Scanners Best Business Crypto Accounts Best Crypto Screeners Cannabis News Earnings Interviews Deals Regulations Psychedelics TV YouTube Video Podcasts Trading School Personal Finance Compare Online Brokers Stock Brokers Forex Brokers Futures Brokers Crypto Brokers Options Brokers ETF Brokers Mutual Fund Brokers Index Fund Brokers Bond Brokers Short Selling Brokers Stock Apps All Broker Reviews Insurance Auto Home Medicare Life Vision Dental Business Pet Health Motorcycle Renters Workers Comp Top Stocks Penny Stocks Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $50 Stocks Under $100 Alternative Investing Invest in Art Invest in Land Invest in Real Estate Invest in Wine Invest in Gold Mortgages Refinance Purchase Find a Mortgage Broker Alts Best Real Estate Crowdfunding Platforms REITs Versus Crowdfunding How to Invest in Artwork Best Alternative Investments Best Alternative Investment Platforms Crypto Get Started Is Bitcoin a Good Investment? Is Ethereum a Good Investment? What is Blockchain Best Altcoins How to Buy Cryptocurrency? DeFi Crypto and DeFi 101 What is DeFi? Decentralized Exchanges Best DeFi Yield Farms Digital Securities NFTs NFT Release Calendar What is a Non-Fungible Token (NFT)? How to Buy Non-Fungible Tokens (NFTs) CryptoPunks Watchlist Are NFTs a Scam or a Digital Bubble? Best In Crypto Best Crypto Apps Best Crypto Portfolio Trackers Best Crypto Day Trading Strategies Best Crypto IRA Best Cryptocurrency Scanners Best Business Crypto Accounts Best Crypto Screeners Cannabis News Earnings Interviews Deals Regulations Psychedelics TV YouTube Video Podcasts Trading School My Stocks Tools Calendars Analyst Ratings Calendar Dividend Calendar Conference Call Calendar Earnings Calendar Economic Calendar FDA Calendar Guidance Calendar IPO Calendar M&A Calendar Retail Sales Calendar SPAC Calendar Stock Split Calendar Trade Ideas Insider Trades Trade Idea Feed Analyst Ratings Unusual Options Activity Heatmaps Short Interest Most Shorted Largest Increase Largest Decrease Calculators Margin Calculator 100x Options Profit Calculator Premium QQQ – –% DIA – –% SPY – –% TLT – –% GLD – –% BTC/USD – –% PRUDENTIAL INVESTMENT PORTFOLIOS, INC. 10 (FormNPORT-P) (0001752724-22-143632) Accepted: Form Type: NPORT-P Accession Number: 0001752724-22-143632	https://www.benzinga.com/secfilings/22/06/27831940/prudential-investment-portfolios-inc-10-formnport-p-0001752724-22-143632	2022-06-24T23:52:11Z	https://www.benzinga.com/secfilings/22/06/27831940/prudential-investment-portfolios-inc-10-formnport-p-0001752724-22-143632	true	254241
Shares of Hologic Inc. HOLX, +0.54% inched 0.54% higher to $70.93 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +3.06% rising 3.06% to 3,911.74 and the Dow Jones Industrial Average DJIA, +2.68% rising 2.68% to 31,500.68. This was the stock's second consecutive day of gains. Hologic Inc. closed $10.11 below its 52-week high ($81.04), which the company achieved on September 10th. The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson JNJ, +1.46% rose 1.46% to $182.29, Abbott Laboratories ABT, +3.05% rose 3.05% to $109.45, and Thermo Fisher Scientific Inc. TMO, +0.78% rose 0.78% to $544.81. Trading volume (2.8 M) eclipsed its 50-day average volume of 2.2 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.	https://www.marketwatch.com/story/hologic-inc-stock-rises-friday-still-underperforms-market-01656104263-c8d382726e9a	2022-06-24T23:53:27Z	https://www.marketwatch.com/story/hologic-inc-stock-rises-friday-still-underperforms-market-01656104263-c8d382726e9a	false	3658
WSU Ph.D. candidate researches link between white identity politics and support for voter suppression – Today@Wayne When Wayne State University political science doctoral student Jim O’Donnell considers how political and social opinion among white Americans have been radically shifting in the past several years, he doesn’t necessarily need to consult reams of research or pore over sociological studies. Sometimes, O’Donnell says, it’s as... worldnewz247.com	https://www.newsbreak.com/news/2644483704589/wsu-ph-d-candidate-researches-link-between-white-identity-politics-and-support-for-voter-suppression-today-wayne	2022-06-24T23:57:52Z	https://www.newsbreak.com/news/2644483704589/wsu-ph-d-candidate-researches-link-between-white-identity-politics-and-support-for-voter-suppression-today-wayne	false	null
Shares of Juniper Networks Inc. JNPR, +3.30% rose 3.30% to $29.15 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +3.06% rising 3.06% to 3,911.74 and the Dow Jones Industrial Average DJIA, +2.68% rising 2.68% to 31,500.68. This was the stock's second consecutive day of gains. Juniper Networks Inc. closed $8.99 short of its 52-week high ($38.14), which the company reached on March 31st. The stock outperformed some of its competitors Friday, as Cisco Systems Inc. CSCO, +2.73% rose 2.73% to $44.10, International Business Machines Corp. IBM, +2.61% rose 2.61% to $142.06, and Telefon AB L.M. Ericsson ADR ERIC, +3.03% rose 3.03% to $7.83. Trading volume (3.7 M) remained 485,600 below its 50-day average volume of 4.1 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.	https://www.marketwatch.com/story/juniper-networks-inc-stock-outperforms-competitors-on-strong-trading-day-01656104508-2d11c1927852	2022-06-24T23:58:33Z	https://www.marketwatch.com/story/juniper-networks-inc-stock-outperforms-competitors-on-strong-trading-day-01656104508-2d11c1927852	true	3658
Mason celebrates 40th anniversary and upgrades their office space this summer! Mason Investment Advisory Services, Inc., turns 40 this year and is moving to an upgraded office space. The company plans to maintain in-office presence. RESTON, Va., June 23, 2022 /PRNewswire/ -- Mason Investment Advisory Services, Inc., a Reston, VA based registered investment advisory firm, is excited to celebrate its 40th anniversary this summer and will move to a new and upgraded office location next week. While some firms have chosen to move to a 100% virtual workplace, Mason believes that it is still important to maintain a physical office presence while also allowing for the flexibility of remote work. Mason's new headquarters will be in the Reston Town Center outside of Washington, DC. As Mason celebrates its special anniversary, we are taking the opportunity to say thank you to our private and institutional clients. Mason staff find it rewarding to be able to continue to work with many of our original private clients, their family members, children, and grandchildren. Mason is also very appreciative of its original and newer institutional client staff, committees, and boards. Mason's Founder and Chairman, William N. Mason, III, said that "as fiduciaries, we are committed to objectivity, which keeps our focus exactly where it should be – on our clients." As an independent firm with no proprietary products, Mason holds its work to the highest fiduciary standards. As Mason has grown its reputation, expanded its client base, and increased its assets under management, it has also increased its business profile among investment advisory companies. Over the last year, Mason crossed $11 billion in assets under management for the first time, and was listed at number 13 on both the Barron's Top 100 Institutional Consulting Teams list and the CNBC FA 100 list. Mason is extremely proud to be recognized by both Barron's and CNBC and believe that it is a testament to Mason's service model and its clients' trust and commitment to Mason's brand of wealth management. Please click the following links for more information about Mason, its private client practice, and or its institutional client practice. Founded in 1982, Mason works with private individuals, families, and institutions (foundations, endowments, corporate funds, and retirement plans) in more than 40 states, is independently held, and does not create any proprietary products. Mason has over $11 billion in assets under management and aggregated/reporting only assets. Mason is an investment advisor registered with the SEC. Please note that SEC registration does not constitute an endorsement of the firm by the Commissioner, nor does it indicate that the firm's advisors have attained a particular level of skill or ability. View original content to download multimedia:https://www.prnewswire.com/news-releases/mason-celebrates-40th-anniversary-and-upgrades-their-office-space-this-summer-301573649.html SOURCE Mason Investment Advisory Services, Inc. Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu! Jetzt informieren!	https://www.finanzen.at/nachrichten/aktien/mason-celebrates-40th-anniversary-and-upgrades-their-office-space-this-summer!-1031546727	2022-06-25T00:00:15Z	https://www.finanzen.at/nachrichten/aktien/mason-celebrates-40th-anniversary-and-upgrades-their-office-space-this-summer!-1031546727	false	2
The Jan. 6 hearings have us to believe a big lie that President Trump was detached from reality. I think these hearings are a conspiracy and unconstitutional. I quote a section of Mr. George Will of the Washington Post: “Congress has neither a constitutional power nor an institutional aptitude for building a criminal case against Donald Trump. If the committee attempts this, it will sink into the quicksand of fascinating but legally problematic definitions of conspiracy and of speech that becomes illegal by inciting illegality.” Do those that are on the hearing committee think they are above the law? Those meaning Democrats. John Benick, Trevorton	https://www.dailyitem.com/opinion/believing-a-big-lie/article_c9f893f8-f27f-11ec-9470-f3c107e890e4.html	2022-06-25T00:01:20Z	https://www.dailyitem.com/opinion/believing-a-big-lie/article_c9f893f8-f27f-11ec-9470-f3c107e890e4.html	true	null
Shares of Nielsen Holdings PLC NLSN, +1.64% rose 1.64% to $23.53 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +3.06% rising 3.06% to 3,911.74 and the Dow Jones Industrial Average DJIA, +2.68% rising 2.68% to 31,500.68. This was the stock's fifth consecutive day of gains. Nielsen Holdings PLC closed $4.26 below its 52-week high ($27.79), which the company achieved on April 7th. The stock underperformed when compared to some of its competitors Friday, as Gartner Inc. IT, +4.22% rose 4.22% to $251.29 and comScore Inc. SCOR, +2.00% rose 2.00% to $2.04. Trading volume (2.1 M) remained 2.4 million below its 50-day average volume of 4.5 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.	https://www.marketwatch.com/story/nielsen-holdings-plc-stock-rises-friday-still-underperforms-market-01656105010-39d593b834b2	2022-06-25T00:06:05Z	https://www.marketwatch.com/story/nielsen-holdings-plc-stock-rises-friday-still-underperforms-market-01656105010-39d593b834b2	true	null
SmokeOut BBQ Open today 11:00 AM - 11:00 PM No reviews yet Orders through Toast are commission free and go directly to this restaurant All hours Location 1850 Winderly Ln, Pickerington OH 43147 Open today 11:00 AM - 11:00 PM No reviews yet Orders through Toast are commission free and go directly to this restaurant 1850 Winderly Ln, Pickerington OH 43147	https://www.toasttab.com/local/smokeoutbbq/r-6fc3d4aa-9ef3-458c-87e9-45c5787c2870	2022-06-25T00:08:05Z	https://www.toasttab.com/local/smokeoutbbq/r-6fc3d4aa-9ef3-458c-87e9-45c5787c2870	true	null
Sen. Collins, Shaheen to introduce bill that could lower cost of insulin PORTLAND, Maine — Two New England lawmakers will introduce a bipartisan bill Wednesday that could lower the cost of insulin. Sens. Susan Collins and Jeanne Shaheen co-chair the Senate Diabetes Caucus. Their bill would create a program where patients would receive protections on insulin products at reduced prices.... www.wmtw.com	https://www.newsbreak.com/news/2644319931214/sen-collins-shaheen-to-introduce-bill-that-could-lower-cost-of-insulin	2022-06-25T00:08:10Z	https://www.newsbreak.com/news/2644319931214/sen-collins-shaheen-to-introduce-bill-that-could-lower-cost-of-insulin	false	null
NORTH PORT, Fla. — The attorney for the family of Brian Laundrie released the contents of a suicide letter Friday. In the letter, Laundrie claimed responsibility for the death of Gabby Petito. Petito was reported missing on Sept. 11, and her body was found in Wyoming's Bridger-Teton on Sept. 19. Petito's remains were found in Wyoming at the Grand Teton National Park on Sept. 19. Laundrie was then sought by police and his body was found on October 20, 2021. In the letter, Brian said Gabby fell and was in pain. On page 7 of the letter, Laundrie talked about what he did. "I don't know the extent of gabbys injurys (sic), only that she was in extreme pain," Laudrie wrote. "I ended her life. I thought it was merciful, that it is what she wanted, but I see now all the mistakes I made. I panicked. I was in shock. But from the moment I decided, took away her pain, I knew I couldn't go on without her." On the next page, Laundrie said he "rushed home to spend the time I had left with my family." He said he "wanted to drive north and let James or T.J. kill me, but I wouldn't want them to spend time in jail over my mistake, even though I'm sure they would have (unknown) too. RECOMMENDED: - Judge to decide if Petito-Laundrie case goes to trial - Parents of Brian Laundrie file motion to dismiss lawsuit filed by Gabby Petito's parents - Parents of Gabby Petito file lawsuit against parents of Brian Laundrie - Autopsy determines Brian Laundrie died by suicide - FBI: Laundrie claimed responsibility for death of Petito in notebook Laundrie said in his letter he was "ending my life not because of a fear of punishment, but rather because I can't stand to live another day without her (Gabby)." "I'm sorry for everyone's loss," Laundrie wrote. "Please do not make life harder for my family. They lost a son and a daughter. The wonderful girl in the world. Gabby I'm sorry." He concluded by writing, "I have killed myself by this creek in the hopes that animals may tear me apart. That it may make some of her family happy. Please pick up all of my things. Gabby hated people who litter." The full letter can be seen below. Brian Laundrie Suicide Letter by ABC Action News on Scribd This story was originally published by Tim Kephart at WFTS in Tampa, Florida.	https://www.turnto23.com/news/national/brian-laundries-suicide-letter-says-he-ended-gabby-petitos-life	2022-06-25T00:15:48Z	https://www.turnto23.com/news/national/brian-laundries-suicide-letter-says-he-ended-gabby-petitos-life	false	10
Shares of Sherwin-Williams Co. SHW, +2.83% rose 2.83% to $231.25 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +3.06% rising 3.06% to 3,911.74 and the Dow Jones Industrial Average DJIA, +2.68% rising 2.68% to 31,500.68. This was the stock's third consecutive day of gains. Sherwin-Williams Co. closed $122.90 below its 52-week high ($354.15), which the company reached on December 30th. The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Home Depot Inc. HD, +2.75% rose 2.75% to $283.00, PPG Industries Inc. PPG, +5.81% rose 5.81% to $121.01, and Masco Corp. MAS, +4.58% rose 4.58% to $51.80. Trading volume (2.7 M) eclipsed its 50-day average volume of 1.9 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.	https://www.marketwatch.com/story/sherwin-williams-co-stock-rises-friday-still-underperforms-market-01656105605-1192db7f8cf4	2022-06-25T00:18:11Z	https://www.marketwatch.com/story/sherwin-williams-co-stock-rises-friday-still-underperforms-market-01656105605-1192db7f8cf4	false	3658
Johnson says increasing cost of living in UK ‘should not be reason to abandon support for Ukraine’ This item is part of our running news digest June 9, 2022 7:15 pm Although Russia’s war has driven up prices in the U.K., abandoning Ukraine would be “morally repugnant” and would "encourage” Russian dictator Vladimir Putin, U.K. Prime Minister Boris Johnson said. “(Putin) would be able to continue to twist the knife in the wound, the crocodile would simply come back for more and he would be able to claim that his aggression and his violence had paid off,” Johnson said as quoted by The Guardian.	https://kyivindependent.com/uncategorized/johnson-says-increasing-cost-of-living-in-uk-should-not-be-reason-to-abandon-support-for-ukraine	2022-06-25T00:19:12Z	https://kyivindependent.com/uncategorized/johnson-says-increasing-cost-of-living-in-uk-should-not-be-reason-to-abandon-support-for-ukraine	false	null
Which Samsung side-by-side refrigerator is best? Side-by-side refrigerators are designed with two tall, narrow compartments, both extending the full height of the refrigerator. One side is for the refrigerator and the other is for the freezer. In most cases, the refrigerator compartment is larger than the freezer. Samsung is a well-regarded maker of appliances and electronics of all kinds. If you are looking for a Samsung smart appliance with Alexa and Wi-Fi built right in, take a look at the Samsung 26.7-Cubic-Foot Side-by-Side Refrigerator With Touch Screen Controls. What to know before you buy a Samsung side-by-side refrigerator Size Because side-by-side refrigerators have narrower doors than traditional freezer-over and freezer-under models, they need less clearance than refrigerators with full-width doors. Open doors on side-by-sides don’t extend as far into your kitchen, either, so they leave you more space to move around. Is a side-by-side refrigerator right for you? Pros - More storage: In general, side-by-side refrigerators have more storage space than other styles. - Narrower doors: They take up less room and are a great choice in smaller kitchens. - Easy organization: You can put your most-used refrigerated and frozen foods on the top shelves, where they’re at eye level and easy to get at. - Kid control: You can set items for small kids on lower shelves and items you don’t want them handling on higher shelves. - Findable frozens: Side-by-side refrigerators’ freezers have more shelves, so frozen foods are less likely to get lost. Cons - Space gobblers: In general, side-by-side refrigerators take up more space. - Narrow compartments: Some side-by-side refrigerators have freezer compartments narrower than the width of a pizza box, so storing larger items could be a problem. - Higher prices: Side-by-sides cost more than traditional freezer-over and freezer-under models. Measure first - Depth: Measure from the wall to the front of the counter. Side-by-side refrigerators are anywhere from 32 to 40 inches wide. - Width: Measure from cabinet to cabinet or from cabinet to wall. Side-by-side refrigerators are anywhere from 29 to 32 inches deep. If you plan on placing your refrigerator next to a wall, leave three inches between the wall and the hinged side of the door so it can open fully and freely. What to look for in a quality Samsung side-by-side refrigerator Capacity Choose a Samsung side-by-side big enough for your household’s food storage needs. Samsung makes side-by-sides with capacities from 22 to 28 cubic feet. Organization Look for adjustable shelves and bins that open and close easily. Special racks let you save space by storing bottles on their sides. Also, look for LED interior lighting and space in the refrigerator for tall items. Samsung’s Family Hub Family Hub refrigerators keep you connected by letting you control your Samsung smart appliances, stream music while you cook, share family photos on the on-door screen, see who’s at the door and more, all from your refrigerator door. With Wi-Fi connectivity, Alexa built in and the power to connect anytime from anywhere, a Family Hub makes your refrigerator the hub of your kitchen activities. Family Hub food features - Quick view inside: Tap or swipe to see what’s inside. - Smart recipes: Instant access to recipes and videos with just a touch. - Shopping lists: Create lists and share them with others. - Same-day pickup or delivery: Send your shopping list to Fresh Direct and Instacart. - Meal planner: Plan your meals based on the food that’s inside your refrigerator. Other Family Hub features - Display digital photos and videos. - Draw on the whiteboard and write notes, memos and to-do lists. - Sync calendars and events. - Search and browse the internet. How much you can expect to spend on a Samsung side-by-side refrigerator Samsung makes side-by-sides from $1,350-$2,400, depending on their size and features. Samsung side-by-side refrigerator FAQ Are side-by-side refrigerators the same thing as french door refrigerators? A. One is oriented vertically and the other horizontally. Both have doors that open outward, but side-by-side models have one tall side that is exclusively refrigerator while the opposite side is all freezer space. French door models are designed so the refrigerator compartment takes up the entire top and the bottom freezer pulls out like a large drawer. What are dual evaporators? A. Evaporators make the inside of refrigerators and freezers cold by removing moisture from the air. Fruits and vegetables need high humidity to stay fresh while freezer air should be dry. Having two separate evaporators prevents air from the refrigerator from mingling with air from the freezer, maintaining their separate humidities. What’s the best Samsung side-by-side refrigerator to buy? Top Samsung side-by-side refrigerator Samsung 26.7-Cubic-Foot Counter Depth Side-by-Side Refrigerator With Touch Screen Controls What you need to know: Alexa and Wi-Fi are built into this smart appliance. What you’ll love: You can see inside your refrigerator from anywhere and search recipes using what you have on hand. The touch screen hub lets you shop, send notes and sync schedules. You can organize your fresh and frozen foods on 16 shelves and in four pull-out drawers. What you should consider: The shelves are not adjustable. Where to buy: Sold by Home Depot Top Samsung side-by-side refrigerator for the money Samsung 27.4-Cubic-Foot Large-Capacity Stainless Steel Side-by-Side Refrigerator What you need to know: This large refrigerator has an integrated dispenser with a touch display for easy access to water, cubed or crushed ice. What you’ll love: The in-door ice maker has a spacious bin and the stainless steel exterior is fingerprint-resistant. Multi-vent technology cools every shelf evenly. The no-handle doors give it a sleek appearance while letting it fit in a 36-by-33-inch space. What you should consider: Some reviewers say it should make ice more quickly. Where to buy: Sold by Home Depot Worth checking out Samsung 22-Cubic-Foot Counter Depth Side-by-Side Refrigerator What you need to know: This is a great choice for those who prefer white appliances to the look of stainless steel. What you’ll love: Samsung’s twin cooling feature keeps perishable produce fresher longer with high humidity on the refrigerator side and protects against freezer burn with dry air on the freezer side. LED lighting brightens every corner and the automatic in-door ice dispenser saves space while producing 5.5 pounds of ice per day. What you should consider: Some users have complained the ice maker is too noisy. Where to buy: Sold by Home Depot Want to shop the best products at the best prices? Check out Daily Deals from BestReviews. Sign up here to receive the BestReviews weekly newsletter for useful advice on new products and noteworthy deals. David Allan Van writes for BestReviews. BestReviews has helped millions of consumers simplify their purchasing decisions, saving them time and money. Copyright 2022 BestReviews, a Nexstar company. All rights reserved.	https://www.kxan.com/reviews/br/beauty-personal-care-br/storage-br/samsung-side-by-side-refrigerator/	2022-06-25T00:32:23Z	https://www.kxan.com/reviews/br/beauty-personal-care-br/storage-br/samsung-side-by-side-refrigerator/	true	29
MILWAUKEE, June 24, 2022 /PRNewswire/ -- Ademi LLP is investigating USA Truck (NASDAQ: USAK) for possible breaches of fiduciary duty and other violations of law in its transaction with DB Schenker. Click here to learn how to join the action: https://www.ademilaw.com/case/usa-truck-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. Ademi LLP alleges USA Truck's financial outlook and prospects are excellent and yet USA Truck holders will receive only $31.72 per share in cash, which values USA Truck at approximately $435 million, including assumed cash and debt. The transaction agreement unreasonably limits competing bids for USA Truck by imposing a significant penalty if USA Truck accepts a superior bid. USA Truck insiders will receive substantial benefits as part of change of control arrangements. We are investigating the conduct of USA Truck's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for USA Truck. If you own USA Truck common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/usa-truck-inc. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Ademi LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001 View original content to download multimedia: SOURCE Ademi LLP	https://www.wrdw.com/prnewswire/2022/06/24/shareholder-alert-ademi-llp-investigates-whether-usa-truck-inc-has-obtained-fair-price-its-transaction-with-db-schenker/	2022-06-25T00:39:00Z	https://www.wrdw.com/prnewswire/2022/06/24/shareholder-alert-ademi-llp-investigates-whether-usa-truck-inc-has-obtained-fair-price-its-transaction-with-db-schenker/	false	695
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/milwaukee-brewers/articles/39893055	2022-06-25T00:42:08Z	https://sportspyder.com/mlb/milwaukee-brewers/articles/39893055	true	null
Officers with the Colorado Springs Police Department are investigating a homicide in the 2700 block of East Las Vegas Street, officials with the department announced Friday. The department's violent crimes unit is investigating. No other details were immediately provided by police. There have been at least 25 homicides in the city this year. There were at least 40 homicides last year, making 2021 the deadliest year on record.	https://gazette.com/news/crime/police-investigating-homicide-in-southern-colorado-springs/article_25380b52-f408-11ec-af16-8b46f27daf96.html	2022-06-25T00:45:59Z	https://gazette.com/news/crime/police-investigating-homicide-in-southern-colorado-springs/article_25380b52-f408-11ec-af16-8b46f27daf96.html	false	null
Sarina Wiegman vowed England Women would “stay grounded” after they thumped reigning champions the Netherlands 5-1 in their penultimate warm-up match ahead of next month’s home European Championship. The Lionesses came from behind to claim the eye-catching victory at Elland Road, their 11th win in 13 matches unbeaten under Wiegman. The Dutchwoman, who guided the Netherlands to Euro 2017 glory and the 2019 World Cup final prior to becoming England boss last September, said when asked about her side being spoken about as favourites to lift the trophy this summer: “I think there are many favourites for this tournament and we are one of them. “But we know where we want to go to and we stick to our strategy and plans, and whether we would lose or win now, we’re not going to all of a sudden sit, we call it, on a pink cloud. We stay grounded. “Even if we had lost today, then still we know what we can improve, what we do well, and we want to take the next step in our style of play. “Of course, the expectation will go higher, but now it’s a moment. I think we’re in a good place, but we still need to improve a couple of things, and we know that.” After the first half had seen Lucy Bronze cancel out Lieke Martens’ opener, England had a let-off seven minutes into the second half when Sherida Spitse, on her 200th Netherlands appearance, struck a penalty off a post and wide. A minute later, Beth Mead put the hosts ahead with a close-range finish, fellow substitute Ella Toone and Lauren Hemp then added efforts in the 72nd and 74th minutes, and Mead subsequently netted her second late on to wrap things up. Wiegman said: “I thought it was a very good match. We had a hard time the first half, I think the Netherlands did very well and we didn’t play to our strengths, we were struggling, and I think we played a very good second half. “It gives confidence because we know we have lots of depth in our team, lots of quality. I have a hard choice to make for the first XI. “It was for us a good learning moment (in the first half), that we were behind. We haven’t been behind since I came in, so it was good to see the reaction of the team. Even when we were struggling, we were on it and able to bring the game to the level that we should be able to play.” England play the final of their three warm-up fixtures against Switzerland in Zurich next week before taking on Austria at Old Trafford in the opening match of the Euros on July 6. After last week’s 3-0 victory over Belgium at Molineux, Wiegman had said that “more ruthlessness” would be required at the summer’s tournament. Asked how she felt about the ruthlessness against the Netherlands, Wiegman said: “Very happy. “We have been talking about we have to be more ruthless, but I think tonight, we scored the goals, we were really on it, and that’s really nice to see.” Wiegman’s successor as Netherlands boss, Englishman Mark Parsons, expressed his view that England were Euros favourites, and also said he had “let down” his team in the second half. Parsons said: “When the (final) whistle went, I knew I was going to be analysing a shorter game, with 60 minutes. “There would be no point in looking any further because I let them down. At that point the organisation should have been a lot safer, more defensive, because the legs had gone and England were just getting fresher and fresher with their changes, with the home crowd. “I think England will be favourites in the Euros, where they’re at, the quality of players, the home crowd, the resources that the WSL have been putting in, the work the clubs have been doing. You add all that up and it’s very hard to see that they’re not favourites.” Subscribe or register today to discover more from DonegalLive.ie Buy the e-paper of the Donegal Democrat, Donegal People's Press, Donegal Post and Inish Times here for instant access to Donegal's premier news titles. Keep up with the latest news from Donegal with our daily newsletter featuring the most important stories of the day delivered to your inbox every evening at 5pm.	https://www.ireland-live.ie/news/football/845001/sarina-wiegma-wants-england-women-to-remain-grounded-after-win-over-netherlands.html	2022-06-25T00:51:07Z	https://www.ireland-live.ie/news/football/845001/sarina-wiegma-wants-england-women-to-remain-grounded-after-win-over-netherlands.html	true	3
National runner-up North Carolina, a strong contender for the No. 1 spot in the preseason polls with four starters returning, will play at Indiana in the ACC/Big Ten Challenge on Nov. 30. The two conferences announced Friday the 14 matchups for the 24th edition of the three-day event, which the ACC leads 12-8 with three ties. The Big Ten won 8-6 last season for its third straight win. The ACC has a 144-121 advantage in all games since the genesis in 1999. The other headliner matchup for Nov. 30 has Ohio State at Duke, which carries the nation’s No. 1 recruiting class in new coach Jon Scheyer’s first year. The four other games on Nov. 30 are Purdue at Florida State, Boston College at Nebraska and Rutgers at Miami and Michigan State at Notre Dame. The latter two matchups feature a pair of NCAA Tournament teams from 2022. The six-game slate on Nov. 29 features Virginia at Michigan. Syracuse at Illinois, Maryland at Louisville, Penn State at Clemson, Wake Forest at Wisconsin and Georgia Tech at Iowa are the other matchups. On Nov. 28, Minnesota plays at Virginia Tech and Pittsburgh visits Northwestern. ___ More AP college basketball: https://apnews.com/hub/college-basketball and https://apnews.com/hub/ap-top-25-college-basketball-poll and https://twitter.com/AP_Top25	https://www.wrbl.com/sports/ap-sports/unc-indiana-ohio-state-duke-headline-acc-big-10-challenge/	2022-06-25T00:52:10Z	https://www.wrbl.com/sports/ap-sports/unc-indiana-ohio-state-duke-headline-acc-big-10-challenge/	true	35
Press Release: RIDOT and Congressional Delegation Break Ground on Cranston Canyon Project RHODE ISLAND, June 24 - U.S. Senators Jack Reed and Sheldon Whitehouse, Rhode Island Department of Transportation (RIDOT) Director Peter Alviti and other state and local leaders today gathered on Phenix Avenue in Cranston to break ground for the $85 million Cranston Canyon Project. The project will address deteriorated bridges along the western end of Route 37 and its intersection with I-295 and make many safety improvements along the "canyon" section of I-295 – the nickname given for the rocky outcropping on this section of the Interstate. The improvements also will reduce chronic congestion issues on both highways, which reduces vehicle emissions. The Cranston Canyon is a design-build project, and was awarded to Aetna Bridge with AECOM, the lead design firm. The design-build process is advantageous because it often provides innovative solutions to the construction of the project, including keeping traffic moving through these busy corridors with the least amount of disruption possible. It also allows design and construction activities to take place at the same time. This approach, in concert with the use of accelerated bridge construction methods, will shave a year off the construction schedule. "RIDOT is able to move ahead with this project thanks in large part to the efforts of our Congressional delegation which once more went to bat for us and helped secure a $21 million federal BUILD grant," Director Alviti said. "With these extra funds, we have been able to put together a very comprehensive project to solve traffic problems, fix deteriorated bridges and make these highways safer; all in a single project." "Anyone who has driven through the 'Cranston Canyon' section of I-295 when traffic is backed up knows it can be a commuter's congestion nightmare. But, soon, this nightmare will be a thing of the past. RIDOT will be adding a new third lane to I-295 North, helping to address that congestion and making this commute much more enjoyable and efficient. This project will also allow RIDOT to repair a number of structurally deficient bridges and boost traffic safety," said Senator Reed, a senior member of the Appropriations Transportation, Housing and Urban Development, and Related Agencies (THUD) Subcommittee. Reed helped create the BUILD grant program (formerly known as TIGER) and has led efforts to fund it. "Projects like this are why the Congressional delegation works so hard to land federal funding for infrastructure upgrades," Senator Whitehouse said. "I'm pleased federal dollars will help Rhode Islanders travel an important stretch of road more safely and efficiently, and glad to have partners like Senator Reed and Congressmen Langevin and Cicilline fighting with me in Washington to bring those dollars home." Highlights of the Cranston Canyon Project include: - • Rebuilding six bridges and building one new bridge along the Route 37 corridor west of Pontiac Avenue in Cranston - • Creating a third lane at I-295 North with new pavement and minor widening, which will work as an auxiliary lane from the Route 37 interchange to the Route 6 interchange in Johnston - • Shifting the ramp from Route 37 East to I-295 North from the high-speed lane to the right lane, improving safety and reducing conflicting movements - • Repositioning the ramp from I-295 North to Route 37 West to eliminate a conflicting weave - • Widening the ramp from Route 37 West to I-295 North to improve sight lines and reduce crashes The Cranston Canyon project will be completed in 2026. It continues RIDOT's efforts to address all the bridges on the Route 37 corridor, representing a second phase which began in 2020 with the $79.5 million Route 37 Bridges Project. That project is addressing 15 bridges from Post Road to Pontiac Avenue and is scheduled to be finished in 2023. Approximately 84,000 vehicles travel on I-295 North between Route 37 and Route 14 and 36,500 vehicles travel on Route 37, west of Pontiac Avenue. All construction projects are subject to changes in schedule and scope depending on needs, circumstances, findings, and weather. The Cranston Canyon Project is made possible by RhodeWorks, RIDOT's ongoing commitment to repair structurally deficient bridges and bring Rhode Island's transportation infrastructure into a state of good repair, promote economic development, and create jobs. Learn more at www.ridot.net/RhodeWorks.	https://www.einpresswire.com/article/578383489/press-release-ridot-and-congressional-delegation-break-ground-on-cranston-canyon-project	2022-06-25T00:53:16Z	https://www.einpresswire.com/article/578383489/press-release-ridot-and-congressional-delegation-break-ground-on-cranston-canyon-project	false	3
Abyss Token (ABYSS) traded flat against the U.S. dollar during the 1-day period ending at 20:00 PM E.T. on June 24th. One Abyss Token coin can now be bought for $0.0151 or 0.00000144 BTC on major exchanges. In the last week, Abyss Token has traded flat against the U.S. dollar. Abyss Token has a market cap of $3.45 million and $144,653.00 worth of Abyss Token was traded on exchanges in the last day. Here is how other cryptocurrencies have performed in the last day: - Binance USD (BUSD) traded up 0.1% against the dollar and now trades at $1.00 or 0.00004685 BTC. - BITCOIN ADDITIONAL (BTCA) traded 6.3% higher against the dollar and now trades at $21,353.23 or 1.00000000 BTC. - Mammoth (MMT) traded down 0% against the dollar and now trades at $1.78 or 0.00008354 BTC. - Crypto.com Coin (CRO) traded up 5% against the dollar and now trades at $0.41 or 0.00001075 BTC. - Parkgene (GENE) traded flat against the dollar and now trades at $25.59 or 0.00045023 BTC. - Dai (DAI) traded up 0% against the dollar and now trades at $1.00 or 0.00004687 BTC. - DREP (DREP) traded flat against the dollar and now trades at $1.96 or 0.00003398 BTC. - DREP [old] (DREP) traded flat against the dollar and now trades at $1.96 or 0.00003399 BTC. - THETA (THETA) traded flat against the dollar and now trades at $5.25 or 0.00010640 BTC. - Polygon (MATIC) traded 6.7% higher against the dollar and now trades at $0.61 or 0.00002839 BTC. Abyss Token Profile According to CryptoCompare, “Abyss Finance provides Decentralized (DeFi) and Centralized (CeFi) Finance solutions for projects in multiple industries. The Abyss is the platform where gamers can play games, socialize and get rewarded. We offer MMO/MMORPG games and share a part of our revenue with gamers. Come to The Abyss and earn from the referral system, gaming achievements, and other activities. “ Buying and Selling Abyss Token It is usually not currently possible to buy alternative cryptocurrencies such as Abyss Token directly using U.S. dollars. Investors seeking to acquire Abyss Token should first buy Bitcoin or Ethereum using an exchange that deals in U.S. dollars such as Gemini, GDAX or Changelly. Investors can then use their newly-acquired Bitcoin or Ethereum to buy Abyss Token using one of the exchanges listed above. Receive News & Updates for Abyss Token Daily - Enter your email address below to receive a concise daily summary of the latest news and updates for Abyss Token and related cryptocurrencies with MarketBeat.com's FREE CryptoBeat newsletter.	https://www.themarketsdaily.com/2022/06/25/abyss-token-abyss-price-tops-0-0151-on-exchanges-2.html	2022-06-25T00:59:22Z	https://www.themarketsdaily.com/2022/06/25/abyss-token-abyss-price-tops-0-0151-on-exchanges-2.html	false	83781
BETHESDA, Md. (AP) — After another sparkling start, In Gee Chun finally hit a wayward tee shot — into the thick rough on the eighth hole at Congressional Country Club. It was the closest she’s come to a shaky stretch through the first two days of the Women’s PGA Championship. Chun recovered from a couple bogeys on the front nine and shot a 3-under 69 on Friday to increase her lead to six strokes at the tournament’s halfway point. Chun led by five after the first round, equaling the biggest 18-hole advantage in the history of women’s major championships. Bogeys at Nos. 7 and 8 in the second round prevented her from pulling even further ahead, but she was still impressive in following up Thursday’s stellar performance. “I really don’t want to think about yesterday. It was almost a perfect game I had,” said Chun, who is 11 under par through two rounds. “If I can think about yesterday, then I feel like I couldn’t make good focus on my game today.” Lydia Ko (67) and Jennifer Kupcho (68) were second. Kupcho took the first major of the season in early April at the Chevron Championship and won a playoff Sunday in Michigan for her second LPGA Tour title. Kupcho sounds comfortable having to chase down Chun. “I think being behind and trying to catch up is better,” she said. “I mean, I had the lead at Chevron by a few strokes, so I know how it feels to be in her position. Being behind is at least my preferred way.” Caroline Inglis (68) was another stroke back at 4 under, along with Brooke Henderson (69), Hannah Green (69), Sei Young Kim (69) and Jennifer Chang (70). After wet conditions for the first round brought the course’s length into focus, it was a clear, warm day Friday, and Congressional was a bit more forgiving. Ko’s impressive performance set the tone early on. Like Chun, Ko is trying for her third major title and first since 2016. Chun began with three birdies in the first five holes. Then she missed the green on the par-3 seventh and took a bogey. On No. 8, a 245-yard par 4, her tee shot went into the rough on the edge of a greenside bunker — the first fairway she’d missed all tournament. Chun punched out of it backwards, then failed to get up and down for par. Still, those were her only two bogeys of the round, and she’s kept the field at arm’s length. She finished with a birdie on the 433-yard 18th, hitting a 7-iron at a pin positioned toward the back of the green, just in front of the water. She made the 10-foot putt for her fifth birdie of the day. “I really want to make the finish with birdie, so I try and make really good focus. I did everything on that putt,” she said. “That’s why I say I’m so happy I made it.” Hye-Jin Choi and Pornanong Phatlum both shot 72 after first-round 69s. They now trail by eight. Lexi Thompson matched Ko with a 67, highlighted by an eagle when she holed out a wedge from 102 yards on the par-4 17th. “I took one more club extra to control the spin,” Thompson said. “I had spun back a good amount of shots. So I tried to take one more and chip it, and I ended up spinning it back. It was still really going fast with the spin, but ended up going in. I just went off the crowd because we can’t see anything from down there.” U.S. Women’s Open champ Minjee Lee (68) was with Thompson at 3 under. Defending Women’s PGA champ Nelly Korda (74) was at 1 over. NOTES: Gerina Mendoza, who shot 79 in the first round, rebounded with a bogey-free 68 to make the cut. … On the wrong side of the cut were Angela Stanford (73), Christina Kim (73), Cristie Kerr (71), Brittany Lincicome (74) and Lizette Salas (72). ___ Follow Noah Trister at https://twitter.com/noahtrister ___ More AP golf: https://apnews.com/hub/golf and https://twitter.com/AP_Sports	https://www.mystateline.com/sports/ap-sports/chun-shoots-69-to-lead-by-6-at-womens-pga-championship/	2022-06-25T01:00:41Z	https://www.mystateline.com/sports/ap-sports/chun-shoots-69-to-lead-by-6-at-womens-pga-championship/	false	21
Did you lose money on investments in DENTSPLY SIRONA? If so, please visit DENTSPLY SIRONA Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, June 24, 2022 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Dentsply Sirona, Inc. ("Dentsply" or the "Company") (NASDAQ: XRAY) between June 9, 2021 and May 9, 2022, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the Southern District of Ohio and alleges violations of the Securities Exchange Act of 1934. Dentsply produces a wide array of dental supplies, ranging from anesthetics, plaque and gum disease prevention, tooth polishers, and artificial teeth. The Company sells approximately two-thirds of its dental consumable and technology and equipment products through third-party distributors. As (former) executives of Dentsply, Defendants Donald M. Casey, Jr. ("Casey") and Jorge Gomez ("Gomez") were eligible for significant cash- and stock-based incentive compensation. Indeed, up to 89% of their annual compensation was awarded based on the Company's ability to meet certain milestones linked to Dentsply's financial performance. Given the challenges posed by the ongoing COVID-19 pandemic, Dentsply bifurcated its Annual Incentive plans for executives into two six-month periods. The 2021 First Half Annual Incentive Plan and the 2021 Second Half Annual Incentive Plan each provided for potential incentive payments based on achievement of performance criteria during the first two and the last two quarters of 2021, respectively. The funding levels for each plan were wholly dependent on the Company's financial performance for the applicable half of 2021. For the first half of the year, Dentsply met the applicable financial performance targets, entitling top executives, including Casey and Gomez, to the maximum compensation under the 2021 First Half Annual Incentive Plan. However, to ensure that they received at least some of their awards under the 2021 Second Half Annual Incentive Plan, Plaintiff alleges that Defendants appear to have orchestrated a scheme to inflate the Company's revenue and earnings by manipulating the way in which Dentsply recognized revenue tied to certain distributor rebate and incentive programs. Plaintiff alleges that Defendants made materially false and misleading statements throughout the Class Period. Specifically, Plaintiff alleges that Dentsply touted its "go-to-market strategy" and "more sophisticated and strategic incentive plans" as drivers of the Company's success. Dentsply also assured investors that it complied with Generally Accepted Accounting Principles ("GAAP") and maintained adequate internal controls over financial reporting, yet the Company announced revenues and earnings that were inflated by the improper recognition of revenue. On April 11, 2022, Dentsply announced that Defendant Gomez had "resigned" as Chief Financial Officer, but assured investors that his departure was "not the result of any dispute or disagreement with the Company, the Company's management or the Board of Directors of the Company on any matter relating to the Company's operations, policies or practices." The truth began to emerge on April 19, 2022, when Dentsply suddenly announced that its Board of Directors had terminated Defendant Casey, the Company's Chief Executive Officer, effective immediately and with no succession plan in place. As a result of this disclosure, Dentsply shares declined by $6.52 per share, or 13%, from $48.72 per share to $42.20 per share. Then, on May 10, 2022, Dentsply announced that, following reports from several internal whistleblowers, the Audit and Finance Committee of its Board of Directors (the "Audit Committee") had commenced an investigation regarding certain financial reporting matters. Specifically, Dentsply disclosed that the Audit Committee was investigating "the Company's use of incentives to sell products to distributors in the third and fourth quarters of 2021" and "whether those incentives were appropriately accounted for" in the Company's periodic reports with the SEC. The Company also disclosed that the Audit Committee is investigating allegations that "certain former and current members of senior management directed the Company's use of these incentives and other actions to achieve executive compensation targets in 2021." On this news, the Company's stock declined over 7% to close at $36.38 per share on May 10, 2022. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. If you purchased XRAY common stock, and/or would like to discuss your legal rights and options please visit DENTSPLY SIRONA Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years. ATTORNEY ADVERTISING. © 2022 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 pallocco@bernlieb.com View original content to download multimedia: SOURCE Bernstein Liebhard LLP	https://www.wtok.com/prnewswire/2022/06/24/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-deadline-file-lead-plaintiff-motion-securities-class-action-lawsuit-against-dentsply-sirona-inc-nasdaq-xray/	2022-06-25T01:02:11Z	https://www.wtok.com/prnewswire/2022/06/24/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-deadline-file-lead-plaintiff-motion-securities-class-action-lawsuit-against-dentsply-sirona-inc-nasdaq-xray/	true	66
x Subscribe to Ukraine Daily: Top news in your mailbox We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.	https://kyivindependent.com/tag/navigation	2022-06-25T01:03:34Z	https://kyivindependent.com/tag/navigation	false	null
WASHINGTON (NEXSTAR) — Security is ramped up Friday night in Washington following the Supreme Court’s ruling on abortion rights. Moments after the supreme court issued its long-expected abortion ruling, a crowd grew outside the fenced court building to protest outside the court — including some members of congress. “Protest peacefully,” said President Joe Biden on Friday, “Violence is never acceptable.” He was calling on abortion rights supporters to remain calm following the Supreme Court’s landmark decision to overturn Roe v. Wade. Michigan Democratic Sen. Gary Peters, D-Mich., says that while he understands the blowback, protestors should take their rage to the polls. Capitol police have increased security and say they are working closely with Supreme Court Police and local law enforcement to keep the area around the court and Capitol safe. But some Republican lawmakers say they remain concerned about the safety of the conservative Supreme Court justices. On Friday, Iowa Sen. Chuck Grassley, R-Iowa, sent a letter to the Department of Justice and Homeland Security asking they “ensure that the court and justices’ families are protected from pro-abortion violent extremist groups.” Republican Senators Roger Marshall, R-Kan., and Josh Hawley, R-Mo., say the danger is real. “Whatever the Supreme Court justices and their families need to be safe we need to do that,” said Marshall. “We’ve had an assassination attempt against a Supreme Court justice. It doesn’t get more violent that,” Hawley said. Last week, President Biden signed bipartisan legislation to expand supreme court security. U.S. marshals are currently protecting each justice and their families.	https://www.wkrg.com/washington-dc/more-security-for-scotus-after-roe-tossed/	2022-06-25T01:03:43Z	https://www.wkrg.com/washington-dc/more-security-for-scotus-after-roe-tossed/	false	13
You need to enable JavaScript to run this app.	https://sportspyder.com/nhl/st-louis-blues/articles/39892915	2022-06-25T01:12:53Z	https://sportspyder.com/nhl/st-louis-blues/articles/39892915	false	null
MALE and female members of a Nkayi family in Matabeleland North Province, who lost 21 cattle after dozing them with a deadly grain protectant, have been sleeping in the same room since the fatal accident last Sunday to guard against any member attempting suicide. The cattle were given a tablet each of the aluminium phosphide which is used for fumigating stored grain, seeds, tobacco among others leading to their death. Of the 22 that were dozed, one is still alive although it is not yet clear if it will fully recover. The devastated family now also has only one other cow and some calves. Mrs Sakhiwe Moyo (48), a niece to the family matriarch, Mrs Janet Mpofu (99), said some relatives had considered consulting traditional healers and prophets over the incident, but the family ended up deciding not to do so. She said the family’s homestead still resembles a post-funeral venue as neighbours continue visiting to console the family. Mrs Moyo said both male and female family members numbering eight have been sleeping in the same room since last Sunday to monitor each other as there are fears that some may fail to deal with the loss. “We are in a difficult situation, for now, batshayekile abadala and we are monitoring them just in case someone has a negative thought about it. We are not blaming anyone because it was just a mistake. My grandmother is 99 years old and will be turning 100 next February and she was so much dependent on the cattle as she cannot move much. They used cattle for water and firewood gathering so this will affect us in a big way,” she said. “When you come to our homestead, you will be forgiven for thinking that we are mourning a person who died. The community is coming in to support us, some are providing water and every necessary thing. My two uncles and grandmother have not moved much and have not yet resumed any duties because they are still coming to terms with the loss.” Mrs Moyo said she almost fainted when she received the news of the death of the cattle. I was coming from seeing a relative who is not feeling well when I received a phone call about the death of the cattle. They told me ukuthi sekulomonakalo ngapha so I initially thought maybe it was a person who had died and when they told me that 18 cattle had died my heart skipped. When I arrived two more died,” she said. “We are a big family and when this happened due to its devastating impact, some suggested we go and find out what happened from inyanga and prophets. We reasoned together as a united family since some of us are Christians and we view this as isilingo that befell the family. There was just a breakdown of communication and nothing more.” Mrs Moyo said a deadly grain protectant was sent home in May two days before schools opened and the person who delivered it told the family that they were tablets for dozing cattle. She said Mr Orderly Mpofu who administered the “doze” initially questioned it as it was not like the other tablets he was used to. “Because he was doubting, he asked one of his daughters-in-law to read and explain to him what was written but it seems she failed to understand. Even the person who was assisting him did not know about it. I was also hoping to doze my cattle once they finish dozing theirs and the number could have been much bigger,” she said. Mrs Moyo said so far, they have not received any help but there are some people who have phoned consoling the family. She said the family is open to any assistance from well-wishers to help them cope with the loss. “My grandmother is old and the cattle were making it easy for those taking care of her to do that. She will feel the impact more and those taking care of her. The cattle were buried in a long and deep trench that was dug inside the kraal and that will always be in our minds. We have agreed as a family that if there are people who may want to assist us, we welcome such a gesture. Those willing to help anyhow can reach me on 0713 449 636,” she said. Efforts to get a comment from Matabeleland North provincial veterinary officer Dr Pollex Moyo were fruitless. Chronicle	http://www.newsdzezimbabwe.co.uk/2022/06/family-on-suicide-watch-following-death.html	2022-06-25T01:20:10Z	http://www.newsdzezimbabwe.co.uk/2022/06/family-on-suicide-watch-following-death.html	true	2
Greene County Supervisors Agree to Help Pay for Pioneer Cemetery Land Survey The Greene County Board of Supervisors met Monday in regular session. The Board approved an amendment to a plat of survey for a property south of Jefferson along the Raccoon River Valley Trail. Attorney Keith Pedersen said following a family member passing away, when the land went to auction, part of... www.raccoonvalleyradio.com	https://www.newsbreak.com/news/2642341379527/greene-county-supervisors-agree-to-help-pay-for-pioneer-cemetery-land-survey	2022-06-25T01:20:49Z	https://www.newsbreak.com/news/2642341379527/greene-county-supervisors-agree-to-help-pay-for-pioneer-cemetery-land-survey	true	null
Gnosis (GNO) traded up 7.8% against the U.S. dollar during the 24-hour period ending at 18:00 PM E.T. on June 24th. During the last week, Gnosis has traded 12.2% higher against the U.S. dollar. One Gnosis coin can currently be purchased for approximately $127.19 or 0.00595048 BTC on major cryptocurrency exchanges. Gnosis has a market cap of $328.10 million and $16.00 million worth of Gnosis was traded on exchanges in the last 24 hours. Here is how related cryptocurrencies have performed during the last 24 hours: - Binance USD (BUSD) traded down 0.1% against the dollar and now trades at $1.00 or 0.00004679 BTC. - BITCOIN ADDITIONAL (BTCA) traded up 6.9% against the dollar and now trades at $21,377.16 or 1.00010978 BTC. - Mammoth (MMT) traded 0.1% lower against the dollar and now trades at $1.78 or 0.00008345 BTC. - Crypto.com Coin (CRO) traded up 5% against the dollar and now trades at $0.41 or 0.00001075 BTC. - Parkgene (GENE) traded flat against the dollar and now trades at $25.59 or 0.00045023 BTC. - Dai (DAI) traded 0% higher against the dollar and now trades at $1.00 or 0.00004682 BTC. - DREP (DREP) traded flat against the dollar and now trades at $1.96 or 0.00003398 BTC. - DREP [old] (DREP) traded flat against the dollar and now trades at $1.96 or 0.00003399 BTC. - THETA (THETA) traded flat against the dollar and now trades at $5.25 or 0.00010640 BTC. - Polygon (MATIC) traded 9.7% higher against the dollar and now trades at $0.61 or 0.00002851 BTC. Gnosis Coin Profile According to CryptoCompare, “Gnosis is a decentralized prediction market built on the Ethereum protocol. Gnosis provides an open platform for anyone to predict the outcome of any event and plans to drastically simplify the creation of customized prediction market applications. GNO is an Ethereum-based token that is used to incentivize long-term participation in the Gnosis platform. “ Buying and Selling Gnosis It is usually not presently possible to purchase alternative cryptocurrencies such as Gnosis directly using US dollars. Investors seeking to trade Gnosis should first purchase Ethereum or Bitcoin using an exchange that deals in US dollars such as Coinbase, GDAX or Changelly. Investors can then use their newly-acquired Ethereum or Bitcoin to purchase Gnosis using one of the aforementioned exchanges. Receive News & Updates for Gnosis Daily - Enter your email address below to receive a concise daily summary of the latest news and updates for Gnosis and related cryptocurrencies with MarketBeat.com's FREE CryptoBeat newsletter.	https://theenterpriseleader.com/2022/06/24/gnosis-price-tops-127-19-on-exchanges-gno.html	2022-06-25T01:27:30Z	https://theenterpriseleader.com/2022/06/24/gnosis-price-tops-127-19-on-exchanges-gno.html	false	83781
VINchain (VIN) traded up 15% against the US dollar during the 24-hour period ending at 20:00 PM ET on June 24th. During the last week, VINchain has traded up 11.2% against the US dollar. One VINchain coin can currently be purchased for approximately $0.0023 or 0.00000011 BTC on major exchanges. VINchain has a total market cap of $1.38 million and approximately $124,103.00 worth of VINchain was traded on exchanges in the last day. Here’s how other cryptocurrencies have performed during the last day: - Binance USD (BUSD) traded 0% lower against the dollar and now trades at $1.00 or 0.00004729 BTC. - BITCOIN ADDITIONAL (BTCA) traded up 5.5% against the dollar and now trades at $21,168.92 or 0.99982238 BTC. - Mammoth (MMT) traded down 0% against the dollar and now trades at $1.78 or 0.00008424 BTC. - Crypto.com Coin (CRO) traded up 5% against the dollar and now trades at $0.41 or 0.00001075 BTC. - Parkgene (GENE) traded flat against the dollar and now trades at $25.59 or 0.00045023 BTC. - Dai (DAI) traded down 0.1% against the dollar and now trades at $1.00 or 0.00004724 BTC. - DREP (DREP) traded flat against the dollar and now trades at $1.96 or 0.00003398 BTC. - DREP [old] (DREP) traded flat against the dollar and now trades at $1.96 or 0.00003399 BTC. - THETA (THETA) traded flat against the dollar and now trades at $5.25 or 0.00010640 BTC. - Polygon (MATIC) traded 1.2% higher against the dollar and now trades at $0.60 or 0.00002836 BTC. About VINchain According to CryptoCompare, “VINchain is creating a blockchain database of used vehicles information that is accessible by everyone. The VinChain Token is an ERC20 token built on the Ethereum network and is used as a utility token on all the apps in the VinChain platform. “ VINchain Coin Trading It is usually not presently possible to purchase alternative cryptocurrencies such as VINchain directly using U.S. dollars. Investors seeking to trade VINchain should first purchase Bitcoin or Ethereum using an exchange that deals in U.S. dollars such as Gemini, Changelly or GDAX. Investors can then use their newly-acquired Bitcoin or Ethereum to purchase VINchain using one of the aforementioned exchanges. Receive News & Updates for VINchain Daily - Enter your email address below to receive a concise daily summary of the latest news and updates for VINchain and related cryptocurrencies with MarketBeat.com's FREE CryptoBeat newsletter.	https://theenterpriseleader.com/2022/06/24/vinchain-vin-trading-up-11-2-over-last-7-days.html	2022-06-25T01:33:02Z	https://theenterpriseleader.com/2022/06/24/vinchain-vin-trading-up-11-2-over-last-7-days.html	true	83781
CROMWELL, Conn. (AP) — Xander Schauffele shot his second straight 7-under 63 on Friday to take a five-stroke lead in the Travelers Championship. The Olympic champion shot a 31 on the front nine at TPC River Highlands with four birdies, then had a 32 on the back, making birdies on 11, 14 and 17. He has hit 33 of 36 greens in regulation and is the only player in the tournament without a bogey. His closest call came close at the par-3 16th, where he hit his tee shot found the rough behind a greenside bunker. “It plays really interesting with the wind swirling through there,” Schauffele said. "It was my least committed swing of the week and just really happy to get up and down there and save par." Kevin Kisner (64), Nick Hardy (64), defending champion Harris English (65), Cam Davis (66) and Patrick Cantlay (67) were tied for second at 9-under. First-round leaders Rory McIlroy and J.T. Poston followed opening 62s with 70s to drop six strokes back. Adam Svensson of Surrey, B.C., was the top Canadian at 5-under after shooting a second-round 64. MacKenzie Hughes of Dundas, Ont., turned in a 66 to sit 4-under. Michael Gligic of Burlington, Ont., and Ben Silverman of Thornhill, Ont., made the 2-under cut with both shooting a 68. Roger Sloan of Merritt, B.C., missed the cut at 1-under. Cantlay, who shot a 60 at TPC River Highlands as an amateur in 2011, played in the same morning group as English. “(I’m) still right here in this tournament, and looking forward to the weekend,” Cantlay said. “I enjoy the challenge, and that’s all you can do in golf, is give yourself as many chances as you possibly can.” English, who won on the eighth hole of a playoff last year, is playing in his third tournament since returning in May from Valentine’s Day surgery to repair a torn labrum in his right hip. “The toughest thing is walking and playing,” English said. “I mean, I feel like back home I can go hit a bunch of balls on the range, but up and down these hills and being on your feet for five or six hours is the toughest part. It’s getting better and better, and I feel like the more I play competitive rounds out here, it’s just going to get stronger.” Hardy, starting on the back nine had four consecutive birdies on 16, 17, 18 and 1. He also is coming back from injury after damaging the tendon is his left wrist in April. “I just was in great rhythm,” Hardy said. “That’s kind of been the name of the game for me since I came back. Just being in good rhythm. I think I’m swinging the club well and my mind is in a good spot.” Kisner had some good luck on 15 when his tee shot went left and rolled toward the course’s signature lake before getting hung up on a microphone cable, inches from the water. He ended up saving par. “Five shots is not insurmountable but I’m a going to need (Schauffele) to slow down a little bit,” Kisner said. Schauffele, played one group ahead of McIlroy, who was still leading by a stroke at 13 under before getting into trouble on the 12th hole. McIlory hit his tee shot left and out of bounds into the woods, then found the deep rough to the right on his next shot. He put the ball into a green-side bunker from there, then chipped out short of the green and into the rough again, before finishing with a quadruple bogey. He left the hole trailing by three strokes and then found more trouble on the 15th. He went right on his tee shot, finding the high grass, then ran his third shot over the green, down the hill and into the water. He finished that hole with a 6. But he made birdie on 16, finishing with an even-par 70 when his birdie putt lipped out on 18. “I should be closer to the lead,” he said. “Feel like I let a lot of guys into the golf tournament because of it.” The last player to make a quadruple bogey and go on to win a PGA Tour event was Adam Scott at the 2016 Honda Classic. Scott put two shots in the water on the par-3 15th hole. The cut was at 2 under, with 2017 winner Jordan Spieth (1 over) dropping out with Sam Burns (even par), Zach Johnson (4 over) and Jason Day (6 over). ___ More AP golf: https://apnews.com/hub/golf and https://twitter.com/AP_Sports	https://www.chroniclejournal.com/sports/national_sports/xander-schauffele-shoots-63-to-take-5-shot-lead-at-travelers/article_46a4deeb-2993-5183-95b8-108ce61f0f72.html	2022-06-25T01:37:40Z	https://www.chroniclejournal.com/sports/national_sports/xander-schauffele-shoots-63-to-take-5-shot-lead-at-travelers/article_46a4deeb-2993-5183-95b8-108ce61f0f72.html	false	19
Juul can continue to sell its electronic cigarettes, at least for now, after a federal appeals court on Friday temporarily blocked a government ban. Juul filed an emergency motion earlier Friday, seeking the temporary hold while it appeals the sales ban. The e-cigarette maker had asked the court to pause what it called an "extraordinary and unlawful action" by the Food and Drug Administration that would have required it to immediately halt its business. The FDA said Thursday that Juul must stop selling its vaping device and its tobacco and menthol flavored cartridges. The action was part of a sweeping effort by the agency to bring scientific scrutiny to the multibillion-dollar vaping industry after years of regulatory delays. To stay on the market, companies must show that their e-cigarettes benefit public health. In practice, that means proving that adult smokers who use them are likely to quit or reduce their smoking, while teens are unlikely to get hooked on them. The FDA said Juul's application left regulators with significant questions and didn't include enough information to evaluate any potential health risks. Juul said it submitted enough information and data to address all issues raised. A three-judge panel of the U.S. Court of Appeals for the District of Columbia Circuit granted Juul's request for a hold while the court reviews the case. While Juul remains a top seller, its share of the U.S. e-cigarette market has dipped to about half. The company was widely blamed for a surge in underage vaping a few years ago, but a recent federal survey showed a drop in the teen vaping rate and a shift away from Juul's products. The devices heat a nicotine solution into a vapor that's inhaled, bypassing many of the toxic chemicals produced by burning tobacco. The company said in its Friday court filing that it submitted a 125,000-page application to the FDA nearly two years ago. It said the application included several studies to evaluate the health risks among Juul users. Juul said that the FDA cannot argue that there was a "critical and urgent public interest" in immediately removing its products from the market when the agency allowed them to be sold during its review. The company noted that the FDA denied its application while authorizing those submitted by competitors with similar products. The FDA has OK'd e-cigarettes from R.J. Reynolds, Logic and other companies, while rejecting many others. In 2019, Juul was pressured into halting all advertising and eliminating its fruit and dessert flavors after they became popular among middle and high school students. The next year, the FDA limited flavors in small vaping devices to just tobacco and menthol. Copyright 2022 NPR. To see more, visit https://www.npr.org.	https://www.wkyufm.org/news/news/2022-06-24/juul-can-keep-selling-its-vaping-products-in-the-u-s-for-now	2022-06-25T01:37:40Z	https://www.wkyufm.org/news/news/2022-06-24/juul-can-keep-selling-its-vaping-products-in-the-u-s-for-now	true	73
Alaska abortion access unchanged, for now, after Roe v. Wade is overturned JUNEAU, Alaska (KTUU) - Abortion access in Alaska will not be impacted by the U.S. Supreme Court’s decision to overturn Roe v. Wade, but pro-life supporters want to change that. Alaska was one of a handful of states that had legalized abortion before the landmark 1973 decision on abortion was issued. Federal constitutional abortion protections were struck down on Friday, but the state’s constitutional right to privacy was overwhelmingly approved by voters in 1972, and it remains intact. The Alaska Supreme Court ruled that those strong privacy protections extended to reproductive rights and abortion access in 1997. Republican Gov. Mike Dunleavy, who identifies as pro-life, pledged to introduce a constitutional amendment at the next legislative session “to answer the question whether abortion shall, or not be a constitutionally protected right. If passed, the amendment would not appear on the ballot until 2024. “I have always had faith in the people of Alaska to make the right decision when it comes to our constitution and protecting our fundamental rights and this issue is no different. My position on this issue has been made clear. Alaskans should have the opportunity to make their position clear as well,” he said through a prepared statement. But with sharp divisions in the state Capitol, that is a high bar to overcome. Two-thirds of the House of Representatives and the Senate would need to pass a constitutional amendment, which would then need to be supported by a majority of voters. The Alaska Legislature adjourned its regular session in May, meaning it is not set to convene again until after November’s election in January next year. Alaska voters could have their say on the issue before then. Every 10 years, Alaska voters are constitutionally required to be asked if they want to hold a constitutional convention. It’s a process that would likely take several years to even begin, but delegates could add or amend articles to Alaska’s constitution, including one that’s been proposed to take decisions about abortions away from state judges. Jim Minnery, president of the Christian Alaska Family Council, was ecstatic on Friday. He has been advocating for Alaskans to vote “yes” on the constitutional convention question to protect “unborn Alaskans.” He said for the faithful, it may seem “divinely appointed” that the constitutional convention question will be on the ballot a few months after Roe v. Wade has been struck down. But it is not certain a convention would end or restrict abortion access in Alaska; delegates may not approve an article to do that, and any constitutional changes would then need to be approved by a majority of Alaska voters after a convention wraps up its work. Abortion and abortion access are poised to become central issues in this year’s elections. Candidates and elected leaders from across the political spectrum released a flood of statements after the court’s decision was announced on Friday, expressing both joy and outrage. Wasilla Republican Rep. Chris Kurka, who is also running to be Alaska’s next governor, is strongly pro-life, having led Alaska Right to Life before he was elected in 2020. He said that Dunleavy’s constitutional amendment plans are “pie in the sky” and that he should immediately call an abortion-related special session on the road system. The governor’s office did not respond to a request for comment on Friday whether he would do that, or if Dunleavy would support the constitutional convention vote. Dunleavy has previously declined to take a public position on that question. Independent former Gov. Bill Walker identifies as pro-life, but he released a statement on Friday, saying that he would defend Alaska’s constitution and a woman’s right to choose. Walker said he would campaign in opposition to a constitutional convention. Former Democratic state legislator Les Gara identifies as the only pro-choice gubernatorial candidate in this year’s race. He says that Alaska’s abortion rights may not be as secure as they appear. Two of the Alaska’s Supreme Court justices will retire in the next three years, having passed the mandatory retirement age of 70, and Gara said it will be critical who the next governor appoints to replace them. At a federal level, Sen. Lisa Murkowski, R-Alaska, released a statement in support of a woman’s right to choose and noted that she has supported legislation to codify reproductive rights. But she has been criticized on social media for voting to confirm two of the five conservative Supreme Court justices who joined together to strike down Roe v. Wade. Pro-life Republican challenger Kelly Tshibaka said that the court’s decision represents “a victory for millions of pre-born Americans to come” while Democratic U.S. Senate candidate Pat Chesbro said she was “outraged” by its impacts on a woman’s right to choose. Copyright 2022 KTUU. All rights reserved.	https://www.alaskasnewssource.com/2022/06/25/alaska-abortion-access-unchanged-now-after-roe-v-wade-is-overturned/	2022-06-25T01:42:04Z	https://www.alaskasnewssource.com/2022/06/25/alaska-abortion-access-unchanged-now-after-roe-v-wade-is-overturned/	true	1
As discussed in our previous Client Alert, the Transparency in Coverage Rule (the "Rule") requires group health plans to disclose two machine readable files ("MRFs") beginning July 1, 2022. The first MRF must disclose information on in-network pricing for certain items and services, and the second MRF must disclose out-of-network allowed amounts. This Client Alert provides additional guidance on disclosing the MRFs by the July 1 deadline. Are self-insured group health plans subject to the Rule? Yes, self-insured plans are subject to the Rule and must provide the MRFs. Are fully insured plans subject to the Rule? Yes, fully insured plans are subject to the Rule and must provide the MRFs. Are grandfathered plans subject to the Rule? No. The Rule applies to non-grandfathered plans, not grandfathered plans. What information is included in the in-network MRF? The in-network MRF must include rates for all covered items and services, except prescription drugs subject to a fee-for-service reimbursement arrangement. For each coverage option, this includes: - The plan's name and 14-digit Health Insurance Oversight System (HIOS) identifier, the 5-digit HIOS identifier where the 14-digit identifier is not available, and if no HIOS identifier is available, the Employer Identification Number. - A billing code. - All applicable rates, which may include negotiated rates, underlying fee schedule rates, and derived amounts. - Other information relating to the rates, reimbursement arrangement, and providers. What information is included in the out-of-network MRF? The out-of-network MRF must include for each coverage option: - The plan's 14-digit HIOS Identifier, the 5-digit HIOS identifier where the 14-digit identifier is not available, and the Employer Identification Number where no HIOS identifier is available - A billing code. - Unique out-of-network allowed amounts and billed charges with respect to covered items or services for specified time periods. Information relating to the allowed amount, including the amount of each item or service and provider information. Do the MRFs have to be publicly available? Yes. The MRFs must be publicly available, free of charge, and available without conditions. This means a plan cannot require individuals to create credentials, user accounts, or submit personally identifiable information before giving them access to the MRFs, and the MRFs cannot be password protected. May the MRFs be provided in a proprietary file format? No. The MRFs must be provided in a nonproprietary, open format. A portable document format (PDF) file, for example, would not meet this requirement due to its proprietary nature. Does a plan need to contract with a third party to create and host the MRFs? The Rule does not require a plan to contract with a third party to create and host the MRFs. Regulators anticipate that plans will contract with third parties to create, host, maintain, and update the MRFs. We encourage all plan sponsors to amend existing contracts with their insurers and TPAs to facilitate compliance with the Rule. Do self-insured and fully-insured plans have to post a link to the MRFs on their public website? The Rule is not completely clear on this issue, but the answer is likely yes. If a third party has posted the MRFs on its website, the plan should post a link to the MRFs on its public website. In addition to linking to the MRFs on the public website, links can be included on intranet websites, in SPDs, and open enrollment materials. What is the deadline for making the files publicly available? The effective deadline for making the files publicly available is July 1, 2022, as that is when the U.S. Department of Labor will begin enforcement. What if a plan or employer does not have a public website? The regulations are not clear on what happens in this circumstance. The regulations do not explicitly require an employer to create a website; they assume a website exists. The regulations require that a group health plan or health insurance issuer make the information available on a website. As such, an employer may want to consider creating a public microsite to link to the MRFs. We anticipate future guidance will address this frequently asked question. Are the MRFs different than the notice regarding balance/surprise billing prohibitions? Yes. As noted in our previous Client Alert, the Consolidated Appropriations Act, 2021, added a new disclosure obligation relating to prohibitions on balance billing. Each group health plan and health insurance issuer offering group health insurance coverage must make publicly available, post on a public website of the plan or issuer, and include on certain explanations of benefits information regarding balance billing prohibitions. The U.S. Department of Labor issued a model notice that can be used for this purpose. This notice applies to plan or policy years beginning on or after January 1, 2022. Next Steps Employers should: - Check with its plan administrator or insurer to confirm that the MRFs are available on their websites. - Post links to the MRFs on their public websites. - Amend their contract with the insurer, third-party administrator, or other third party to create, host, maintain, and update the MRFs in accordance with the Rule. - Confirm the balance/surprise billing prohibition notice is publicly available, posted on their public website, and included with applicable explanations of benefits. The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.	https://www.mondaq.com:443/unitedstates/employee-benefits-compensation/1205648/deadline-for-transparency-in-coverage-compliance-fast-approaching	2022-06-25T01:42:27Z	https://www.mondaq.com:443/unitedstates/employee-benefits-compensation/1205648/deadline-for-transparency-in-coverage-compliance-fast-approaching	false	1
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/los-angeles-dodgers/articles/39893613	2022-06-25T01:44:32Z	https://sportspyder.com/mlb/los-angeles-dodgers/articles/39893613	true	null
UVALDE, Texas (AP) — Almost 300 high school seniors received their diplomas Friday in Uvalde in the shadow of the massacre of 19 elementary school students and two children 5 1/2 weeks earlier. The red-gowned Uvalde High School seniors sat in 100-degree heat at the school stadium with 21 “Uvalde Strong” placards arrayed before their ranks as school and student leaders spoke. Uvalde school Superintendent Hal Harrell and school principal Randy Harris praised the students for their strength and resilience through three COVID-19 pandemic years, three changes of principals and then the May 14 mass shooting at the South Texas town's Robb Elementary School. “Love the people in your life while you have them because you don't know what the future holds for anyone,” class valedictorian Abigail Kone said in her address. “Our community has definitely learned about the unexpected. Something that should have never happened happened. Our lives have been altered. But we still stand together as a community,” she said. After reading off the names of the 19 slain children and teachers, Kone said, "These loved ones of families were taken too soon. They won't be given the opportunity to follow their dreams or watch their families grow up. “So tonight, I would like to include these children of Robb Elementary as honorary members of the Class of 2022 family,” she said to prolonged applause.	https://www.trumbulltimes.com/news/article/Graduating-Uvalde-High-School-class-remembers-17264773.php	2022-06-25T01:47:05Z	https://www.trumbulltimes.com/news/article/Graduating-Uvalde-High-School-class-remembers-17264773.php	false	26
President Biden called it a sad day for the court and the country after the Supreme Court ruled Friday morning to overturn Roe v. Wade, the 1973 decision protecting legal access to abortion across the country. NPR White House correspondent Asma Khalid joins us. This article was originally published on WBUR.org. Copyright 2022 NPR. To see more, visit https://www.npr.org.	https://www.wypr.org/2022-06-24/biden-calls-scotus-abortion-decision-a-sad-day	2022-06-25T01:49:10Z	https://www.wypr.org/2022-06-24/biden-calls-scotus-abortion-decision-a-sad-day	true	null
Latest from Kristy Hamilton Advertisement Advertisement Advertisement Advertisement Advertisement © 2022 IFLScience. All Rights Reserved © 1986-2021 IFLScience. All Rights Reserved Kristy Hamilton West Coast Editor Kristy is an environmental and brain science journalist. She has reported stories from rural Greece after the 2007 fires, ate pizza with Bill Nye while discussing climate change in California, followed dumpster divers on a salvaging mission in Seattle, and filed stories from NASA headquarters. Previously, she worked as a podcast host, writer, and video editor for Science Magazine in Washington, DC, who snagged her from a cortical dynamics laboratory, where she was a research assistant investigating the neural mechanisms underpinning language. Her brain is one that likes to think about the brain and anything else that twists the mind in strange and unexpected directions. This includes deep explorations into the environment, sustainability, and the enigmatic human mind in reaction to it all. In her spare time, she is a climber, traveller, and an aficionado of the ocean and mountains in equal measure. Read IFLScience Editorial PolicyAdvertisement Advertisement Advertisement Advertisement	https://www.iflscience.com/kristy-hamilton	2022-06-25T01:54:24Z	https://www.iflscience.com/kristy-hamilton	true	1
WV Press News Sharing WASHINGTON, DC – Today, U.S. Senator Joe Manchin, D-W.Va., released the following statement on the decision by the Supreme Court of the United States to overturn Roe v. Wade. “I am deeply disappointed that the Supreme Court has voted to overturn Roe v. Wade. It has been the law of the land for nearly 50 years and was understood to be settled precedent. I trusted Justice Gorsuch and Justice Kavanaugh when they testified under oath that they also believed Roe v. Wade was settled legal precedent and I am alarmed they chose to reject the stability the ruling has provided for two generations of Americans. “As a Catholic, I was raised pro-life and will always consider myself pro-life. But I have come to accept that my definition of pro-life may not be someone else’s definition of pro-life. I believe that exceptions should be made in instances of rape, incest and when the life of the mother is in jeopardy. But let me be clear, I support legislation that would codify the rights Roe v. Wade previously protected. I am hopeful Democrats and Republicans will come together to put forward a piece of legislation that would do just that.”	https://wvpress.org/wvpa-sharing/u-s-senator-manchin-disappointed-by-supreme-court-of-the-united-states-decision-to-overturn-roe-v-wade/	2022-06-25T01:57:04Z	https://wvpress.org/wvpa-sharing/u-s-senator-manchin-disappointed-by-supreme-court-of-the-united-states-decision-to-overturn-roe-v-wade/	false	2
Which Samsung side-by-side refrigerator is best? Side-by-side refrigerators are designed with two tall, narrow compartments, both extending the full height of the refrigerator. One side is for the refrigerator and the other is for the freezer. In most cases, the refrigerator compartment is larger than the freezer. Samsung is a well-regarded maker of appliances and electronics of all kinds. If you are looking for a Samsung smart appliance with Alexa and Wi-Fi built right in, take a look at the Samsung 26.7-Cubic-Foot Side-by-Side Refrigerator With Touch Screen Controls. What to know before you buy a Samsung side-by-side refrigerator Size Because side-by-side refrigerators have narrower doors than traditional freezer-over and freezer-under models, they need less clearance than refrigerators with full-width doors. Open doors on side-by-sides don’t extend as far into your kitchen, either, so they leave you more space to move around. Is a side-by-side refrigerator right for you? Pros - More storage: In general, side-by-side refrigerators have more storage space than other styles. - Narrower doors: They take up less room and are a great choice in smaller kitchens. - Easy organization: You can put your most-used refrigerated and frozen foods on the top shelves, where they’re at eye level and easy to get at. - Kid control: You can set items for small kids on lower shelves and items you don’t want them handling on higher shelves. - Findable frozens: Side-by-side refrigerators’ freezers have more shelves, so frozen foods are less likely to get lost. Cons - Space gobblers: In general, side-by-side refrigerators take up more space. - Narrow compartments: Some side-by-side refrigerators have freezer compartments narrower than the width of a pizza box, so storing larger items could be a problem. - Higher prices: Side-by-sides cost more than traditional freezer-over and freezer-under models. Measure first - Depth: Measure from the wall to the front of the counter. Side-by-side refrigerators are anywhere from 32 to 40 inches wide. - Width: Measure from cabinet to cabinet or from cabinet to wall. Side-by-side refrigerators are anywhere from 29 to 32 inches deep. If you plan on placing your refrigerator next to a wall, leave three inches between the wall and the hinged side of the door so it can open fully and freely. What to look for in a quality Samsung side-by-side refrigerator Capacity Choose a Samsung side-by-side big enough for your household’s food storage needs. Samsung makes side-by-sides with capacities from 22 to 28 cubic feet. Organization Look for adjustable shelves and bins that open and close easily. Special racks let you save space by storing bottles on their sides. Also, look for LED interior lighting and space in the refrigerator for tall items. Samsung’s Family Hub Family Hub refrigerators keep you connected by letting you control your Samsung smart appliances, stream music while you cook, share family photos on the on-door screen, see who’s at the door and more, all from your refrigerator door. With Wi-Fi connectivity, Alexa built in and the power to connect anytime from anywhere, a Family Hub makes your refrigerator the hub of your kitchen activities. Family Hub food features - Quick view inside: Tap or swipe to see what’s inside. - Smart recipes: Instant access to recipes and videos with just a touch. - Shopping lists: Create lists and share them with others. - Same-day pickup or delivery: Send your shopping list to Fresh Direct and Instacart. - Meal planner: Plan your meals based on the food that’s inside your refrigerator. Other Family Hub features - Display digital photos and videos. - Draw on the whiteboard and write notes, memos and to-do lists. - Sync calendars and events. - Search and browse the internet. How much you can expect to spend on a Samsung side-by-side refrigerator Samsung makes side-by-sides from $1,350-$2,400, depending on their size and features. Samsung side-by-side refrigerator FAQ Are side-by-side refrigerators the same thing as french door refrigerators? A. One is oriented vertically and the other horizontally. Both have doors that open outward, but side-by-side models have one tall side that is exclusively refrigerator while the opposite side is all freezer space. French door models are designed so the refrigerator compartment takes up the entire top and the bottom freezer pulls out like a large drawer. What are dual evaporators? A. Evaporators make the inside of refrigerators and freezers cold by removing moisture from the air. Fruits and vegetables need high humidity to stay fresh while freezer air should be dry. Having two separate evaporators prevents air from the refrigerator from mingling with air from the freezer, maintaining their separate humidities. What’s the best Samsung side-by-side refrigerator to buy? Top Samsung side-by-side refrigerator Samsung 26.7-Cubic-Foot Counter Depth Side-by-Side Refrigerator With Touch Screen Controls What you need to know: Alexa and Wi-Fi are built into this smart appliance. What you’ll love: You can see inside your refrigerator from anywhere and search recipes using what you have on hand. The touch screen hub lets you shop, send notes and sync schedules. You can organize your fresh and frozen foods on 16 shelves and in four pull-out drawers. What you should consider: The shelves are not adjustable. Where to buy: Sold by Home Depot Top Samsung side-by-side refrigerator for the money Samsung 27.4-Cubic-Foot Large-Capacity Stainless Steel Side-by-Side Refrigerator What you need to know: This large refrigerator has an integrated dispenser with a touch display for easy access to water, cubed or crushed ice. What you’ll love: The in-door ice maker has a spacious bin and the stainless steel exterior is fingerprint-resistant. Multi-vent technology cools every shelf evenly. The no-handle doors give it a sleek appearance while letting it fit in a 36-by-33-inch space. What you should consider: Some reviewers say it should make ice more quickly. Where to buy: Sold by Home Depot Worth checking out Samsung 22-Cubic-Foot Counter Depth Side-by-Side Refrigerator What you need to know: This is a great choice for those who prefer white appliances to the look of stainless steel. What you’ll love: Samsung’s twin cooling feature keeps perishable produce fresher longer with high humidity on the refrigerator side and protects against freezer burn with dry air on the freezer side. LED lighting brightens every corner and the automatic in-door ice dispenser saves space while producing 5.5 pounds of ice per day. What you should consider: Some users have complained the ice maker is too noisy. Where to buy: Sold by Home Depot Want to shop the best products at the best prices? Check out Daily Deals from BestReviews. Sign up here to receive the BestReviews weekly newsletter for useful advice on new products and noteworthy deals. David Allan Van writes for BestReviews. BestReviews has helped millions of consumers simplify their purchasing decisions, saving them time and money. Copyright 2022 BestReviews, a Nexstar company. All rights reserved.	https://www.wsav.com/reviews/br/beauty-personal-care-br/storage-br/samsung-side-by-side-refrigerator/	2022-06-25T02:07:30Z	https://www.wsav.com/reviews/br/beauty-personal-care-br/storage-br/samsung-side-by-side-refrigerator/	true	29
Anne Hathaway Reveals Her Favorite Outfit From The Devil Wears Fashion Oscar-winning American actress Anne Hathaway is an icon of cinema and popular culture thanks to his immense talent, his great film career, his outstanding appearances in series programs and of course, his great sense of fashion, sophisticated and elegant that delights us on every occasion. Celebrating his many successes, including the 21st anniversary of the classic “The Princess Diaries”as well as of course the fantastic “El Diablo Viste a la Moda”, among many other successful films under his belt, such as “Les Miserables”, “Interstellar” or “The Witches”the 39-year-old actress conducted an interview for the interview magazinewhere it also adorns the cover of its most recent edition. You can read: Summer 2022: the style trends you must follow to be fashionable The theme around the photo shoot is the ‘sporty chic‘ and on the main page, for example, which the actress and the magazine share online, we can see Anne Hathaway in a chic and avant-garde style with a protective vest and sports shoulder padsclutching a skipping rope and glamorously made up in peach eyeshadow and pink lipsIn addition to loose hair. She looks fabulous in other outfits she shares that balance out a versatile sophistication with the sports arena. In one image for example, jump rope in a strappy jumper synthetic material with buckle belt, sneakers and gloves. While in other of the several images it stands out with a notched dress made of attached belts, strapless, with thigh slit. Or in high-waisted jeans and a terry cloth top, which shows off his figure as he lifts hand weights. For the interview, Anne Hathaway also answered several questions for the section ‘Ask me anything’, in Spanish ‘Ask me whatever’and that were sent by friends of the actress or by other media personalities. The designer Michael Cors asks him what his favorite outfit was that he wore in the movie The Devil Wears Fashion. “It’s a chicken and egg question, because what I consider my style is heavily influenced by working with Patricia Field and having conversations with her about putting together outfits. But I love what I wore to the James Hoult party, that Chanel velvet coat that came down to my knees, and then the miniskirt and the stockings and the baggy boots”, answers the actress. The outfit in question is in fact the one that the character of Andy, the protagonist of the story, uses for a meeting-party that he attends. It consists of a mini-dress that matches with black stockings, knee-high boots, long coat and many golden necklacesvery fashionista. Follow us on	https://d1softballnews.com/anne-hathaway-reveals-her-favorite-outfit-from-the-devil-wears-fashion/	2022-06-25T02:09:20Z	https://d1softballnews.com/anne-hathaway-reveals-her-favorite-outfit-from-the-devil-wears-fashion/	false	1
ALBUQUERQUE, N.M. (KRQE) – A pair of Apple Airpods helped lead police to a woman accused of stealing a car and a purse. Police in Albuquerque, New Mexico, received a call from a victim saying his car window had been smashed and his wife’s purse was taken. The couple were able to ping the Airpods she’d had inside her bag to a home near Interstate 40. They later gave police a description of the suspect and the vehicle she was in. Police confirmed the vehicle as stolen and arrested 45-year-old Rebecca Henderson. According to a criminal complaint, Henderson admitted to stealing the purse and also said she stole the vehicle after seeing the keys inside.	https://www.wjbf.com/news/crime-news/stolen-airpods-help-lead-police-to-car-theft-suspect-officials-say/	2022-06-25T02:11:02Z	https://www.wjbf.com/news/crime-news/stolen-airpods-help-lead-police-to-car-theft-suspect-officials-say/	false	null
Bozeman city commissioners are scheduled to vote next week on a proposed city budget that includes tax increases for residents and pay raises for employees. The $169.7 million proposed budget includes $35 million in capital projects and would raise property taxes by 9.92%, or a $256 annual increase for the typical homeowner. In presentations to the city commission in recent weeks, City Manager Jeff Mihelich has said they are hoping that raising salaries and increasing benefits for city employees will help address the city’s staffing issues. Largely attributed to high housing cost and a competitive market, the city has struggled with both retaining employees and filling open positions, resulting in a vacancy rate that regularly hovers close to 20%. “Position turnover is robust, and that’s not a good thing,” Mihelich said at a commission meeting in June. “We have to do something to address that.” The budget also includes adding additional employees to the city’s payroll to total to almost 513 full-time employees. The large capital projects in the proposed budget include the relocation of fire station No. 2 from South 19th Avenue to the Montana State University campus, which is funded from a levy voters passed in November 2021. Other capital projects include renovations at the Swim Center and Lindley Center, work on the Sourdough Transmission Main, which is funded from the federal American Recovery Plan Act, and annual replacements of water and wastewater pipes. Expenditures in the recommended budget are proposed to grow about 7% percent from last year, which Mihelich said at a city commission meeting is also partially driven by inflation, which is over 8%, according to the U.S. Bureau of Labor Statistics. The budget also includes five mills, or $750,000 in revenue, for affordable housing. Mihelich said at a commission meeting in June that he believes that funding could result in incentives to build 150 new affordable units in Bozeman. The budget also proposes to allocate $1.2 million to social service agencies, something commissioners have pushed city staff to prioritize. The $1.2 million includes a requested $150,000 to Family Promise of Gallatin Valley, $400,000 to the Human Resources Development Council’s Streamline service and $250,000 to HRDC’s other services. The budget is one of a handful of items on the city commission’s agenda for their Tuesday meeting. During the budget discussions, commissioners have the option to propose amendments to the proposed budget.	https://www.bozemandailychronicle.com/news/city/bozeman-commission-set-to-vote-on-city-budget/article_d811a7ea-780c-567f-bf90-865329f49cbf.html	2022-06-25T02:20:17Z	https://www.bozemandailychronicle.com/news/city/bozeman-commission-set-to-vote-on-city-budget/article_d811a7ea-780c-567f-bf90-865329f49cbf.html	false	1
The U.S. Supreme Court’s decision overturning abortion protection affirmed by the court’s 1973 landmark ruling in Roe v. Wade sparked vigils by local abortion-rights activists who gathered Friday evening in Santa Maria, San Luis Obispo and Santa Barbara. Women’s March of Santa Maria organized a vigil at 5:30 p.m. in front of City Hall at North Broadway and East Cook Street to protest the Supreme Court decision in Dobbs v. Jackson Women’s Health Organization. Abortion-rights supporters decried the decision and vowed to protect abortion rights in California, while anti-abortion activists hailed the ruling and said they would use their votes to remove politicians who back pro-abortion legislation. “We are outraged and ready to fight,” Jenna Tosh, president and chief executive officer of Planned Parenthood California Central Coast, said in a statement. “The Supreme Court has taken away the constitutional right to abortion, a right we’ve had for nearly 50 years. “The court, now dominated by justices hostile to reproductive freedom, has robbed millions of the power to control decisions about their bodies, their lives and their futures,” she said. But the Santa Maria-based Right to Life of the Central Coast said in a statement from its board of directors that the court’s decision brought “thankful rejoicing and renewed dedication to helping mothers-to-be and protecting innocent lives.” “[The] decision in the Dobbs case struck down Roe’s outrageous invention of a nationwide constitutional right to kill babies in the womb and later supporting decisions,” the statement said, adding the Roe v. Wade decision “stripping the right to life from the unborn was a travesty of justice.” Luz Reyes-Martin, spokeswoman for the abortion-rights organization Planned Parenthood in Santa Maria Valley, said she had expected the Supreme Court decision, based on Justice Samuel Alito’s draft opinion that was leaked in May. “So what this decision means is [enacting abortion laws] becomes state by state,” Reyes-Martin said Friday. “I think what’s really important [is] the right to safe abortions still exists in California.” Santa Maria City Councilwoman Etta Waterfield, who said she has long been an anti-abortion activist, agreed about what the Supreme Court decision means. “The reality is it doesn’t take abortion off the plate at all,” she said. “What it does is bring it back to the state level. Now we have the opportunity to vote in or vote out pro-choice or pro-life [individuals]. In my case, I will vote for pro-life.” Waterfield became emotional as she recalled the experience of her mother-in-law Jane Russell, an actress, singer and model in the 1940s and ’50s, who had an abortion when she was younger and was haunted by it all her life. She said Russell helped push through federal legislation making international adoptions legal and created WAIF, the first international adoption organization that facilitated some 40,000 adoptions. “She never forgot the child she aborted,” Waterfield said. “You just don’t understand what an abortion does to a woman.” Reyes-Martin said Planned Parenthood will work to protect abortion rights in California, noting efforts are underway to place a California constitutional amendment on the November ballot to protect those rights. The proposed amendment, which must pass the state Assembly and Senate before the end of the month to make it on the ballot, is just one of 14 abortion-related measures moving through the state Legislature. Reyes-Martin said 13 states already had laws banning abortions in place that became effective as soon as the Supreme Court issued its decision, and another 13 states are reportedly moving quickly to pass legislation banning abortions. “Gov. Gavin Newsom aims to turn California into an abortion magnet, and the Legislature is considering several deplorable bills to encourage more abortions,” Right to Life said in its statement, specifically mentioning Assembly Bill 1918, Assembly Bill 2223 and Senate Bill 1142. The group urged residents to contact local legislators to oppose California’s “outrageous bills” and Constitutional Amendment 10. Federal legislators representing California also denounced the Supreme Court’s decision. “This decision, which overturns a half-century of legal precedent, is a betrayal of our Constitution and a betrayal of millions of women who count on its protections to retain control of their own body and choices,” said Rep. Salud Carbajal, D-Santa Barbara. “As more than half of all U.S. states stand ready to eradicate women’s reproductive rights in the wake of this decision, the majority of Americans who support a woman’s right to choose must see this as a call to action.” Democratic Sen. Alex Padilla, a member of the Senate Judiciary Committee, also criticized the Supreme Court justices and said the decision puts a number of individual rights at risk. “The right to an abortion is an essential right,” Padilla said. “But today, six right-wing justices on the Supreme Court cast aside half a century of precedent to overturn Roe v. Wade. “This draconian decision will deprive millions of Americans of the basic freedom to make decisions for their own bodies,” he said. “It also jeopardizes other fundamental civil rights, like the right to marry who you love, the right to privacy and the right to access contraception.”	https://santamariatimes.com/news/local/govt-and-politics/supreme-court-s-abortion-ruling-sparks-vigils-mixed-reactions/article_55d9aa98-e31e-5230-87e3-45b84d9c5d71.html	2022-06-25T02:20:42Z	https://santamariatimes.com/news/local/govt-and-politics/supreme-court-s-abortion-ruling-sparks-vigils-mixed-reactions/article_55d9aa98-e31e-5230-87e3-45b84d9c5d71.html	true	3
Council approves tuition, academic programs and trust fund guidelines FRANKFORT, Ky. — The Council on Postsecondary Education gave final approval to campus proposals for tuition and mandatory fees. Overall, the tuition rate change for resident undergraduates averages 1.5% across the system, the third-lowest increase in recent history. All submitted proposals complied with the Council’s tuition ceilings set... www.lanereport.com	https://www.newsbreak.com/news/2642373740883/council-approves-tuition-academic-programs-and-trust-fund-guidelines	2022-06-25T02:23:52Z	https://www.newsbreak.com/news/2642373740883/council-approves-tuition-academic-programs-and-trust-fund-guidelines	false	null
A Hindu outfit Friday demanded no new licenses should be issued by the Gurugram municipal corporation to set up new meat shops in the city. The Hindu Sangharsh Samiti submitted a memorandum addressed to Haryana Chief Minister Manohar Lal Khattar demanding that the civic authorities should abandon the process to issue any such license. Claiming that Khattar himself had promised that no fresh license would be issued for meat sale in the “holy" city of Gurugram as it is home to the Sheetla Mata Shrine, the Samiti demanded all 126 applications seeking fresh licenses be trashed. The Samiti has threatened protests in case the civic agency goes ahead with the process. In its memorandum addressed to the CM, the Samiti said, “It was in October 2017 that you promised that no fresh meat sale licences will be issued in respect of Sheetla Mata Temple and Guru Dronacharya. We want this application process cancelled. In addition, all current meat shops should be moved out of 10 km perimeter of the Sheetla Mata temple, and existing illegal shops closed." Gurugram has 119 licensed meat shops and over 1,500 unregistered ones. Fresh licenses have not been issued for years. “When there are norms for other holy cities why should Gurugram be any different," the Samiti asked. Saying that the Sheetla Mata temple is a revered shrine for the people of Haryana, Uttar Pradesh and Rajasthan, the Samiti demanded the area around it should be meat-free. “A separate market or area should be earmarked for registered legal sale and illegal shops should be shut. This is non-negotiable and the CM himself had announced it. We will not accept this (issuance of licenses) lying down," said Mahaveer Bhardwaj, Chairman of Sanyukt Hindu Sangharsh Samiti. Read all the Latest News , Breaking News , watch Top Videos and Live TV here.	https://www.news18.com/amp/news/india/hindu-outfit-demands-ino-fresh-license-be-issued-for-meat-sale-in-gurugram-5436235.html	2022-06-25T02:48:09Z	https://www.news18.com/amp/news/india/hindu-outfit-demands-ino-fresh-license-be-issued-for-meat-sale-in-gurugram-5436235.html	true	3
Kraigg Brathwaite and John Campbell consolidated a dominant position for the West Indies in reaching 67 without loss at stumps after their bowlers dismissed Bangladesh for 234 on the first day of the second and final Test in St Lucia on Friday. A day that started well for the home captain when he won the toss to give his bowlers first use of a sporting pitch ended with Brathwaite unbeaten on 30 and Campbell 32 not out, the pair laying the platform going into day two when they will be seeking to take a step closer to a 2-0 series sweep of their opponents. Alzarri Joseph and Jayden Seales led the West Indies bowling effort with three wickets each while debutant Anderson Phillip, who took the first wicket of the match with just his second ball in Test cricket, and the versatile Kyle Mayers claimed two apiece. That reinforced not just their skipper’s decision at the toss but also the selectors’ choice in opting for an additional seamer in Phillip at the expense of first Test debutant and spinner Gudakesh Motie. Given their reputation of vulnerability in these conditions against a concerted fast bowling attack, the visitors were indebted to a counter-attacking 53 from middle-order batter Liton Das and Tamim Iqbal’s 46. It looked very ominous for Bangladesh at the start of play when, with just the third delivery of the match, Kemar Roach forced Tamim to fend off a sharp lifter in an experience reminiscent of what the West Indies endured a year earlier when they were battered, bruised and humiliated by the South African fast bowlers in back-to-back Tests at the venue. This time the shoe was on the other foot though, even if Roach, poised on 249 Test wickets, went wicketless through the first innings with the supporting bowlers more than eager to fill the breach left by the luckless senior seamer. Tamim gives Bangladesh strong start Tamim and opening partner Mahmudul Hasan Joy displayed much more determination than many would have expected in an opening stand of 41 and it took the introduction of Phillip just before the end of the first hour’s play to make the breakthrough. With a full-length delivery, the fast-medium bowler breached the defence of Hasan Joy to get the West Indies going. Tamim continued to bat resolutely, mixing solid defence with unrestrained aggression when the rare loose ball came along. However the left-hander’s own impetuousity proved his undoing as a loose drive at Joseph gave Jermaine Blackwood a comfortable catch at cover-point with the lunch interval looming. Four wickets in the afternoon session kept Bangladesh on the back foot although Liton’s experience and occasional aggression ensured that his team were not completely bogged down. He reached his half-century in the final session but lost Mehidy Hasan Miraz to an excellent diving catch by Devon Thomas at backward-point off Mayers, the substitute fielder setting the standard for a good day in the field for the West Indies. It was not a good final session for the bowlers however as they lost their composure with Shoriful Islam, one of two changes to the Bangladesh line-up from the first Test, and Ebadot Hossain swinging powerfully and often at anything within reach. Their combined efforts ensured that 43 runs were added for the last two wickets to give themselves and the other bowlers something to work with. But the inadequacy of that total was put in perspective by the ease of the unbroken stand between Brathwaite and Campbell, suggesting that captain Shakib Al Hasan and the other bowlers will face a tough task to limit the West Indies progress. Apart from drafting in Shoriful at the expense of fellow-seamer Mustafizur Rahman, Bangladesh also opted for Anamul Haque over out-of-form former captain Mominul Haque for this match. Get all the latest updates on Cricket News, Cricket Photos, Cricket Videos and Cricket Scores here	https://www.news18.com/cricketnext/amp/news/wi-vs-ban-2022-2nd-test-west-indies-solid-after-bowling-out-bangladesh-for-234-on-day-1-5436271.html	2022-06-25T02:49:29Z	https://www.news18.com/cricketnext/amp/news/wi-vs-ban-2022-2nd-test-west-indies-solid-after-bowling-out-bangladesh-for-234-on-day-1-5436271.html	true	4
Did you lose money on investments in Teladoc Health? If so, please visit Teladoc Health, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, June 24, 2022 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) between October 28, 2021 and April 27, 2022, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934. Teladoc provides virtual healthcare services in the U.S. and internationally through Business-to-Business ("B2B") and Direct-to-Consumer ("D2C") distribution channels. The Company offers its customers various virtual products and services addressing, among other medical issues, mental health through its BetterHelp D2C product, and chronic conditions. Teladoc touts itself as "the first and only company to provide a comprehensive and integrated whole person virtual healthcare solution that both provides and enables care for a full spectrum of clinical conditions[.]" Despite recent market concerns over new entrants to the telehealth field, such Amazon.com, Inc. ("Amazon") and Walmart Inc. ("Walmart"), the Company has continued to assure investors of the Company's dominant market position in the industry. Plaintiff alleges that Defendants made materially false and misleading statements throughout the Class Period. Specifically, Plaintiff alleges that Defendants failed to disclose that: (i) increased competition, among other factors, was negatively impacting Teladoc's BetterHelp and chronic care businesses; (ii) the growth of those businesses was less sustainable than Defendants had led investors to believe; (iii) as a result, Teladoc's revenue and adjusted EBITDA projections for FY 2022 were unrealistic; and (iv) as a result of all the foregoing, Teladoc would be forced to recognize a significant non-cash goodwill impairment charge. On April 27, 2022, Teladoc announced its first quarter ("Q1") 2022 financial results, including revenue of $565.4 million, which missed consensus estimates by $3.23 million, and "[n]et loss per share of $41.58, primarily driven by [a] non-cash goodwill impairment charge of $6.6 billion or $41.11 per share[.]" Additionally, the Company revised its FY 2022 revenue guidance to $2.4 - $2.5 billion and adjusted EBITDA guidance to $240 - $265 million "to reflect dynamics we are currently experiencing in the [D2C] mental health and chronic condition markets." On a conference call with investors and analysts that day to discuss Teladoc's Q1 2022 results, Defendants largely attributed the Company's poor performance, revised FY 2022 guidance, and $6.6 billion non-cash goodwill impairment charge to increased competition in its BetterHelp and chronic care businesses. On this news, the Company's stock price fell over 40% to close at $33.51 per share on April 28, 2022. If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. If you purchased TDOC securities, and/or would like to discuss your legal rights and options please visit Teladoc Health, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years. ATTORNEY ADVERTISING. © 2022 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 pallocco@bernlieb.com View original content to download multimedia: SOURCE Bernstein Liebhard LLP	https://www.wilx.com/prnewswire/2022/06/25/teladoc-health-inc-nyse-tdoc-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-deadline-file-lead-plaintiff-motion-securities-class-action-lawsuit-against-teladoc-health-inc-nyse-tdoc/	2022-06-25T02:51:40Z	https://www.wilx.com/prnewswire/2022/06/25/teladoc-health-inc-nyse-tdoc-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-deadline-file-lead-plaintiff-motion-securities-class-action-lawsuit-against-teladoc-health-inc-nyse-tdoc/	true	72
Profile Subscribe Login Subscribe home Results Horse Racing bet365 Echuca Partly Cloudy Heavy 8 Brought to you by: All R 1 3, 12, 10 R 2 19m R 3 54m R 4 1h 29m R 5 05:01 R 6 05:40 R 7 06:20 R3 Maiden Plte 2100m Class: 3-Y-O & Up, Maiden, Set Weights Class: 3-Y-O & Up, Maiden, Set Weights Prize: $25,000 1st: $13,750 2nd: $4,250 3rd: $2,000 Track Info: RAIL - Out 3m 1000m - 400m, True Remainder. Saturday 25 June 2022 03:51AM Track Profile: bet365 Echuca Results are not available yet. Go to Form Guide home news form Feed Results Add to your Blackbook Comments Remove from Blackbook? No Yes	https://www.racenet.com.au/results/horse-racing/bet365-echuca-20220625/northern-hire-group-maiden-plate-race-3	2022-06-25T02:56:55Z	https://www.racenet.com.au/results/horse-racing/bet365-echuca-20220625/northern-hire-group-maiden-plate-race-3	true	null

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.